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Abstract 
 
Sepsis is the overwhelming inflammatory response to infection, especially bacterial 
infection and associated bacterial products. It has major healthcare impacts, affecting an 
estimated  19-30 million persons/year worldwide with a mortality of 30-70%. Despite 
intense research, no specific therapy has been established for sepsis and in addition to the 
high mortality, the associated economic costs are very high. For example, recent data 
shows that the annual cost of patients with sepsis is more than $20 billion in the USA, 
and £2.5 billion in the UK. Therefore, novel targets and new therapies for sepsis are 
required which will have an important impact on both mortality and economic benefits. 
Recent work has demonstrated that the phopsholipid modifying enzyme, LPCAT, has a 
role in the regulation of inflammatory responses to bacterial infections. However, the 
mechanism of action in this regard is not well understood. This project aimed to identify 
the role of LPCAT-2 in inflammatory response to infections. This project has utilized the 
RAW264.7 murine macrophage cell line as an experimental model and LPS or 
Pam3CSK4 as infectious stimuli to investigate the role of overexpressing LPCAT-2 as 
well as silencing the over-expressed LPCAT-2 using siRNA technique. RAW264.7 cells 
transiently or stably transfected with the LPCAT-2 gene were used to study the role of 
LPCAT-2 in the inflammatory responses of macrophages. LPCAT-2 was successfully 
over-expressed in RAW264.7 cells and the overexpression was successfully confirmed 
with real time polymerase chain reaction (RT-PCR) and western blotting. The 
overexpression of LPCAT-2 significantly upregulated the pro-inflammatory cytokines 
TNF-α and IL-6, at both gene expression, and protein level, while the anti-inflammatory 
cytokine, IL-10, was down regulated in these cells. Moreover, overexpression of LPCAT-
2 significantly decreased the expression of TLR4, peroxisome proliferator-activated 
receptors –gamma (PPARγ) and CD206 (a marker of M2 macrophages) while it 
significantly increased CD14, TLR2, COX-2 and iNOS (M1 markers). LPCAT-2 gene 
expression was also increased when PPARγ was blocked with the selective (PPAR-γ) 
antagonist T0070907. Importantly, silencing the transiently over-expressed murine 
LPCAT-2 resulted in a significant reduction in TNF-alpha and a significant increase in 
IL-10 gene expression. Both the transient and stably transfected RAW264.7 cells have 
been used to study the role of LPCAT-2 in regulating inflammatory responses in 
macrophages. The results have significantly added to knowledge of the role of LPCAT-2 
in the inflammatory response and will aid in the development of novel therapies for 
inflammatory conditions such as sepsis.  
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1. General introduction and literature review. 
1.1. Sepsis.  
1.1.1. Definitions and Incidence.   
Sepsis is defined as ‘life-threatening organ dysfunction caused by a dysregulated host 
response to infection’ (Singer et al., 2016). The continuum that is characteristic of the 
development of this disease informed the necessity of a definition which would combine 
the various aspects typically defining its presence.  
Sepsis has been frequently referred to as a systemic response to infection due to the 
presence of bacteria and bacterial products, such as lipopolysaccharide (LPS), in the 
blood (Adib-Conquy et al., 2000; Kawai et al., 2010; Adib-Conquy et al., 2012; Guzzo 
et al., 2012; Hagar et al., 2013; Kayagaki et al., 2013; Boomer et al., 2014). It is a major 
healthcare problem that annually affects 19 - 30 million patient worldwide with a 
mortality of 25 – 70 %, and the incidence is increasing compared to 20-40 years ago 
because the medications was not well developed, the patient with this illness would have 
been died or even died due to any accident before being able to discover the exact reason 
of the death, compared to the high medical technology that have prolonged the patient 
life in intensive care units (ICU) (Bloos et al., 2014; Boomer et al., 2014; Ramachandran, 
2014; Page et al., 2015; Global Sepsis Alliance, 2016; Papali et al., 2017; Patel et al., 
2017).  
Despite the fact that sepsis is a major cause of morbidity and mortality worldwide due to 
the impact of multiple bacterial infection, there remains no specific therapy (Brun-
Buisson et al.,1995; Angus et al.,1997; Brightbill, 1999; Schorr et al., 2007; Logters et 
al., 2009; Adhikari et al., 2010; Paul et al., 2010; Daniels, 2011; Pavlaki et al., 2013; 
Ramachandran, 2014; Papali et al., 2015; Powell et al., 2015; Global Sepsis Alliance, 
2016; Papali et al., 2017;  Patel et al., 2017; Rannikko et al., 2017). It is significantly 
common than heart attack, and leading cause of death than any cancer 
(Changsirivathanathamrong et al., 2011; Darcy et al., 2011; Dellinger et al., 2013; 
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Wilding & Bodmer, 2014; Cohen et al., 2015; Papali et al., 2017; Patel et al., 2017; 
Rannikko et al., 2017). Nevertheless, even in the most developed countries less than half 
of the adult population have heard of it. It is also remains the leading cause of death in 
the least developed countries (Chalupka et al., 2012; Perner et al., 2012; Wiens et al., 
2012; Langley et al., 2013; Boomer et al., 2014; Wiersinga et al., 2014; Mickiewicz et 
al., 2014; Global Sepsis Alliance, 2016; Papali et al., 2017; Patel et al., 2017; Rannikko 
et al., 2017). 
In the United States alone, sepsis affects more than 500,000 patients a year, with a 
mortality of 30 -70 % (Angus et al., 2006; Cheng & Shi, 2009; Guzzo et al., 2011). In 
addition, sepsis is considered the leading cause of death in intensive care units (ICUs) 
(Hoesel & Ward, 2004, Zahorec et al., 2005; Daniels, 2011; Gaieski et al., 2013; Reinhart 
et al., 2013; Fujishima et al., 2014; Rhee et al., 2015; Falcone et al., 2016; Civitarese et 
al., 2017; Rannikko et al., 2017).   
The economic impact is also significant with estimated costs in the USA of $ 22,000 per 
case and an annual cost of $ 16.7 Billion (Angus et al., 2001; Schorr et al., 2007; Lozano 
et al., 2014). The need to better clinically define sepsis led to a consensus conference by 
the American College of Chest Physicians/Society of Critical Care Medicine 
(ACCP/SCCM), in 1992 (Bone et al., 1992).  
The definitions published by the consensus committee, were of the essential criteria for 
the systemic inflammatory response syndrome (SIRS) and specific characterizations 
(definitions) for sepsis, severe sepsis, septic shock and multiple organ dysfunction 
syndromes (MODS).  
The criteria for SIRS is defined by two or more of the following; core body temperature 
is > 38 ºC or < 36 ºC, Heart rate (HR) is ≥ 90 beat per minute (bpm), Respiration is ≥ 20 
per minute (or Partial pressure of carbon dioxide (CO2) in the blood (PaCO2) is < 32 mm 
Hg) White blood cell (WBC) count is ≥12,000 / μl (mm3) or ≤ 4000/ μl or >10% immature 
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forms (Shen et al., 2010; Seymour et al., 2012; Wiens et al., 2012; Schulte et al., 2013; 
Schorr et al., 2014; Rhee et al., 2014;  Yealy et al., 2014; Rhee et al., 2015; Seymour et 
al., 2016; Shankar-Hari et al., 2016; Rhodes et al., 2017).  
The definition of sepsis was set as a clinical definition of SIRS criteria caused by known 
or suspected infection. However, these definitions of sepsis and ‘severe sepsis’ were 
found to be misleading and SIRS criteria could be achieved in non-life-threatening 
situations.  
Therefore, following the 2016 consensus meeting it was suggested that sepsis should be 
defined as life-threatening organ dysfunction caused by a dysregulated host response to 
infection and septic shock should be defined as a subset of sepsis in which particularly 
profound circulatory, cellular, and metabolic abnormalities are associated with a greater 
risk of mortality than with sepsis alone (Singer et al., 2016).  
Patients vary in their responses; the severity of their sepsis and the speed in which its 
development is affected by their inherited characteristics and the presence of coexisting 
illnesses, and the number and virulence of infecting microbes (Martin et al., 2003; 
Kissoon et al., 2011; Martin et al., 2012; Angus & van der Poll, 2013; Jovanovich et al., 
2014; Kumar et al., 2014; Nygard et al., 2014; Mayr et al., 2014; Assuncao et al., 2014; 
Moore et al., 2015; Jiménez-Sousa et al., 2015; Jolley et al., 2015; Moskowitz et al., 
2017; Minasyan et al., 2017).  
Most types of micro-organisms can cause sepsis, including bacteria, fungi, viruses and 
parasites. However, viral infections accompanied by seasonal influenza viruses, the 
Dengue and Ebola viruses could progress to an acute organ damage resulting in death 
from multiple organ dysfunction and septic shock (Clark et al., 2004; Maier et al., 2004; 
Harrison et al., 2006; Kim et al.,2008; Feldman & Geisbert, 2011; Hall et al., 2011; Jawad 
et al., 2012; Lagu et al., 2012; Paessler & Walker, 2013; Iwashyna et al., 2014; Liu et al., 
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2014; Hashmi, 2015; Ojard et al., 2015; Guirgis et al., 2016; Kempker & Martin, 2016; 
Jeganathan et al., 2017).  
Gram-positive organisms causing sepsis to have increased in frequency over time and are 
now almost as common as gram-negative infections (Martin et al., 2003; Finfer et al., 
2004; Vincent et al., 2006; Anzaldi et al., 2011; Dellinger et al., 2013; Packiriswamy et 
al., 2013; Hoeniglet al., 2014; Henriksen et al., 2015; Kempker & Martin, 2016). This 
almost equal cause between Gram-positive and Gram-negative bacteria contrasts with the 
situation 40 years ago, when the majority were Gram-negative. Currently, most patients 
with sepsis seen in ICU and have indwelling catheters that could introduce skin flora 
internally and the majority of such organisms are Gram-positive (Karlsson et al., 2007; 
Iwashyna et al., 2010; Husak et al., 2010; Kissoon et al., 2011; Iskander et al., 2013; 
Mayr et al., 2014; Kumar, 2014; Lozano et al., 2014; Ogura et al., 2014; Singer et al., 
2014; Henriksen et al., 2015; Singer et al., 2016; Jeganathan et al., 2017).  
The more frequent use of broad-spectrum antibiotics in the treatment of increasingly ill 
patients who remain in the ICU for longer periods of time has probably contributed to an 
increased bacterial resistance over time (Reacher et al., 2000; Carlet et al., 2004; Ranieri 
et al., 2012; Schmerler et al., 2012; Standage et al., 2012; Rogers et al., 2014; Caironi et 
al., 2014; Lozano et al., 2014; Asfar et al., 2014; Cohen et al., 2015; Jolley et al., 2015; 
Gutierrez et al., 2015; Singer et al., 2016). 
Sepsis occurs due to the presence of bacteria and bacterial products, such as 
lipopolysaccharide (LPS), in the circulation. Despite the advantages of modern medicine 
including vaccines, antibiotics and intensive care, the incidence of sepsis is increasing. 
Worldwide yearly estimated morbidity rate is approximately 20 to 30 million patients to 
be affected, with over 6 million cases of neonatal and early childhood sepsis (Clark et al., 
2004; Iwashyna et al., 2010; Lagu et al., 2012; Guzzo et al., 2012; Iskander et al., 2013; 
Hagar et al., 2013; Iwashyna et al., 2014; Kaukonen et al., 2014). In addition, the maternal 
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incidence of sepsis is over 100,000 cases (Angus et al., 2013; The Global Sepsis Alliance, 
2015; The Global Sepsis Alliance, 2016).   
Sepsis, is higher in infants and elderly people than in other age groups. It is also higher 
in males than in females, and blacks than whites (Adrie et al., 2005; Mayr et al., 2010; 
Hall et al., 2011; Gutierrez et al., 2015; The Global Sepsis Alliance, 2016). Patients with 
chronic illnesses, for example, diabetes, cancer, AIDS, renal or hepatic diseases, are also 
at higher risk, as are pregnant women and those with a severe burn or physical injuries 
(The Global Sepsis Alliance, 2015, 2016; Jeganathan et al., 2017).  
Furthermore, the annual mortality is over 7.3 million (Angus, 2011). Sepsis is one of the 
leading causes of death in the advanced world, corresponding to myocardial infarction in 
its yearly incidence combined with a high impact on the economy (Seymour et al., 2010; 
Wiens et al., 2012; Richards, 2013; Schorr et al., 2014; The Global Sepsis Alliance, 2016; 
Adrie et al., 2017).  
Recent estimates suggest an annual incidence of sepsis of about 300 cases per 100,000 
people; in comparison, myocardial infarction has been estimated to affect 208 per 100,000 
per year while stroke is 223 per 100,000 (Feigin et al., 2009; Yeh et al., 2010; Hashmi, 
2015; The Global Sepsis Alliance, 2016). The annual rate of sepsis incidence, in the USA 
has been increasing between 8-13 % (Vincent et al., 2006, Hall et al., 2011; Wiens et al., 
2012).  
In addition, Sepsis is considered as the leading cause of death in intensive care units 
(ICUs) (Hoesel & Ward, 2004; Karlsson et al., 2007; Daniels, 2011; Myr et al., 2010; 
McPhersonet al., 2013; Richards, 2013; Assuncao et al., 2014; Arefian et al., 2017; Adrie 
et al., 2017; Jeganathan et al., 2017). Many individuals who survive severe sepsis are 
completely recovered with no long-term effects but others who survived to the hospital 
discharge system after sepsis remained at increased risk for death during the following 
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months and years (Rice, 2006; Winters et al., 2010; Phua et al., 2011; Bloos & Reinhart, 
2014; Schorr et al., 2014; Adrie et al., 2017; Jeganathan et al., 2017).  
Those who survived also could have physical or neuro-cognitive functioning 
impairments, mood disorders, and a low quality of life Iwashyna et al., (2010). Wang et 
al., (2012) stated: “We do not know for certain how many people are affected by such 
problems, but it is likely to be at least 20% of survivors”. Moreover, there is some 
evidence that an episode of severe sepsis can disorder a person’s immune system, making 
them more susceptible to future infections (Wang et al., 2012; Henriksen et al., 2015).  
The agency for healthcare research and quality has listed sepsis as the most expensive 
status treated in U.S. hospitals, which has been costed more than $20 billion in 2011 
increasing annually average of 11.9 % (Torio et al., 2011). 
In the UK, the intensive care national audit and research centre (ICNARC) data estimates 
that over 140,000 patients each year develop sepsis and the mortality rate is increasing at 
a percentage rate of 1.5 % per annum. In addition, in 2010 about 78,000 of these patients 
admitted to intensive care units (ICU), with a mortality of 30 – 80 % (Daniels, 2011) with 
an approximate cost to the NHS of £ 2.5 billion (Dombrovskiy et al., 2007; Danial, 2009; 
Richards, 2013; Vincent et al., 2014; Ferrario et al., 2016: Esposito et al., 2017).  
Sepsis should be treated as an emergency (Daniels, 2011; McPherson et al., 2013; Asfar, 
et al., 2014; Vincent et al., 2014; Adrie et al., 2017; Jeganathan et al., 2017). Recent 
studies and quality enhancement initiatives have been demonstrated that the early 
recognition of the condition was following by the intravenous fluids administration and 
antibiotics are key to survival (Barochia et al., 2010; Dellinger et al., 2013; The ProCESS 
Investigators, 2014; Investigators et al., 2014; De Backer et al., 2014; Corrêa et al., 2015; 
De Pascale et al., 2016; Adrie et al., 2017; Jeganathan et al., 2017).  
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1. 2. Pathophysiology of Sepsis.  
1.2.1. Lipopolysaccharide. 
 
Sepsis is triggered by pathogens or their products in blood. Pathogen-associated 
molecular patterns (PAMP) is a term that refers to pathogen molecules that induce a host 
response including production of inﬂammatory mediators (Cohen, 2002).  
Examples of PAMPS include molecules from Gram-negative and Gram-positive bacterial 
membranes. Of these, the lipopolysaccharide (LPS) (also called endotoxin) present in the 
outer membrane of Gram – negative bacteria have been strongly associated with the 
induction of sepsis (Rietschel et al., 1994; Van Amersfoort et al., 2003; Jackson & Parton, 
2004; Harrison et al., 2006; Rosenfeld & Shai, 2006; Guzzo et al., 2011).  
Understanding and modulating the production of LPS-induced mediators such as TNFα 
has therefore been the focus of research aimed for developing specific therapies for septic 
shock (Seymour et al., 2012; Schorr et al., 2014, Wensink et al., 2014).  
LPS can be released into the circulation from invading bacteria, either spontaneously 
during growth or due to immune-mediated lysis of bacteria (Wright et al., 1990; Miyake, 
2004; Wiersinga et al., 2014).  
It has three regions (Figure 1), a lipid A molecule that anchors the LPS in the outer 
membrane, a core sugar consisting of 3-deoxy-D-manno-oct-2-ulosonic acid (Kdo) 
moieties, and the O antigen, which consists of repeating oligosaccharide units. O antigen 
is an extremely variable region since variety bacteria possess diversity repeating numbers 
of polysaccharide (Raetz & Whitfield, 2002; Holst, 2011).  
The lipid A element of LPS is recognized by Toll-like receptor 4 (TLR4) with its co-
receptor MD-2 on host cells (Kawai and Akira, 2007; Kawai & Akira, 2010; Wiersinga 
et al., 2014; Wensink et al., 2014; Kim et al., 2017). Lipid A, the hydrophobic domain of 
LPS, is composed of two glucosamine units with attached acyl chains and generally 
containing one phosphate group on each carbohydrate (Figure 1). It is the main 
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component of the outer monolayer of the outer membranes of Gram-negative bacteria. 
i.e. lipid A; a membrane anchored phospholipid contains 6 acyl groups and 2 phosphate 
groups. Numbers of acyl and phosphate groups could vary from one bacterial species to 
another, for examples the difference between the chemical structures of the major species 
of lipid A produced by E. coli (Figure 2) (Zähringer et al., 1999; Hirschfeld et al., 2001; 
Holst, 2011).  
Attached to the lipid A are non-repeating “core” oligosaccharide and a distal 
polysaccharide (or O-antigen) that are not essential for bacterial growth in the laboratory 
but, in vivo are required for bacteria to resist some antibiotics, the complement system, 
and other external factors (Raetz & Whitfield, 2002). 
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Figure 1. Schematic of the basic structure of lipopolysaccharide. 
 
LPS consists of three regions: lipid A (chair structure indicates di-glucosamine head 
group, blue circles indicate phosphate groups, wavy lines indicate acyl chains), core 
sugars, and O-antigen, that consists of repeating units (denoted in brackets, with an “n”) 
of oligosaccharides (Adopted from Raetz & Whitfield, 2002).  
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Figure 2. Chemical structure of E. coli  lipid A. 
 
The main structural differences between types of LPS in different bacteria is depended 
on the nature and number of fatty acids, presence or absence of the second phosphate in 
position 4′, and substitution of the position 1 phosphate. For more detailed comparison is 
presented in reference (Zähringer et al.,1999). 
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1. 3. The innate immune system and the response to LPS. 
The innate immune system represents the first line of host defense during infection and 
thus plays an essential role in the priming recognition followed by triggering of 
immunological mediators for instance cytokines and chemokines (Medzhitov et al., 1997, 
1998; Yang et al., 1997; Dinarello, 2000; Miyake, 2004; Guzzo et al., 2012; Hagar et al., 
2013). The adaptive immune system is responsible for eradication of pathogenic microbes 
in the late stage of infection (Hashimoto-Tane et al., 2010; Owen et al., 2013). 
 As part of the innate immune system, the (PRR) are a family of receptors present on the 
cell wall or in the cytosol of most cell types such as monocytes, macrophages and 
dendritic cells that recognise pathogen-associated molecular patterns (PAMPs) 
(Hirschfeld et al., 2002; Heumann et al., 2002; Hořejší et al., 2005; Kim et al., 2007; 
Akira et al., 2009; Aliche-Djoudi et al., 2011; Płóciennikowska et al., 2015). Toll-like 
receptors (TLRs) are type of Pattern recognition receptors (PRR) trans-membrane protein 
which were first discovered in Drosophila flies (Nüsslein-Volhard & Wieschaus, 1980).  
It is known that LPS signals via TLR 4, is one of the most potent molecules triggers an 
overwhelming immune response that might lead to severe health conditions and even 
death (Akira et al., 2001; Akira, 2003; Akira & Takeda, 2004 & 2005; Akira et al., 2006; 
Akira et al., 2009; Yamamoto et al., 2011; Schorr et al., 2014; Płóciennikowska et al., 
2015). 
 
1.3.1. The role of Macrophages.  
 
The early information about macrophages as a fundamental actor in the immune system 
could be outlined to the observations and experiments conducted by the Ukranian scientist 
llya Metchnikoff, for which he won a Nobel Prize in 1908.  Apart from their central role 
of antigen presentation, it has been long recognised that the release of cytokines from 
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primed macrophages is a vital event in the pathogenesis of sepsis (Nathan, 1987; Ayala 
et al., 1992).  
Ayala et al., (1992) discovered that the cytokines IL-1, IL-6 and TNF-alpha were released 
from macrophages in response to a polymicrobial infection. Furthermore, functions of 
macrophages are essential to generation and resolution of inflammation and tissue repair 
(Mosser & Edwards, 2008; Guzzo et al., 2012; Ha et al., 2012; Hamazaki et al., 2013; 
Hashimoto et al., 2013).  
Cirelli and colleagues, (1995) showed that TNF-positive mononuclear phagocytes were 
found in sheep lungs alongside a progressive increase within the plasma levels of the 
cytokine with continuous LPS infusion (Cirelli et al.,1995). It was also determined that 
these cells possibly contribute to both the increasing circulating levels of TNF-alpha and 
the development of acute lung injury. In addition, following LPS injection in mice, 
peritoneal and alveolar macrophages were found to release TNF in in vitro cultures 
(Fitting et al., 2004).  
Ge and colleagues have also shown that after injection of LPS or bacteria, in situ analysis 
shows that spleen macrophages produce abundant amounts of IL-1 (Ge et al., 1997). 
Furthermore, bone marrow monocytes contain TNF, and Kupffer cells are also an 
important source of IL-1 and TNF (Cavallion & Adib-Conquy, 2005). Ertel and his 
colleagues (1992) discovered that haemorrhage-induced suppression of macrophage as 
well as the splenocyte functions which is leads to a decreasing in cytokine production. 
Therefore, it reduced susceptibility to sepsis (Ertel et al., 1992). 
Macrophages show much plasticity in their functions and their phenotype can be 
described between to polar extremes from ‘classical activation' or M1 polarization in 
which they express anti-bacterial and inflammatory mediators, to ‘alternative activation' 
or M2 polarization when they function in resolution of inflammation and tissue repair 
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(Benoit et al., 2008; Shaykhiev et al., 2009; Mantovani & Sica, 2013; Liu et al., 2014; 
Martimez & Gordon, 20014; Chang et al., 2015).  
In vitro experiments have shown that stimulation of macrophages with lipopolysaccharide 
and interferon-γ (IFNγ) promotes the differentiation of “classically activated” M1 
macrophages that release destructive proinflammatory mediators (Ding et al., 1988; 
Mitchell et al., 2011; Mills, 2012).  
In contrast, interleukin (IL)-4 and IL-10 induce an “alternatively activated” M2 
phenotype that possesses neuroprotective properties (Bouhlel et al., 2007; Kigerl et al., 
2009; Goerdt et al., 1999; Mandal et al., 2011; Durafourt et al., 2012; Ming et al., 2012; 
Mingeot-Leclercq et al., 2012; Mills, 2012; Mills et al., 2014).  
  
1.3. 2. Toll-like receptors.  
 
Innate immunity is triggered by the recognition of pathogen-associated molecular patterns 
(PAMPs), by pattern recognition receptors expressed by macrophages and other host cells 
(Lien, 1999; Lien, 2000; Kumar et al., 2009a; Kumar et al., 2011). This primary 
recognition is crucially important for the rapid innate immune response, and for directing 
the later pathogen-specific adaptive immune responses. Since the identification of TLR4 
as the lipopolysaccharide (LPS) receptor in 1998, it has long been expected to trigger all 
the responses to LPS (Poltorak et al., 1998; Aderem &Ulevitch, 2000; Beutler et al., 2001; 
Beutler & Poltorak, 2001; Lee & Hwang, 2006; Liu et al., 2008; Kumar et al., 2009b).  
LPS triggers monocytes and macrophages to produce cytokines such as TNF-α, IL-1, and 
IL-6 (Akiraet al.,1990; Shapira, et al.,1994; Kielian et al., 2004; Płóciennikowska et al., 
2015). These cytokines serve as endogenous mediators of inflammation via receptor-
mediated interactions with different target cells. Cytokine production is important for the 
efficient control of growth and diffusion of invading pathogens (Rothe et al.,1993; Tracy 
& Cerami, 1994; Armstrong et al., 1996; Chen et al., 2011).  
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However, cytokine overproduction is harmful for the host, and may lead to multiple organ 
failure and death. The primary characteristic feature of severe sepsis is multiple organ 
dysfunction caused by excessive production of inflammatory cytokines (Dobrovolskaia 
& Vogel, 2002; Cohen, 2002; Heumann & Roger, 2002; Van Amersfoot et al., 2003; Liu 
et al., 2006;  Iwamura, & Nakayama, 2008; Hashimoto-Tane et al., 2010; Iskander et al., 
2013; Hussell et al., 2014).  
Upon recognition of the PAMPs, TLRs trigger production of pro-inflammatory mediators 
helping to eradicate infection. Currently, thirteen TLRs have been identified and 
described in mammals, twelve of which are expressed in mice and ten in humans (Chen 
et al., 2011; Płóciennikowska et al., 2015). 
A considerable amount of evidence backs a model where LPS or LPS-containing bodies 
(including intact bacteria) form complexes with a serum protein known as LPS-binding 
protein (LBP) the role of which is to bring LPS to the cell surface by binding to LPS and 
forming a ternary complex with the LPS receptor molecule CD14 (Dauphinee & Karsan, 
2006; Kumar et al., 2009b; Płóciennikowska et al., 2015; Kim et al., 2017).  
Then, the LPS-LBP complex is transferred and binds to soluble CD14 (sCD14) or the 
membrane-bound CD14 that binds to the extracellular domain of TLR4-MD2 complexes 
(Ulevitch & Tobias, 1999; Heumann & Roger, 2002; Płóciennikowska et al., 2015), 
followed by TLR4 oligomerisation and activation of the signaling cascade (Jin et al., 
2008; John et al., 2010; Płóciennikowska et al., 2015; Kim et al., 2017).  
The dimerization of the receptor complex induces the assembly of TIRAP, MyD88, and 
IRAK kinases in a myddosome at the TIR domain of TLR4 prompting a signaling 
pathway leading to production of pro-inflammatory cytokines (Kawai & Akira, 2010; 
Kainu, 2012; Płóciennikowska et al., 2015; Kim et al., 2017).  
After endocytosis, TRAM and TRIF associate with TLR4 triggering a signaling pathway 
which controls production of type I interferons and some other cytokines as shown in 
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figure 2. CD14 is a cell surface GPI-anchored protein that lacks a transmembrane domain 
and thus lacks the capability to directly initiate intracellular signaling events (Kim et al., 
2007; Kawai  et al., 2010; Kennedy et al., 2011; Płóciennikowska et al., 2015; Kim et al., 
2017).  
In addition, MD2 is a secreted glycoprotein which is a crucial extracellular adaptor 
molecule for LPS-initiated signaling events, possibly by aiding in ligand recognition 
(Shimazu et al., 1999; Kim et al., 2007; Kim et al., 2017). The discovery of the role of 
TLRs has significantly advanced the field of innate immunology and was honored with 
the Nobel Prize to Jules Hoffmann and Bruce Beutler in 2011.  
Beutler’s group first revealed that TLR4 is activated by lipopolysaccharide (LPS, 
endotoxin) (Figure 3) (Płóciennikowska et al., 2015). It was revealed that when the 
intracellular signaling pathway of constitutively active TLR4 in Jurkat cells is activated, 
a transcription factor, nuclear factor kappa B (NF-ΚB) is activated (Medzihtov et 
al.,1997; Lee et al., 2006; Jin et al., 2007; Kim et al., 2017). These findings have led to 
the assumption that human TLR4 played a vital role in this early stage of the induction of 
innate immunity.  
While TLR4 is the LPS receptor, ligands for the other TLRs have been discovered. TLR2 
is mainly responsible for Gram-positive cell-wall structures recognition (Takeuchi, 1999; 
Takeuchi et al., 1999; Yoshimura et al., 1999; Lucero et al., 2004; Lu et al., 2008; 
Takeuchi & Akira, 2010), while TLR5 is the receptor for flagellin recognition (Hayashi 
et al., 2001; Takeda et al., 2003) and TLR9 is responsible for recognition of coupled 
protein G (CpG) elements in bacterial DNA (Takeshita et al., 2001; Takeda et al., 2003; 
Kumar et al., 2011; Packiriswamy et al., 2013).  
Then, the activated MyD88/MAL activates IRAK4, TRAF6, TAK1, and IKK complexes, 
while TRIF/TRAM signals by RIP1 to TRAF6/TAK1 and IKK. Next, both these 
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pathways unite at NF-κB (Luo et al., 2003; Lu et al., 2008; Takeuchi & Akira, 2010; 
Płóciennikowska et al., 2015).  
The cytoplasmic NF-κB complex is retained in the inactive state through IκB that is in 
turn degraded via proteasomes, resulting in the translocation of NF-κB into the nucleus. 
Moreover, activating NF-κB, TAK1 also phosphorylates MAPKs to further reinforce the 
inflammatory response (Figure 3) (Ninomiya-Tsuji, 1999; O'Neill, 2006; Carmody et al., 
2007; Boomer et al., 2014; Płóciennikowska et al., 2015) 
However, the TRIF/TRAM pathway triggers IRF3 to mount an antiviral response. As a 
conclusion, all these signaling pathways contribute to eradicating infection and play an 
important role in sustaining the normal physiological functions in intestinal epithelial 
cells as well (Yesudhas et al., 2014; Płóciennikowska et al., 2015).  
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Figure 3. Initiation of TLR4 signaling pathway mediated by LPS. 
 
LPS is bonded to the LBP, to bring the LPS to the cell membrane surface via forming 
LBP-LPS complex, this complex then, jointed the membrane-bound CD14, CD14 which 
is binding to the extracellular domain of TLR4-MD2 complexes, then followed by TLR4 
oligomerisation and activation of the signaling cascade pathway through either the 
endocytosis or MyD88-dependent pathway to control the synthesis of which controls 
production of type I interferons and proinflammatory cytokines.  (Figure adapted from 
(Płóciennikowska et al., 2015). 
 
  
MD2 
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Furthermore, the TLR4 signaling cascade originated following LPS binding is boosted 
by homodimerization of the receptor (Zhang et al., 2002; Lu et al., 2008; 
Płóciennikowska et al., 2015). Then, the signal propagation involves recruitment of 
cellular adaptor molecules for TLRs such as myeloid differentiation factor 88 (MyD88), 
MyD88 adaptor-like protein (Mal), which is termed TIRAP, TIR-containing adaptor 
inducing interferon (IFN) β (TRIF), that is known as TIRAP-1 (TICAM-1), and TRIF-
related adaptor molecule (TRAM), also termed TIRAP-2 (TICAM-2). Kinases including 
IRAKs and MAPKs as well (Lee et al., 2006; Kim et al., 2017).  
Moreover, the TLR4 activation leads to induction of both a MyD88-dependent and a 
MyD88-independent pathway. The main players involved in eliciting the functional 
effects of LPS are activated via the NF-κB, mitogen-activated protein kinase (MAPK) 
and phosphatidylinositol 3-kinase (PI3K)/Akt pathways. These pathways controlled the 
equilibrium between cell viability and inflammation (Dauphinee & Karsan, 2006; Lee et 
al., 2006; Jin et al., 2007; Kim et al., 2017).  
Furthermore, the TLR signaling pathway is initiated by MyD88-dependent signaling 
pathway that is used by all TLRs except TLR3. Then, the signaling through the MyD88-
dependent pathway leads to the MAPK and IKK complex activation resulting in 
activation and nuclear translocation of AP-1 and NF-κB, respectively. In this step, the 
TLR4 is capable of signaling via the MyD88-independent pathway as well. The MyD-88 
pathway this is the single signaling mechanism for TLR 3(Jin et al., 2007; 
Płóciennikowska et al., 2015).  
In addition, TRIF is the main adaptor protein in the MyD88-independent pathway and 
can be associated with TRAF6 to activate AP-1 and NF-κB. On the other hand, it also 
activates NF-κB by interacting with RIP-1. TRIF could further interact with TRAF3 and 
the phosphatidylinositol 3-kinase (PI3K)- KT pathway resulting in the nuclear 
translocation of IRF3 and IRF2, respectively (Figure 4) (Jin et al., 2007).  
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The stimulation of macrophages with LPS results in rapid changes in the expression of 
genes encoding cytokines and other inflammatory mediators. The numerous cytokines 
released from macrophages exert diverse cellular effects and they are essential to the 
inflammatory process in sepsis (Flad et al., 1993; Rietschel et al., 1994; Cowdery et al., 
1996; Brunialti et al., 2006; Płóciennikowska et al., 2015; Kim et al., 2015).  
The excessive, sustained and uncontrolled activation of macrophages in sepsis leads to a 
vicious cascade of inflammatory mediator release that amplifies the inflammation to the 
detriment of the host (Rangel-Frausto et al., 1995; Kim et al., 2007; Płóciennikowska et 
al., 2015).   
Furthermore, the pro-inflammatory activity of TLR4 is related to pathological responses 
to endogenous ligands in autoimmune disorders and chronic inflammatory conditions 
associated with the development of atherosclerosis, neurodegenerative diseases, and 
others, which fuels interest in TLR4 signaling (O’Neill et al., 2009; den Dekker et al., 
2010; Trotta et al., 2014).  
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Figure 4. TLR2, TLR3, and TLR4 Signaling Pathways. 
Lipoproteins and LPS were recognized on the cell surface by a heterodimer of TLR1/6 
and TLR2, and via 2 sets of TLR4/MD2 complexes, respectively. TLR signaling pathway 
is initiated by MyD88-dependent signaling pathway that is used by all TLRs except TLR 
3. The signaling through the MyD88-dependent pathway leads to the MAPK and IKK 
complex activation resulting in activation and nuclear translocation of AP-1 and NF-κB, 
respectively. TRIF is the main adaptor protein in the MyD88-independent pathway and 
can be linked with TRAF6 to activate AP-1 and NF-κB. However, it also activates NF-
κB by interacting with RIP1. While TRAF3 is responsible for phosphorylation of IRF3 
by TBK1/IKK-i. NAP1 and SINTBAD were required for the activation of TBK1/IKK-i. 
Phosphorylated IRF3 trans-located into the nucleus to induce expression of type I IFN 
genes (Figure adapted from Jin et al., 2007). 
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1.3.3. NOD- Like receptors (NLRs). 
Nucleotide-binding oligomerisation domain (NOD) -Like receptors (NLRs) are important 
elements of innate immunity which have been detected in species as simple as sea urchins. 
Additionally, NLR- like proteins were observed in plants and they were functionally and 
structurally similar to the mammalian one (Lespinet et al., 2002; Ogura, et al., 2003; 
Martinon & Tschopp, 2005; Hibino et al., 2006; Proell et al., 2008; Laing et al., 2011; 
Lange et al., 2011). NLRs are cytosolic receptors which are expressed predominately by 
macrophages and dendritic cells. To date, in humans, 23 NLRs are described and 33 once 
in mice.  
Generally, NLRs are a cytoplasmic PRR family containing three domains: C- terminal 
region a leucine –rich repeats (LRR) domain that utilised for the ligand sensing, the 
central nucleotide domain NATCH (well-known as NOD) which is required for the self-
oligomerisation as well as activation, and the effector domain at the N-terminus that 
contained either the caspase recruitment domain (CARD) or the pyrin domain (PYD) 
which is mediated interactions with other signaling proteins (Kanneganti et al., 2007) 
(Figure 5). 
The TLRs, LRR structures in NLRs are essential to the recognition of PAMPs, but direct 
evidence of the interaction with identified NLR-agonists has not yet been demonstrated.  
The fundamental central nucleotide domain, NATCH is sharing structural similarities 
with the dominant motif of apoptotic protease-activating factor 1, that promotes formation 
of oligomeric structures. Consequently, a parallel mechanism has been suggested for the 
formation of the NLR inflammasomes platform (Martinon & Tschopp, 2004; Faustin et 
al., 2007; Church et al., 2008; Moher et al., 2009; Conforti-Andreoni et al., 2011). 
Martinon et al., (2002) have described the multi-protein cytoplasmic complexes which 
are facilitating the proinflammatory caspases activation, termed inflammasomes.  
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NALP subfamily of NOD family which has 14 members, each processed a PYD domain 
(Tschop et al., 2003; Murray, 2009; Conforti-Andreoni et al., 2011). Numerous NALPs 
are shown to form inflammasomes after activation led to processing IL-1β (Figure 5). 
Three inflammasomes have been identified according to the NLR protein they engage: 
the NLRP1, NLRP3 and IPAF inflammasomes. Inflammasomes complex formation led 
to the recruitment of ASC, ASC contained both the CARD and PYD domains, which is 
mediating docking of other CARD-containing proteins into inflammasomes, for example, 
caspase-1.  
Therefore, the recruitment and activation of caspase-1 lead into the processing of the IL-
1β pro-form (Figure 5) (Martinon et al., 2004; Mariatthasan et al., 2004; Mariatthasan et 
al., 2006; Masters et al., 2011; Brown et al., 2011). Inflammasome complex formation is 
leading to ASC recruitment. Then ASC is containing both the CARD and the PYD 
domains as well, would mediate docking of other CARD-containing proteins into 
inflammasome, like caspase-1. Then, caspase-1 recruitment and activation will lead to 
the performing of the IL-1β pro-form which is revealed to another possible mechanism 
of action of immune response toward sepsis through the formation of inflammasomes 
complexes and the processing and releasing of pro-form of IL-1β and IL-18 by NOD1 
and NOD2 which is recognising the bacterial molecules that involving in peptidoglycan 
metabolism (Agostini et al., 2004; Mariatthasan et al., 2006; Ogura et al., 2006; Brown 
et al., 2011). While the stimulation of TLR will induce the activation of NF-κB which 
will lead to pro-IL-1β production (Brown et al., 2011). 
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Figure 5. NOD signaling pathways. The NLR family is possessing various effector 
domains which is altering protein interactions. Moreover, the NOD and IPAF subfamily 
has a CARD effector domain, but the NALP subfamily is possessing a PYD domain. It 
showed different mechanism of action of the immune responses depending on the 
causative agents which lead to inflammasomes complexes formation and release of 
cytokines (pro-IL-1β) in presence of NOD1 and NOD2 that recognise the bacterial 
molecules involving in peptidoglycan metabolism, for example, IE-DAP as well as MAD. 
While numerous NALPs could form the inflammasomes on activation leading to IL-1β 
processing. The IPAF-dependent activation of caspase-1 could be induced by the flagellin 
from Salmonella and Legionella. While Anthrax toxin and MAP could activate caspase-
1 in NALP- dependent pathway. (Figure adapted from Brown et al., 2011). 
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1.4. Proinflammatory cytokines. 
Cytokines are host response regulators toward normal and pathological environments for 
instance, infection, immune responses, inflammation, and trauma. Some cytokines act as 
proinflammatory, whereas others act anti-inflammatory to reduce inflammation and 
promoting healing. In the human body, cytokines have been intended to prompt biological 
effects in their local microenvironment where they were produced after exposing to 
pathological infections. In normal tissues, the incidence of cytokine-mediated tissue 
damages is mainly due to highly regulated cytokines release. in addition, excessive 
cytokine secretion from the activated cells through LPS for instance resulting in a local 
tissue damage (Beutler et al., 1986; Dinarello & Wolff, 1993, Shimazu et al., 1999; 
Płóciennikowska et al., 2015; Kim et al., 2017). 
 
1.4.2. Tumour Necrosis Factor Alpha (TNF-α). 
TNF-α is a proinflammatory cytokine released via a number of cells including activated 
macrophages or T-cells as a response to invading microbes or other agents. TNF-α plays 
an essential role in an inflammation initiation in lungs and other tissues (Driscoll et al., 
1997). TNF-α is a key mediator in sepsis development (Tracy & Cerami, 1994; Lee et al., 
2006; Płóciennikowska et al., 2015; Kim et al., 2017). It is one of the most essential 
mediators of the inflammatory diseases, in which it is increasing in some pathogenic 
conditions and potential toxic effects, that resulting in hypersensitivity reactions with 
chronic inflammation (Morrison et al., 1994; Levine et al., 1990; Lee et al., 2006; Kim 
et al., 2017). 
The encoding gene for TNF-α is located on chromosome 6. TNF-α is a proinflammatory 
cytokine released by a number of cells including activated monocytes and macrophages. 
TNF-α is one of the TNF family of ligands that signals by two receptors, TNFR1 and 
TNFR2. TNF-α is cytotoxic to numerous cancer cells and considered a vital factor in 
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mediating the immune response against the bacterial infections (Curtis et al., 2007; Lee 
et al., 2006; Kim et al., 2017).  
Although, TNF-α plays a crucial role in in the activation of innate response. The excessive 
production of TNF-α could initiate pathological changes subsequently from chronic 
inflammation and tissue damage. The TNF-α increasing levels could also play a role in 
the inflammation stimulation as well as septic shock, moreover, in the pathogenesis of 
several chronic diseases such as auto-immune diseases, rheumatoid arthritis (Kodama et 
al., 2005), and diabetes (Shiau et al., 2003).   
 
1.4.3. Interleukin-1. 
IL-1 is an effective intercellular mediator which is involved in inflammatory and 
immunological responses.  
It is induced by monocytes and macrophages during antigen presention and in response 
to a variety of other stimuli including endotoxin (Dinarello & Thompson, 1991; 
Płóciennikowska et al., 2015). The gene for IL -1α and β are located on chromosome 2. 
IL-1α is one of the interleukin 1 family that is synthesised by induced macrophages, 
neutrophils, epithelial cells, endothelial cells and monocytes.  
IL-1β can promote pathogenesis of disorders associated with tissue damage, for instance, 
inflammasome mediated IL-1β over-production which is involved in the pathogenesis of 
type 2 diabetes, liver damage and muscular dystrophy (Rawat et al., 2010; Masters et al., 
2010; Tsutsui et al., 2010). IL-1β is involved in the early pathogenesis and the continued 
severity of a broad pattern of diseases, many arthritic diseases and septic shock (Dinarello, 
2009).  
While IL-1α is pyrogenic during an inflammatory response (Dube et al., 2001) and it has 
multi-inflammatory response controlling functions. Ingeborg et al., (1996) suggested that 
fibroblasts could be involved in turning off the inflammatory response (IL-1α releasing 
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through the activated keratinocytes could act as stimulator for the expressing and 
releasing of IL-8 and IL-6 yield) by reducing IL-1 levels, most, likely through IL-1 
receptor-mediated uptake. 
 
1.4.4. Interleukin-8. 
Interleukin-8 (lL-8) was discovered in 1987 as a novel type of neutrophil activating 
proinflammatory cytokine which is acting as a chemotactic component and an activator 
 to neutrophils, basophil and T-cells (Mukaida et al., 1997) at the inflammation site when 
its released by monocytes and macrophages due to the inflammatory stimulants 
(Baggiolini et al., 1989, Baggiolini and Clark-Lewis, 1992).  
IL-8 is generated in response to inflammatory stimuli containing the proinflammatory 
cytokines IL-1 (Eckmann et al., 1993b) and TNF (Li et al., 2002), and cellular stress 
(Shapiro and Dinarello, 1995), bacterial (Eckmann et al., 1993a) and viral products 
(Mastronarde, 1998). Moreover, it has been proposed that the polymorphism of these 
genes is accompanied with rheumatoid arthritis (Troughton et al., 1996) and Alzheimer's 
disease (Vendramini et al., 2007).  
 
1.4.5. Peroxisome proliferator-activated receptors –gamma (PPAR-γ), 
Cyclo-oxygenase enzymes (COX-2), iNOS and CD206.    
Peroxisome proliferator-activated receptors –gamma (PPAR-γ) is one of the three 
members of the subfamily of ligand-dependent nuclear receptor (NR) transcription factors 
which regulated lipid metabolism, glucose homeostasis, tumor progress and inflammation 
(Evans, 1988; Blumberg and Evans, 1998; Mukherjee et al., 1997; Elbrecht et al., 1996; 
Crosby et al., 2005; Bouhlel et al., 2007; Chawla et al., 2010).    
Karp et al., (1991) documented that during the development of sepsis, the monocytes/ 
macrophages shown a hyper-inflammatory status that last from hours to days, after which 
their status is shifted to lower-inflammatory conditions considered by stimulation with 
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LPS in vitro. Necela et al., (2008) revealed that TLR4 mediate crosstalk between PPARγ 
and NF-KB in macrophage. 
Mueller et al., (1998) revealed that PPARγ are crucial in a diversity of biological 
processes, consists of; adipogenesis, glucose metabolism, and inflammation. Additional 
difficulties in interpretation of studies of PPAR ligands is that some act via both PPAR-
dependent and PPAR-independent pathways (Crosby et al., 2005; Croasdell et al., 2015; 
Assunção et al., 2017). 
The PPARγ antagonist, the synthetic compound, 2-chloro-5-nitro-N-4-pyridinylben-
zamide (T0070907) that is bonded with PPARγ, but has no capability to stimulate the 
transcriptional action of PPARγ, rather antagonised PPARγ agonised to trigger 
transcriptional and adipogenic actions of this receptor (Wright et al., 2000; Yoshikai, 
2001; Funk, 2001; Croasdell et al., 2015).  
Prostaglandins (PGs) are produced from arachidonic acid which is released from cell 
membrane by phospholipase A2 and then altered by the cyclooxygenase enzymes (COX-
1 and COX-2) to enter the PG pathway (Yoshikai, 2001; Funk, 2001; Choi et al., 2005; 
Chien et al., 2013).  
Funk, (2001) revealed that COX-1 is constitutively active, while COX-2 is induced under 
inflammatory situations. COX-2-derived PGs are involved in a diversity of pro- and anti-
inflammatory progressing (Funk, 2001; Matsuoka & Narumiya, 2008).  
The involvement of COX-1 and COX-2 in controlling inflammation is proved via the 
increased cardiovascular risk connected with the inhibition of COX-2 (Choi et al., 2009; 
Cannon & Cannon, 2012).  
Fredenburgh et al., (2011) revealed that COX-2 associated with increased intestinal 
epithelial permeability and leads to exaggerated bacterial translocation and raised 
mortality during peritonitis-induced sepsis. Their results have also suggested that 
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epithelial expression of COX-2 in the ileum is a vital modulator of tight junction protein 
expression and intestinal barrier function during sepsis. 
NF-κB pathway is also well known as the major transcription factor for most 
inflammatory mediators, for instance, inducible isoform of nitric oxide synthase (iNOS), 
COX-2, ICAM-1 (Barnes and Karin, 1997; Chu et al., 1998; Yamamoto and Gaynor,  
2001, Ye,  2001; Corrêa et al., 2007; Reuter et al., 2010).  
Kilburn &Griffith, (1992) stated that the bacterial infection or immunological stimuli 
such us LPS, IFN-γ or IL-1 is causing the expression of iNOS that, when it expressed, 
producing excessive amount of nitric oxide (NO). Rees et al., (1990) reported that the 
excess NO production via macrophages and other cells which were exposing to endotoxin 
might contribute to septic shock, cerebral injury (Dawson et al., 1993), myocardial 
ischemia (Matheis et al.,1992), local inflammatory disorders such as polyarthritis, 
osteoarthritis or systemically, for instance, diabetes, arteriosclerosis (AS), and other 
diseases (Stefanovic-Racic et al., 1993; Connor et al., 1995; Wu & Thiemermann, 1996; 
Corrêa et al., 2007). The network  of M1 and M2 phenotying shifting in magrophages 
due to different microbial stimuli (Green et al., 2013; Martinez & Gordon, 2014) is shown 
in the schematic figure 6.  i.e. this project hypothesed that the over-expressed LPCAT-2 
might promote murine macrophages into M1 by upregulating iNOS (M1-marcophage 
phenotype marker), COX-2 and down regulating CD206 (M2-marcophage phenotype 
marker) and the opposite picture when the LPCAT-2 expressed gene is knocked down.   
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Figure 6. Schematic picture of the network of M1/M2 – macrophage polarization.  
 
Shows the M1 and M2 characteristic products and functions. Adapted from Martinez & 
Gordon, 2014; Green et al., 2013. Immunol.; 190: 270 -277. 
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1.5. Phospholipid metabolism and Cell membranes. 
1.5.1. Phospholipid turnover. 
The bio-membrane lipid bilayer serves as a vital structure that classifies living cells and 
forms organized intracellular membrane organelles for numerous physiological functions.  
The primary and key structural components of membrane lipid bilayers are phospholipids 
(PLs) including phosphatidylcholine (PC), phosphatidylserine (PS), and phosphatidyl-
ethanolamine (PE) with phosphatidylcholine being the most abundant in mammals (Zhao 
et al., 2008). Phospholipids form a membrane system that provides the cell with a 
protective barrier which has selective permeability for different metabolites.  
Within the cell, phospholipids are the major constituents of an essential membrane system 
which delineates individual organelles and provides an individually ordered system for 
intracellular metabolic processes (Choy et al., 1997). In addition, the fatty acid 
composition of phospholipids is key to the many different roles that these molecules 
impart to the cell membrane as membrane curvature, fluidity and dynamics are essential 
for the normal functioning of cells.  
Phospholipid composition is controlled by two major pathways: The de novo pathway 
and the remodeling pathway. Through the use of Acyl-Coenzyme A (CoA’s) and Sn-3-
Glycerophosphate, phospholipids may be formed from diacylglycerol by the de novo 
pathway, originally described in 1956 (Kennedy and Weiss, 1956). 
The acyl groups in glycerophospholipids show a great diversity and are distributed in an 
asymmetrical way. The saturated and the monounsaturated fatty acids are usually 
esterified at the sn-1 position, while the polyunsaturated acyl groups, including those 
contained in arachidonic acid, are located at the sn-2 position. Furthermore, the 
‘Kennedy’ pathway does not fully explain this diversity and asymmetry.  
Therefore, the rapid and continuous replacement of the sn-2 acyl moiety of 
glycerophospholipids has been described by Lands as a remodeling pathway (Lands’ 
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cycle) (Lands, 1958). In the Land’s cycle, it is the concerted activation of phospholipase 
A2s (PLA2s) that remove fatty acyl groups from the sn-2 position and lysophospholipid 
acyltransferases (LPLATs) that replace fatty acyl moieties at these positions that control 
the phospholipid composition. For the most abundant phosphatidylcholine, it is 
lysophosphatidylcholine acyl-transferase (LPCAT) enzymes that re-acylate the 
lysophosphatidylcholine and are key to the PC membrane composition. (Hishikawa et al., 
2008) (Figure 7& 8). 
The activity of LPCAT is found to reside primarily in microsomal fractions of tissues and 
recognition of the activity of this group of enzymes using microsomes from different 
tissues which has been led to the hypothesis that multiple forms of enzymes may exist in 
diversity of tissues with different substrate specificity of fatty acyl-CoAs (Choy et al., 
1997).  
There were attempts to purify the enzyme(s) which have not been successful mainly due 
to their membrane protein nature and the fact that LPCAT activity was typically lost 
during solubilisation and/or further fractionation (Zhao et al., 2008). However, by 
applying genomic methods, LPCAT1 (the first in this family of enzymes) has been 
successfully cloned and characterised by two independent groups (Chen et al., 2006; 
Nikanishi et al., 2006) which then paved the way for cloning and characterisation of three 
more enzyme isoforms with LPCAT activity: LPCAT-2, LPCAT3 and LPCAT4. 
Nakanishi et al., (2006) identified and characterised a mouse lung-type LPCAT expressed 
in alveolar type II cells. While Chen et al., (2006) and Shindou et al., (2007) have 
identified and characterised a LPCAT in alveolar type II cells termed LPCAT1. LPCAT 
enzyme played a critical role in the regulation of surfactant phospholipid biosynthesis. 
1.5.2. The LPCAT family of enzymes. 
The LPCAT enzymes, so far characterized, are found in specific locations, demonstrate 
preference for certain types of fatty acids and validating enzyme activities (Shindou et 
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al., 2009). LPCAT1 has both acyltransferase and acetyltransferase activities and its 
activity is calcium-independent. Moreover, it has been mediated the conversion of 1-acyl-
sn-glycero-3-phosphocholine (LPC) into phosphatidylcholine (PC). It is shown a clear 
preference for saturated fatty acyl-CoAs as well as 1-myristoyl or 1-palmitoyl LPC as 
acyl for both donors and acceptors, respectively. 
Furthermore, the dipalmitoylphosphatidylcholine synthesis has been found in pulmonary 
surfactant, thus playing a vital role in respiratory physiology (Bridges et al., 2001; Chen 
et al., 2006; Nakanishi et al., 2006).  LPCAT-2 also displays acyltransferase and acetyl-
transferase activities. However, unlike LPCAT1, its activity is calcium-dependent. It has 
been revealed to be involved in platelet-activating factor (PAF) biosynthesis through 
catalysing the conversion of the PAF precursor, 1-O-alkyl-sn-glycero-3-phosphocholine 
(lyso-PAF) into 1-O-alkyl-2-acetyl-sn-glycero-3-phosphocholine (PAF). It also changes 
lyso-PAF to 1-O-alkyl-2-acyl-sn-glycero-3-phosphocholine (PC), which is a key 
component of cell membranes and a PAF precursor.  
In addition, acyltransferase activity is preferred in inactive conditions (Figure 4). On the 
other hand, upon the acute inflammatory stimulus, the acetyltransferase activity has been 
heightened and PAF production is increased (Shindou et al., 2007). Additionally, it 
catalyses the transformation of 1-acyl-sn-glycero-3-phosphocholine to 1,2-diacyl-sn-
glycero-3-phospho-choline (Agarwal & Garg, 2010; Moessinger et al., 2011). 
LPCAT3 and LPCAT4 from the membrane bound O-acyltransferase (MBOAT) family 
LPCAT3 (called MBOAT5) has been discovered by two independent groups (Hishikawa 
et al., 2008; Zhao et al., 2008). 
 LPCAT3 is active in mediating 1-O-alkyl-sn-glycero-3-phosphocholine acylation within 
a long chain fatty acyl-CoAs to produce 1-O-alkyl-phosphatidylcholine, a very crucial 
constituent of the cell membrane systems of mammals (Kazachkov et al., 2008). The 
enzyme is normally localised to the endoplasmic reticulum and most richly expressed in 
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the liver, pancreas and adipose tissues. The overexpression of LPCAT3 in tissue culture 
has been established to increase the amount of phospholipids within a relatively more 
saturated acyl chains. However, its inhibition has also been established to result in a rise 
in the amount of phospholipids with more unsaturated acyl chains (Jain et al., 2009). 
Vitally, the preferred substrate of LPCAT3 is unsaturated fatty acyl-CoAs which is 
appears to be the only enzyme in the liver responsible for this function (Zhao et al., 2008).   
LPCAT4 is abundantly expressed in the brain, equivalent to the richness of 
phosphatidylethanolamine in this tissue. Mouse LPCAT4 mRNA has been highly 
expressed in the epididymis, brain, testis, and ovary (Shindou et al., 2009).  
In addition, LPCAT4 displays a significant Acyl-CoA-dependent acyltransferase activity 
toward 1-O-alkenyl-lysophosphatidylethanolamine, Lysophosphatidylglycerol, 1-O-
alkyl-lysophosphatidylcholine, Lysophosphatidylserine, as well as Lysophosphatidyl-
choline.  
Although, it lacked vital acylation activity toward glycerol 3-phosphate, lysophosphatidic 
acid, glycophosphatidylinositol, and diacylglycerol as well, that has been shown several 
but selective functions of LPCAT4 as an enzyme involved in phospholipid remodeling 
(Cao et al., 2008).  
Its activity was not affected by Calcium. While the over-expressed in mammalian cells, 
LPCAT4 is seen to be localized to the endoplasmic reticulum (Cao et al., 2008) (Figure 
10 Appendix 1). 
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Figure 7. Glycerophospholipids biosynthesis Pathways. The Kennedy pathway (de 
novo pathway). 
 
Is the initial synthesis of glycerophospholipids while they are then modified through the 
remodeling pathway (Lands' cycle). Red and blue arrows indicate acyltransferases and 
PLA2s, respectively. G3P, glycerol 3-phosphate; TAG, Triacylglycerol; DAG, 
Diacylglycerol; LPA, Lysopho-sphophosphatidic acid; PC, Phosphatidylcholine; LPC, 
lyso-PC; PAF, Platelet activating factor, Adapted from Shindou and Shimizu, 2009. Biol. 
Chem.; 284:1-5. 
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Figure 8, Land Cycle (the remodeling pathway) Membrane phospholipids  
 
Are remodelled through the concerted actions of phospholipase A2 (PLA2) and 
lysophospholipid acyltransferases. In the case of phosphatidylcholine (PC), PLA2 
removes a fatty acyl group from the sn-2 position to produce lysoPC and this is replaced 
by a different fatty acyl group (shown in green) by LysoPC acyltransferase (LPCAT) 
utilising fatty acyl-CoA as donor. This continuing cylcle allows the compostion of 
phospholpids to be remodelled for different cellular functions. Adapted from Jackson  & 
Parton (2004). Immunobiol.; 209:31-38. 
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1.5.4. LysoPAF Acetyltransferase activity. 
The amino acid residues of LPCAT1 which are essential for each activity (LPC-
acyltransferase or lyso-PAF acetyltransferase activity) were recognized by site-directed 
mutagenesis. Furthermore, the LPCAT1 remodeling pathway for PAF synthesis has been 
found to be non-inflammatory/constitutive (Harayama et al., 2008; Morimoto et al., 2010; 
Morimoto et al., 2014). 
Furthermore, LPCAT-2 (also termed LysoPAFAT), has been found to catalyse both PAF 
and PC synthesis which occurs mainly in inflammatory cells. Thus, a single enzyme 
catalyses membrane LPC-acyltransferase activity of inflammatory cells, whilst, 
producing PAF (lyso-PAF acetyltransferase activity) in response to external stimuli 
(Morimoto et al., 2010; Morimoto et al., 2014).  
Therefore, this activity of LPCAT-2 enzyme is inducible and activated by inflammatory 
stimulation in contrast to that of LPCAT1 which is constitutive (Shindou et al., 2007; 
Harayama et al., 2008; Morimoto et al., 2010, Morimoto et al., 2014). The lyso-PAF 
acetyltransferase activity is shown in the reaction below (Figure 9). 
  
  
 38 
 
 
 
Figure 9. The acetyltransferase activity of the LPCAT-2/LPAFAT enzyme. 
 
Both LPCAT1 and LPCAT-2 have lyso-PAF acetyltransferase activity by which PAF is 
biosynthesized via the de novo pathway (under physiological conditions i.e. non-
inflammatory) or remodeling pathway (inflammatory conditions). However, this figure 
shows the   remodeling pathway (inflammatory conditions), alkyl-PC is cleaved at sn-2 
position via cystolic Phospholipase 2α (cPLA2α) (under inflammatory conditions), 
generating the lyso-PAF(alkyl-LPC), then, PAF is biosynthesized from lyso-PAFthrough 
lyso-PAF acetyltransferase (LPAFAT/LPCAT-2). (Figure taken from 
Lipidlibrary.aocs.org, 2015). 
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1.6. The biological roles and expression of LPCAT in pro and anti-
inflammatory processes. 
Lysophosphatidic acid and lysophosphatidylcholine have been associated with a number 
of a different biological activities from blood vessel development to myelination. The use 
of lysophospholipid by acyltransferase is likely to be essential in the regulation of their 
availability and hence activity (Jackson et al., 2008b).  
 
1.6.1. Inflammatory cells. 
The enzymes have been found to play a part in the control of arachidonate levels in 
inflammatory cells. Studies have been suggested that the initial incorporation of 
arachidonic acid into 1-acyl-2-1yso-GPC of these cells involves a CoA-dependent 
acyltransferase activity which is selective for 1-acyl-linked phospholipids (Chilton et al., 
1996). It has also been shown that both CoA-dependent and CoA-independent 
acyltransferases have an important in activation of macrophage (Jackson, 1997).  
Additionally, the phosphorylation of LPCAT-2 at Ser34 enhance platelet-activating factor 
production in endotoxin-stimulated macrophages (Morimoto et al., 2010; Morimoto et 
al., 2014). Several studies have reveal that the enzymes might mediate both the initiating 
reactions and the inflammatory response of monocytes to cytokine interferon-gamma 
(Jackson and Parton, 2004 and Schmid et al., 2003).  
IFN-gamma cause a significant rise in the activity of the LPCAT and CoAIT enzymes in 
the microsomal fraction of human monocyte cell line MonoMac 6 (MM6), at 
concentrations and over a time-course consistent with a significant role for these enzymes 
in the sensitization of monocytes, thereby revealing the evidence to highlight the role of 
acyltransferases as part of the molecular mechanism underlying inflammation (Neville et 
al., 2005). 
Morimoto et al.,(2010) have attempted to find out which kinase is related to LPS-induced 
phosphorylation of LPCAT-2 by using inhibitors and siRNA against mitogen-activated 
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protein kinases (MAPK) cascades which verified that LPCAT-2 phosphorylation through 
LPS-TLR4 signaling that may directly depend on MAPK-activated protein kinase 2 
(MAPKAP kinase 2 or MK2).  
Their findings indicated that under LPS stimulation, LPCAT-2 phosphorylation depended 
on the MyD88 (myeloid differentiation primary response gene 88), TAK1, p38α, and 
MK2 signaling pathway.  
Furthermore, the only phosphorylated site of LPCAT-2 that enhanced its catalytic 
activities was Ser34 (Morimoto et al., 2010). Lipopolysaccharide (LPS) (Jackson & 
Parton, 2004).  
LPCAT-2 has been recognized as the long-sought lyso-PAF acetyltransferase which is 
involved in PAF biosynthesis within the remodeling pathway. Therefore, its expression 
is mainly detected in inflammatory cells such as peritoneal macrophages and stimulation 
and activation of LPCAT-2 is regulated by LPS (Shindou et al., 2013).  
Furthermore, investigation of PAF by Lyso-PAF acetyltransferase (Lyso-PAFAT) which 
have been proposed that one (LysoPAFAT/LPCAT-2) is inducible and activated by 
inflammatory stimulation, and the other (LPCAT1) is constitutively expressed. In 
addition, each Lyso-PAFAT biosynthesises inflammatory and physiological amounts of 
PAF were depending on the cell type (Harayama et al., 2009). 
 
1.6.4. Lungs and surfactant production. 
The pulmonary surfactants are complexes of lipids and proteins most of which are formed 
and secreted by alveolar type II cells that provided the low surface tension at the air–
liquid interface. There have been significant evidences that the LPCAT enzyme is playing 
a key role in regulating the surfactant phospholipid biosynthesis in alveolar type II cells.  
Thus, this understanding of the regulation of the enzyme might provide key insights into 
surfactant phospholipid biosynthesis (Chen et al., 2006; Harayama et al., 2009). In 
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addition, the cloning and characterization of a cDNA for mouse lung-type LPCAT 
(LPCAT1) have further strengthened these indications. (Nikanishi et al., 2006).  
To investigate the role of LPCAT1 in surfactant production, Bridges and colleagues 
generated mice bearing a hypomorphic allele of LPCAT1 (here referred to as 
LPCAT1GT/GT mice).  
The newly-born LPCAT1GT/GT mice have been developed serious respiratory 
complications of different degrees resulting in the death of some of the animals. In 
addition, there was a substantial decline in LPCAT1 activity and saturated PC content in 
the same group. The surfactant that isolated from the dead LPCAT1GT/GT mice was 
unable to reduce minimum surface tension to the wild-type levels.  
Therefore, their taken together data has been showed that the full LPCAT1 activity is 
essential to the success of the levels of saturated PC which is required for the transition 
to air breathing (Bridges et al., 2010). 
 
1.6.5. Brain. 
The deacylation and reacylation cycle is a key mechanism responsible for the composition 
of polyunsaturated fatty acids into neural membrane glycerophospholipids (Kitson et al., 
2012).  
It four enzymes implication, specifically Acyl-CoA synthetase, Acyl-CoA hydrolase, 
Acyl-CoA: lysophospholipid acyltransferase, and phospholipase A2 (Kitson et al., 2012).  
These enzymes have been purified and categorized from brain tissue (Farooqui et al., 
2000). Furthermore, all the four LPCAT isoforms have been found to be expressed in 
brain tissue where they were involved in infant neurodevelopment and neurological 
diseases accompanying with aging such as Alzheimer's disease and cognitive decline 
(Kitson et al., 2012). 
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1.7. The LPCAT enzyme as a novel target for anti-sepsis therapy. 
Despite intensive research and advances in medical care and technology, there is currently 
no specific treatment for sepsis and mortality and morbidity continues to increase. (Paul 
et al., 2010; Winters et al., 2010; Wiens et al., 2012; Wiens et al., 2013; Wang et al., 
2013(a,b,c); Vincent et al., 2014; Wang et al., 2014(a); Nygard et al., 2014; Wang et al., 
2015; Shankar-Hari et al., 2016 Tsertsvadze et al., 2016) 
 In addition, a lack of responsiveness to antibiotics, new and emerging infections, drug 
resistance, as well as the high costs of drug discovery and manufacture have impacted on 
the lack of advancement for sepsis therapies.. Therefore new approaches to sepsis therapy 
including signal transduction pathways have been identified as an approach for new 
therapies against sepsis (Yan et al., 2006;  Schorr et al., 2007; O’Neill, 2006; Vincent et 
al., 2010; Phua et al., 2011; Wu et al., 2013; Vincent et al., 2014; Wong et al., 2015; 
Tsertsvadze et al., 2016; Rodriguez et al., 2016).  
Several studies have indicated the therapeutic potential of lysoPAF and lysoPC (LPC) in 
experimental models of sepsis and organ failure that suggest the potential role of LPCAT 
inhibition in the treatment of sepsis and possibly other inflammatory conditions (Yan et 
al., 2004; Murch et al., 2006; Nakanishi et al., 2006; Morimoto et al., 2010; Morimoto et 
al., 2014). While in vitro, LPC has been shown to increase the bactericidal activity of 
neutrophils by enhancing hydrogen peroxide production (Yan et al., 2004).  
LPCAT-2 also converts lyso-PAF to PC, which are a main component of cell membranes 
and a precursor of PAF. In addition, PAF production in the body is increased in response 
to extracellular inflammatory stimuli such as bacterial endotoxin (Servillo et al., 2006; 
Morimoto et al., 2010; Shindou et al., 2013; Stanca et al., 2013; Morimoto et al., 2014).    
In addition, Brown & Schmidt (2005) attempted to use acyltransferase inhibitors as 
probes to study the possible role of lysophospholipid acyltransferases in intracellular 
membrane transferring in the secretary and endolytic pathways has been put into view. 
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CI-976 has also been stated as a useful addition to the pool of small molecule inhibitors 
that could be used for studying secretary and endocytic membrane trafficking pathways.  
Jackson and colleagues showed that LPCAT regulates inflammatory responses to LPS 
and other microbial stimuli (Jackson et al., 2008a). They showed that inhibition of 
LPCAT resulted in inhibition of TLR4 translocation into membrane lipid raft domains. 
Their observations suggest a new regulatory mechanism that facilitates the innate immune 
response to microbial molecular patterns and has been suggested a possible pathway for 
the anti-inflammatory activity seen in many phospholipid metabolites.  
This delivered the possibility of the development of new classes of anti-inflammatory and 
antisepsis agents (Jackson et al., 2008a). Furthermore, LPCAT enzymes are potential 
targets for anti-sepsis therapies, Jackson and colleagues have used selective inhibitors for 
LPCAT recognised through high-throughput screening. 5 hydroxyethyl 5,3’ thiophenyl 
pyridine, a non-competitive specific inhibitor of CoA-dependent LPCAT has been 
identified as a promising candidate. 
 Also a cDNA sequence for LPCAT from human monocytes has been identified and this 
sequence is being used to develop inhibitory RNA sequences as potential LPCAT 
inhibitors (Jackson et al., 2008(a)). Inhibitory RNA sequences have the advantage of 
specificity over the chemical inhibitors, and for that reason, they were utilized for gene 
silencing in this research. LPCAT-2 unlike LPCAT1 is vital for stimulation of 
macrophage cytokine gene expression and release in response to stimulation of TLR2 and 
TLR4 through bacterial ligands; but not for TLR-independent stimuli. These findings 
were revealed by performing small interfering RNA (siRNA) knockdown (Abate & 
Jackson, 2015).  
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1.8. Experimental models.   
1.8.1. LPS and Pam3CSK4. 
This project has chosen LPS and Pam3CSK4 (C81H156N10O13S) (TLR4 and TLR2 
ligands respectively) as surrogate models of Gram negative or Gram-positive bacterial 
infections.  
As both Gram-negative and Gram-positive bacterial infections contribute almost equally 
overall to the incidence of sepsis, it was important to include molecular stimuli from both 
these bacterial classes in experimental models of inflammation and sepsis. LPS 
recognition and signaling has been detailed in sections 1.2 and 1.3. Pam3CysSerLys4 
(PAM3CSK4) is a synthetic tripalmitoylated lipopeptide that mimicks the acylated amino 
terminus of bacterial lipoproteins.  Pam3CSK4 is recognized by TLR2 and signals via 
TLR2/TLR1 heterodimers to activate NFkB pathways Which led to cell activation and 
apoptosis through bacterial lipoproteins by TLR2 (Aliprantisao et al., 1999; Ozinsky a. 
et al., 2000).  
Sepsis is induced by bacteria and bacterial products such as Lipopolysaccharides (LPS), 
Lipoproteins, peptidoglycan, which are recognised via pattern recognition receptors 
(PPR) such as CD14 and Toll like receptors (TLRs) (Aderen & Ulevich, 2000; Takeda & 
Akira, 2005). Bacterial products such as LPS (Rietschel et al., 1994, Van Amersfoot et 
al., 2000), and Pam3CSK4, which is a synthetic analogue of Gram-positive bacterial cell 
wall structures, induce over production of cytokines from key immune cells such as 
macrophages (Ozinsky et al., 2000; Soong et al., 2004) and this dysregulated over 
production of cytokines is at the centre of the pathophysiology of sepsis (Jackson et al., 
2008a).  
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1.8.2. Macrophages, the murine RAW264.7 cell line. 
Macrophages are prominent innate immune cells that recognize and respond to bacteria 
and their products. The activation of macrophages with LPS results in rapid changes in 
expression of genes encoding cytokines and other inflammatory mediators (Brunialti et 
al.,2006). This project has used the murine macrophage, RAW264.7 cell line as a model 
cell line to study the role of LPCAT-2 in inflammatory response to bacterial ligands.  
Moreover, several studies have used RAW264.7 cell line as a model for investigation of 
inflammatory responses, Chiou et al., (2000) have utilised RAW264.7 cell line to 
investigate the possible suppression mechanism of the inducible nitric oxide synthase 
(iNOS) expression in macrophages via Andrographolide.  
Huttunen et al., (2000) have also used RAW264.7 cells to study the inflammatory 
responses in macrophages that caused by Mycobacterial strains, which is isolated from 
mold-buildings. While Barthel et al., (2001) studied the effect of bovine natural 
resistance- associated macrophage protein gene 1 (bovine NRAMP1) gene on Brucella 
abortus survival by establishing a stable transfection of bovine NRAMP1 gene into 
murine RAW264.7 cells.  
Furthermore, Li et al., (2000) have investigated the possible mechanism of peroxisome 
proliferator-activated receptor gamma (PPAR-γ) –dependent suppression of the iNOS 
gene in murine macrophages by using 1 µg/ml of LPS. 
In addition, in 2002, Shiojiri and co-workers used RAW264.7 cells to explore the possible 
effects of PPAR-γ specific ligands, rosiglitazone or pioglitazone as suppressors for both 
nitro-tyrosine formation and the expression of inflammatory mediators in adjuvant-
induced murine rheumatoid arthritis (Shiojiri et al., 2002).  
Not only are RAW264 cells well validated as models of leukocyte responses to LPS and 
other bacterial ligands, they also providing ease of use for transfection experiments 
critical for the current investigation. Indeed, Shindou et al., (2007) used RAW264.7 cells 
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to overexpress LPCAT-2 for the first time and study its role as a catalyser of platelet-
activating factor (PAF) production.   
Jiang et al., (2004) in their investigation of the possible mechanisms of activation of 
macrophages (RAW264.7 cells) via transfected mammalian DNA, used calf thymus (CT) 
DNA, FuGENE 6 transfection reagent, RAW264.7 cells, Escherichia coli DNA (bacterial 
DNA) and LPS (Escherichia coli, strain 0111:B4, Sigma).  
Both Liu et al., (2007) and Iyer et al., (2010) investigated the mechanisms by which the 
gene expression of IL-10 could be regulated in macrophages, by using RAW264.7 cells 
and murine bone marrow- derived macrophages (BMDMs) as cell models and LPS 
(Escherichia coli, strain 0217:B8 or Escherichia coli, strain 055:B5, Sigma-Aldrish) (1 
µg/ml) as a stimulus.   
Xu et al., (2007) used RAW264.7 to investigate TLR4 as a sensor for autophagy 
associated with innate immunity while Giang et al., (2009) utilised RAW264.7 cells in a 
comparative study to demonstrate the inhibitory activity of Zeumbone and Zerumbone 
2,3-epoxide on NF-κB, and nitric oxide (NO). In studies on LPCAT characterisation, 
Morimoto et al., (2010) utilised RAW264.7 cells to investigate the LPCAT-2 
phosphorylation at Ser34 to enhance PAF production in endotoxin–stimulated murine 
macrophages. Tarui et al., (2014) utilised RAW264.7 cells and CHO cells stably 
expressing murine PAFR to investigate the effect of selective inhibition of the PAF 
biosynthetic enzyme LPCAT-2.  
Moreover, many of these studies have shown that RAW264 cells can be used to study in 
vitro effects that are also seen in vivo in the corresponding murine models. This is an 
important linkage for in vitro cell models. Shiojiri et al., (2002); Morimoto et al., (2010); 
Iyer et al., (2010); Luu et al., (2014) have all used mice as an animal model for the in 
vivo investigation as well as using RAW264.7 cell line as a model for the in vitro. 
However, showing similar effects in human leukocytes would be required before 
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extrapolating results to human conditions. However, it is difficult to transfect primary 
cells in addition to requiring ethical approval (Wilding & Bodmer, 2014).  
However, there are well-validated models of primary human leukocytes. For example, 
Mono Mac 6 (MM6) cells maintain many features of human monocytes and are 
continuously growing, but they are difficult to transfect (Moesby et al., 1999). Due to 
difficulty in transfecting MM6 cells and using siRNA techniques we developed for 
RAW264.7 cells, the current project did not repeat findings using this cell line.  
Previous work that used an activity assay and a pharmacological inhibitor of LPCAT, 
showed the presence of LPCAT in MM6 cells, and that it has an immuno-regulatory role 
(Jackson et al., 2008).  
 Very recently, Abate & Jackson, (2015) have used ShRNA techniques to show the same 
effects of LPCAT-2 knockdown in MM6 cells as occur in RAW264.7 cells. This result 
suggests that the results obtained in the current study would also occur in other monocyte 
and macrophage cells and probably in vivo.   
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1.8. Rationale for the study.  
Traditional treatments for sepsis have focused on source control, antimicrobials, 
vasopressors, and fluid revival with minimal success at saving the lives of sepsis patients. 
Research has shown that severely septic patients continuously experience undue 
morbidity and mortality despite recent progress in critical care (Iwashyna et al., 2014; 
Kaukonen et al., 2014; Peake et al., 2014; The Global Sepsis Alliance, 2015; Page et al., 
2015; The Global Sepsis Alliance, 2016; Kempker et al., 2016; Papali et al., 2017(a,b); 
Patel et al., 2017; Rhodes et al., 2017).  
Despite, the extensive resources that have been invested in clinical trials of new 
treatments; almost all have failed to improve outcomes i.e. no specific therapy for sepsis 
(Rice, 2006; Shorr et al., 2007; Osuchowski et al., 2007; Daniels,  2011; Phua et al., 2011; 
Reichel et al., 2011; Levy et al., 2012; Perner et al., 2012; Reinhart et al., 2013;  
McPherson et al., 2013;   Liu et al., 2014; ProCESS Investigators et al., 2014; Global 
Sepsis Alliance, 2016; Kim et al., 2017; Patel et al., 2017; Rhodes et al., 2017; Safiri et 
al., 2017).  
In addition, the injurious effects of sepsis last beyond the acute process; patients who 
survive the early episode experience higher rates of death in the first year after hospital 
discharge compared with age-matched controls (Weycker et al., 2003; Shen et al., 2010; 
Daniels, 2011; Levy et al., 2012; Ranieri et al., 2012; Seymour et al., 2012; Stronati et 
al., 2013; Liu et al., 2014; Rhee et al., 2014;  Rogers et al., 2014;  Schorr et al., 2014;  
Singer, 2014; The Global Sepsis Alliance, 2015; Kishore et al., 2015;  Rhee et al., 
2015(a,b) ; The Global Sepsis Alliance, 2016; Seymour, et al., 2016; Stoller et al., 2016; 
Kim et al., 2017; Rhodes et al., 2017; Rannikko et al., 2017). 
The achievement of anti-sepsis therapies clearly depends on sufficiently modulating the 
immune response (with the use of specific treatments) with the least probable adverse 
effect to the host. It is therefore important to understand in more detail the various 
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dynamics of pathophysiological responses that lead to hyperactive or repressed immune 
and inflammatory responses (Riedemann et al., 2003; von Knethen et al., 2007; Rittirsch 
et al., 2007; Wang et al., 2010; Svanes et al., 2010;  Sze et al., 2012; Wang et al., 2012 (a,b); 
Suresh et al., 2013; Wu et al., 2013; Steling et al., 2013; Stronati et al., 2013; Vallés et al., 
2013; Vincent et al., 2013; Vincent et al., 2014; Henriksen et al., 2015; Wang et al., 2015; 
Wong et al., 2015; Papali et al., 2017; Patel et al., 2017).  
Due to the importance to find a novel therapeutic agent in sepsis; Daniels, (2011) has 
summarized the potential target sites for the development of new therapies as pathogen 
recognition such us; lipopolysaccharide, TLRs, neutrophil depletion, cell adhesion, for 
developing novel therapeutic agents in sepsis such as; anti-endotoxin, TLR antagonists-
TAK-242, granulocyte colony-stimulating factor and leucocyte–endothelial interactions 
respectively. There have been also numerous trials of agents that block specific 
inflammatory mediators (eg cytokines) with no outcome on  mortality in clinical sepsis 
trials (Vincent 2006; Angus 2011). 
The LPCAT enzymes offer novel potential of specific therapies for the overwhelming 
inflammatory responses of sepsis; specifically, the control of the PC/LysoPC (LPC) 
balance. In addition, recent studies suggest that LPCAT may regulate inflammatory 
resoponses to different bacterial ligands involving many inflammatory mediators 
(Shinduo et al., 2007: Harayama et al., 2008; Jackson et al., 2008a; Morimoto et al., 2010; 
Shindou et al., 2013; Morimoto et al., 2014).  
However, to exploit LPCAT as a possible target for novel therapies, more information on 
the fundamental role of LPCAT in macrophage responses to bacterial infection need to 
be understood. Moreover, it has been only recently, with the sequencing and cloning of 
LPCAT that different members of this enzyme family have been identified (Chen et al., 
2006; Nakanishi et al., 2006; Shindou et al., 2007; Zhao et al., 2008; Hishikawa et al., 
2008). Identification of the specific LPCAT that regulates macrophage responses and 
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therefore would be the best target for anti-inflammatory or anti-sepsis therapy, also needs 
to be confirmed. 
Work from the Jackson laboratory and others have shown that the phospholipid 
metabolizing enzyme Lysophosphatidylcholine acyltransferase (LPCAT) can control 
inflammatory responses to LPS in macrophages (Jackson et al., 2008; Sevastou et al., 
2013). It was previously shown that LPCAT has a role in inflammatory responses using 
pharmacological inhibitors, although the precise LPCAT species responsible could not be 
determined (Jackson et al., 2008).   
Availability of the gene sequences and cloning of LPCAT species allowed the 
identification of four major family members (LPCAT1-4) each with different but 
overlapping activities. (Chen et al., 2006; Shindou et al., 2007; Edwards & 
Constantinescu, 2009; Hishikawa et al., 2008; Morimoto et al., 2010; Zheng et al., 2012; 
Shindou et al., 2013; Morimoto et al., 2014). The challenge is therefore to determine 
which LPCAT species is responsible for regulating the inflammatory response to LPS 
and other bacterial factors. This knowledge will allow new insights in to the mechanisms 
of inflammation and will be required for new therapies aimed at these targets to be 
developed.  
Recent studies indicate that the stimulation of the isoform LPCAT-2, which is localized 
in cell endoplasmic reticulum and located in lipid droplets where they catalyse the 
formation of PC, and are important in inducing an inflammatory immune response 
(Morimoto et al., 2010; Moessinger et al., 2010; Li et al., 2012; Stanca et al., 2013;  
Morimoto et al., 2014;  Abate & Jackson, 2015).   
The priming of macrophages releases inflammatory mediators (Adib-Conquy et al., 2012; 
Wang et al., 2010 (a,b);  Arroyo-Caro et al., 2013; Schulte et al., 2013; Hishikawa et al., 
2014; Wiersinga et al., 2014; Wang et al., 2014 (b);  Płóciennikowska et al., 2015; 
Walkey et al., 2015; Papali et al., 2017; Patel et al., 2017; Kim et al., 2017). Therefore, 
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the research in this thesis was conducted based on the hypotheses that the LPCAT-2 
enzyme is involved in the inflammatory response of macrophages to inflammatory stimuli 
such as LPS, through regulating inflammatory pathways and potentially also by 
regulating the activation state of the macrophage.  
To answer the primary research questions concerning the role of LPCAT-2 in the 
macrophage inflammatory response, the effect of LPCAT-2 overexpression and 
knockdown on the expression of cytokines and the most suitable reference gene for the 
analysis of these results will be explored.  
In addition, many infections are polymicrobial or involve molecules that can stimulate 
several TLR pathways and the activation of these pathways will be important in 
dysregulated responses leading to sepsis (Harbarth et al., 2003; Weycker et al., 2003; 
Maier et al., 2004; Corrêa et al., 2007; Rittirsch et al., 2007; Wang et al., 2007; Puneet et 
al., 2010; Retamar et al., 2012; Pavlaki et al., 2013; Packiriswamy et al., 2013; Lozano 
et al., 2013; Bloos et al., 2014; Boomer et al., 2014; Liu et al., 2014; Lizza et al., 2014; 
Ramachandran et al., 2014; Yealy et al., 2014). Therefore, this project aims to enhance 
our knowledge of the role of LPCAT-2 in response to different bacterial stimuli by using 
molecular patterns such as lipopolysaccharide as an example of Gram negative bacteria 
stimuli and the synthetic triacylated lipoprotein-TLR1/2 ligand (Pam3CSK4) for Gram 
positive bacteria.  
Knowledge gained from this research will not only improve our understanding of the role 
of phospholipid metabolism in regulating the inflammatory response in macrophages but 
may identify novel molecular targets for the development of new therapies for sepsis.  
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1.9. Hypothesis, Aims and objectives of this project. 
1.9.1. Hypothesis. 
The hypothesis to be tested in this research, is that LPCAT-2 plays a key role in the 
macrophage inflammatory response to infectious stimuli.  
 
1.9.2. Aims. 
To answer the hypothesis, this project aims to study the effect of LPCAT-2 gene 
inhibition and overexpression on macrophage inflammatory responses and explore the 
mechanisms by which LPCAT-2 regulates the inflammatory response in macrophages. 
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1.9.2. Objectives. 
1. To Investigate the effect of LPCAT-2 on LPS- induced inflammatory response using 
RAW264.7 cells transiently over-expressing LPCAT-2. 
2. To study the effect of LPCAT-2 on Pam3CSK4-inflammatory response using 
RAW264.7 cells transiently over-expressing LPCAT-2.  
3. To investigate the mechanisms by which LPCAT-2 regulates the inflammatory 
response in these cells. 
4. To study the effect of LPCAT-2 on the LPS -induced inflammatory response using 
specific siRNA in RAW264.7 cells to knock down the over-expressed LPCAT-2. 
5. To stablish a stably transfected RAW264.7 cell line with plasmid carrying murine or 
human LPCAT-2. 
6. To investigate the effect of LPCAT-2 on LPS-induced inflammatory responses using 
RAW264.7 cell line that stably over-express LPCAT-2. 
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Chapter 2: Materials and Methods 
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2.1. Materials. 
2.1. Cell culture. 
RAW264.7 cell line was obtained from the European Collection of Cell Cultures 
(ECACC) through the Health Protection Agency (HPA), UK) and Dimethyl Sulfoxide 
(DMSO) was obtained from Fisher Scientific UK Ltd., UK. Dulbecco modified Eagle’s 
medium (DMEM) culture media with 25 mM HEPES buffer and 4.5 g/L glucose, L-
glutamine were obtained from Lonza Group Ltd., UK. Foetal bovine serum (FBS) was 
obtained from Biosera supplied by Labtech International Ltd, UK.  
Dublicco’s phosphate buffered saline (PBS) and E coli lipopolysaccharide (LPS) 
O111:B4 were obtained from Sigma-Aldrich Co. LLC., UK. OPTI-MEM® (reduced 
serum medium), Geneticin antibiotic, Lipofectamine 2000 transfection reagent were 
obtained from Life Technologies Ltd., UK while the transfection reagents: JetPrime and 
Interferin were obtained from (Polyplus-transfection Inc., UK). Silencer® select Negative 
control #1 SiRNA and LPCAT-2 SiRNA were obtained from Life Technology Ltd, UK. 
 
2.1.1. Plastic and Glassware. 
25 cm2 tissue culture flasks, 75 cm2 tissue culture flasks, 10 ml serological tips, scrapers, 
7 ml or 30 ml Universal containers, 50 ml  falcon tubes, 1.5 ml Eppendorf tubes, (10, 200, 
1000) µl pipette tips with or without filters, 6 well plates, 12 well plate, 96 well plates, 
50 ml syringe were obtained from Greiner Scientific Laboratory Supplies Ltd., UK while 
10 µl pipette tips without filters, 2 ml Eppendorf tubes, 0.2 µm pore size sartorius, squirt 
bottles, 6 cm diameter single cell culture dishes were obtained from (Fisher Scientific UK 
Ltd., UK). 
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2.1.2 Total RNA extraction. 
Guanidium thiocyanate, water-saturated phenol, sodium acetate (anhydrous), sodium 
citrate, Glacial acetic acid, N-laurosylsarcosine (Sarkosyl), RNase- and DNase-free 
water, Tris-base, 2-mercaptoethanol were obtained from Fisher Scientific UK Ltd., UK. 
1-Bromo-3-chloropropane (1-Bromo-3-chloropropane, I-BCP, Trimethylene 
bromochloride, Trimethylene chlorobromide), 2-isopropanol, ethanol was obtained from 
Sigma-Aldrich Co. LLC., UK. DNase-1 amplification kit was obtained from Sigma-
Aldrich Co. LLC., UK. 
 
2.1.3 Quantitative or real time PCR (qPCR or RT-PCR). 
High Capacity RNA - to - cDNA Kit, Real time PCR kit and Applied Biosystems™ 
MicroAmp™ Fast Optical 96-Well Reaction Plate, 0.1 mL were obtained from Life 
Technologies Ltd. the primers were purchased from Eurofins MWG Operon, Germany.  
 
2.1.4. Agarose gel electrophoresis. 
Electrophoresis grade agarose was obtained from (Fisher Scientific UK Ltd., UK), 
EDTA, 10000x SyBr Safe and acetic acid were obtained from (Sigma-Aldrich Co. LLC., 
UK).  
 
2.1.5 Cloning and purification of plasmid carrying the human or murine 
LPCAT-2 inserts. 
 pCMV6 -entry vector (4.9 kb) plasmids with or without cDNA clones of the murine 
LPCAT- 2 or human LPCAT- 2 (Appendix 1 Materials, Figure 1), Alpha-gold competent 
cells were obtained from Insight Biotechnology Ltd, UK. GenElute™ plasmid MiniPrep 
Kit (MiniPrep Kit, PLN70 SIGMA) was obtained from Sigma-Aldrich Co. 
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 LLC., UK. Luria Britani (LB) broth and Agar –Agar were obtained from Sigma-Aldrich 
Co. LLC., UK. 
 
2.1.6. Western blotting (WB). 
Molecular weight marker and LuminataTM Crescendo Western HRP Substrate were 
obtained from Millipore Corporation Billerica, MA, UK. NuPAGE4-12% Bis-Tris Gel 
1.0 mm x 10 well, Lithium dodecyl sulphate (LDS) sample buffer, Anti-flag Ab/ Goat -
Anti Mouse Secondary Ab and SeeBlue® Pre-Stained standard were obtained from Life 
Technologies Ltd., UK. LPCAT-2 Antibody was obtained from Novus Biologicals Ltd, 
UK, Bovine serum Albumin(BSA) were obtained from Sigma-Aldrich Co. LLC., UK. 
 
2.1.6.1. Estimation of protein concentration. 
Micro BCA assay kit was obtained from Thermo Scientific Pierce, UK. 
 
2.1. 7. ELISA assay. 
Mouse TNF-alpha ELISA duo set-kit (cataluge number: DY410), Mouse IL-6 ELISA duo 
set kit (cataluge number: DY406) were obtained from R&D Systems, Inc., UK. ELISA 
TMB Substrate was obtained from Insight Biotechnology Ltd., UK. Maxisorp 96 well 
ELISA plates, Plate sealers and Tween-20 were obtained from Fisher Scientific UK Ltd., 
UK.  
 
2.1.8. All instruments in this project. 
Mini plate spinner centrifuge, Mini centrifuge (Labnet International.Inc, USA), Nanovue 
systems (GE Healthcare Life Sciences, USA) and Nanodrop 2000 spectrophotometer 
(Thermo-Fisher-Scientific, Waltham, MA, USA). Veriti 96 well Thermal Cycler, Primer 
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express software and StepOnePlus Real- Time PCR System (Thermo-cycler 96 well plate 
Real time-PCR) were obtained from Life Technologies Ltd., UK. EC3 imaging system, 
Ultra Violet Products (UVP) image gel documentation system (UVP ultra violet product, 
Tech, Japan), ImageQuant LAS4000 system device and software were sourced from (GE 
Mini plate spinner centrifuge, Mini centrifuge (Labnet International.Inc, USA), Nanovue 
systems (GE Healthcare Life Sciences, USA) and Nanodrop 2000 spectrophotometer 
(Thermo-Fisher-Scientific, Waltham, MA, USA). Veriti 96 well Thermal Cycler, Primer 
express software and StepOnePlus Real- Time PCR System (Thermo-cycler 96 well plate 
Real time-PCR) were obtained from Life Technologies Ltd., UK. EC3 imaging system, 
Ultra Violet Products (UVP) image gel documentation system (UVP ultra violet product, 
Tech, Japan), ImageQuant LAS4000 system device and software were sourced from (GE 
Healthcare Bio-Sciences AB, Sweden). Spectrafuge 24D (Labnet International.Inc, 
USA), Stuart® orbital Incubator│S150│ (Geneflow, UK) and Sorvall Legend Micro 17R 
Centrifuge, Refrigerated (Thermo-Scientific, UK). Ultrasound Sonicator, Plate shaker 
(Thermo-Fisher-Scientific, UK), Techne DRI-BLOCK® (Techne(Cambridge) Ltd. 
Duxford Cambridge, UK), Jenway 1000 Hotplate and Stirrer (Jenway, UK). SNAP-id. 
ZOOM® Dual power back and XCell SureLockTM Minin-cell was obtained from Life 
Technologies Ltd., UK. Versa Max Micro-Plate Reader with SoftMax Pro Software was 
sourced from Molecular devices, USA. 
 
2.2. Methods. 
2.2.1. Cell culture.  
RAW264.7 cells (Adherent murine macrophage cell line which is derived from an 
Abelson murine leukaemia virus-induced tumour and isolated in 1978) were maintained 
in DMEM media with 25 hepes and 4.5 g/l glucose supplemented with 200 mM L-
glutamine, 10 % Foetal bovine serum (FBS) as suggested by the supplier.  
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The cells were allowed to grow up to 50 -70 % confluence at 37 ºC in a humidified 
atmosphere in 5 % carbon dioxide (CO2). The cells were sub-cultured in a class 2 cabinet 
twice a week under sterile conditions with a media changing to feed the cells in between. 
 
2.2.1.1. Cell Viability Determination. 
Cell viability was determined by the Trypan blue dye exclusion method. This method was 
carried out by a 1 : 8 serial dilution of the cells and then, cell stained with an equal volume 
of the Trypan blue dye.  
The percentage of unstained cells (viable cells) vs the stained cells (dead cells) (viewed 
and counted under the inverted Microscope at X10 magnification) were used to calculate 
the percentage of viable cells. The acceptable percentage of cell viability test to set any 
experiment was 95 % and above. 
 
2.2.1.2. Freezing and Storage cells. 
Upon delivery, RAW264.7 cells were stored in liquid nitrogen. The cryovial were taken 
out from the liquid nitrogen tank following the standard operating procedure (SOP) for 
Liquid nitrogen handling /sample storage. The liquid Nitrogen tanks (Mr frosty) were also 
used for the long-term storage of the cells, which were previously kept in 
cryopreservation tubes for 24 hours at -80 °C until it was ready to be used. 
 
2.2.1.3. RAW 264.7 cells Cryopreservation and thawing. 
Adherent RAW264.7 cells of early passage were scraped, centrifuged at speed 160 g for 
5 minutes at room temperature and then counted using a haemocytometer. Cell viability 
was assessed as described in section 2.2.1.1. The cells were cryopreserved by re-
suspended the cells with 500 µL of complete DMEM medium and 500 µL of 20 % 
dimethyl sulphoxide (DMSO) solution added drop wise while shaking in cryo-
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preservation tubes. The cells were immediately stored at -80 °C for 24 hours before they 
were transferred to liquid nitrogen (Mr frosty) for long term storage.  
Recovering of the frozen cells, the cryovial was removed from liquid nitrogen and rapidly 
thawed, and then immediately transferred into a universal container containing 10ml of 
supplemented growth cell culture media (DMEM). They were further centrifuged at a 
speed of 160 g for 5 minutes at room temperature (RT) to remove DMSO.  
Then, the cell pellets were re-suspended again in 10 ml of fresh DMEM medium and re-
centrifuged at a speed of 160 g for 5 minutes at room temperature (RT), and then 
transferred into a 25 cm2 tissue culture flask until 80 % confluence was reached. The cells 
were then cultured as stated in section 2.2.1 above.  
 
2.2.1.4. Transfection RAW264.7 cell culture using Lipofectamine 2000 
transfection reagent.  
RAW264.7 cells were plated in 6 wells plate (RT-PCR or WB) at a concentration of 1 x 
106 cell/ well (2.5 ml of DMEM medium) and were incubated at 37 ºC for 24 hours prior 
to transfection with 2.5 µg of purified pCMV6 -entry vector plasmid carrying the murine 
LPCAT-2 (mLPCAT-2) recombinant gene into 150 µL of reduced serum media (OPTI-
MEM medium) in separate sterile eppendorf tubes. 
Then, 6, 9, 12, and 15 µL of lipofectamine 2000 reagent were respectively added to 150 
µl of reduced serum media (OPTI-MEM medium) in separate sterile eppendorf tubes. 
Both eppendorf tubes were incubated for 5 minutes at room temperature.  
Following this, 150 µl of mLPCAT-2 DNA were combined with 150 µl of the previously 
diluted transfection reagent were incubated for 20 minutes at room temperature. Then, 
250 µl of this mixture was added drop wise to each well to transfect RAW264.7 cells 
using low serum medium (OPTI-MEM) for 24 hours at 37  oC.  
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Next day, the low serum medium for all wells were replaced with the supplemented 
growth medium (DMEM medium) for 24 hours extra at 37 oC in order to transfect 
RAW264.7 cells for 48 hours as an optimisation establishment. RAW264.7 cells that 
transfected with purified empty vector (pCMV6 -entry vector) plasmid was used as 
negative control until the end of this research to study the effect of LPCAT-2 on 
inflammatory responses. 
 
2 .2.1.5. Transfection RAW264.7 cell culture using JetPrime. 
RAW264.7 cells were plated at a cell concentration of 2 x 105 cell/well (2.5 ml of DMEM 
medium) on 6 wells plate were incubated at 37 ºC for 24 hours prior to transfection with 
2.5 µg of purified pCMV6 -entry vector plasmid carrying the murine LPCAT-2 
(mLPCAT-2) recombinant gene into 150 µL of reduced serum media (OPTI-MEM 
medium) in separate sterile eppendorf tubes.  
Then, 6, 9, 12, and 15 µL of JetPrime transfection reagent were respectively added into 
150 µl of reduced serum media (OPTI-MEM medium) in separate sterile eppendorf tubes. 
Next, both eppendorf tubes were incubated for 5 minutes at room temperature.  
Then, 150 µl of mLPCAT-2 DNA was combined with 150 µl of the previously diluted 
JetPrime transfection reagent. All these eppendorf tubes were incubated for 20 minutes 
at room temperature. Then, 250 µl of this mixture was added drop wise into each well to 
transfect RAW264.7 cells using 2 ml of low serum medium (OPTI-MEM)/ well for 24 
hours at 37 oC. The next day, the low serum medium for all wells were replaced with the 
supplemented growth medium (DMEM medium), then incubated at 37 ºC for 24 hours 
extra in order to transfect RAW264.7 cells for 48 hours to establish the transfection 
optimisation. RAW264.7 cells that transfected with purified empty vector (pCMV6 -entry 
vector) plasmid was used as negative control. 
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2.2.1.6. LPCAT-2 gene silencing. 
RAW 264.7 cells were plated in a 6 well plate at a concentration of 1 X 106 cells/well (2.5 
ml of DMEM medium) to overexpress the murine LPCAT-2 gene for 48 hours (see 
section 2.2.1.4).  
Then, the cells were scraped and counted using trypan blue cell viability method (see 
section 2.2.1.1). Then the cells were seeded at a cell concentration of 0.2 X 106 cells/ well 
(2.5 ml of DMEM medium) in DMEM culture medium (complete medium) 
supplemented. RAW 264.7 cells were incubated for 24 hours at 37 oC prior the LPCAT-
2 gene silencing (2.5 ml of DMEM medium). 
The cells were then transfected in reduced serum OPTI-MEM medium with a control 
negative siRNA (Ambion SiRNA, cat#: 4390843) or siRNA directed against LPCAT-2 
(Ambion SiRNA ID s114512) at final concentration of 5 nM using interferin transfection 
reagent (a non-liposomal cationic amphiphile transfection reagent which is developed for 
the delivery of SiRNA into the cells in culture).  After 48 hours, the medium was changed 
and a complete DMEM medium added and then, the cells were stimulated with 1 µg/ml 
of LPS for 6 hours. RAW264.7 over-expressing LPCAT-2 gene is termed ‘LPCAT-2+’. 
 
2.3. Stimulation of RAW 264.7 cells. 
2.3.1. Stimulation of RAW 264.7 cells with LPS.  
RAW264.7 were plated at a concentration of 0.5 x 106 cell / well (2.5 ml of complete 
DMEM medium) in a 6 well plate and incubated in a standard culture condition at 37 ˚C 
(please see section 2.2.1 and 2.2.1.1, 2.2.1.4.). The cells were stimulated with 1 µg /ml of 
Lipopoly-saccharide (LPS) for 6 hours for all the experiment sets. Supernatant were 
collected and stored at -80 ˚C to be ready for ELISA assay. While the cells were treated 
with RNA lysis buffer and stored at -20 ˚C to be ready for total RNA extraction (as 
described in section 2.4.1). 
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2.3.2. Stimulation of RAW 264.7 cells with Pam3CSK4 (Pam3C). 
RAW264.7 were plated at a concentration of 0.5 x 106 cell /well (2.5 ml of DMEM 
medium) in a 6 well plate (qPCR) and incubated in a standard culture condition at 37 ˚C 
(please see section 2.2.1 and 2.2.1.1, 2.2.1.4). The cells were stimulated with 0.5 µg/ml 
Pam3CSK4 (Pam3C) for 6 hours.  
 
2.3.3. The effect of selective peroxisome proliferator-activated receptors 
–gamma (PPAR-γ) antagonist T0070907 on LPCAT2 expression. 
A concentration of (0.1 and 1) mM of the selective PPAR-γ antagonist T0070907 (2-
cloro-5-nitro-N-4-pyridinylbenzaminde) and vehicle (DMSO) is added into a 6 well plate 
RAW264.7 cell line at a concentration of 1 x 106 cell/well into 2.5 ml of complete DMEM 
medium. Then, incubated at 37 ºC for two hours prior LPS stimulation in a concentration 
of 1 µg /ml was added and incubated for 6 hours at 37 ºC. Then, the RNA samples were 
analysed using RT-PCR analysis system. 
 
2.4. Reverse transcription coupled - Real Time polymerase chain 
reaction (RT-PCR). 
2.4.1. Total RNA extraction. 
2.4.1.1. Denaturing solution preparation. 
Stock denaturing solution was prepared by dissolving 25 g of guanidium thiocyanate in 
29.3 ml of water at 65 ºC, followed by 1.76 ml of 0.75 M sodium citrate, pH 7.0, and 2.64 
ml of 10 % sarkosyl. Denaturing solution was activated before use by addition of 72 µl 
of 2- mercaptoethanol to each 10 ml of the stock solution. 
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2.4.1. 2. 2 M sodium acetate, pH 4.0 preparation. 
A 16.42 g of sodium acetate (anhydrous) was added to 35 ml of water and 40 ml glacial 
acetic acid. And then, the pH was adjusted to 4.0 with glacial acetic acid and the final 
volume was brought to 100 ml with water. 
 
2.4.1. 3. Total RNA extraction. 
Total RNA was extracted using acid guanidium thiocyanate – phenol- no chloroform 
extraction method that described by Chomczynski Sacchi (1987) with minor 
modifications which is included using the bromochloropropane instead of chloroform in 
order to introduce the liquid interphase. RNA pellets were re-suspended with 75 % 
ethanol to dissolve the residual guianidinium thiocyanate, twice against its re-suspension. 
However, it was re-suspended only once with 75 % ethanol as described in the original 
extraction method. 
 The RNA denaturation was done using a guanidinium thiocyanate denaturing solution 
(containing 2-Mecarptoethanol). Next, sodium acetate (pH 4) was used for acidification. 
Isopropanol was also used twice to precipitate RNA.  
The final step of RNA extraction was air-drying of all RNA pellets and then, subsequently 
was dissolved in RNase and DNase-free water. Then, treated with DNase -1 kit to remove 
any genomic DNA contamination during the procedure of total RNA extraction method 
and then, all RNA samples were stored at -80 oC (Chomczynski and Sacchi, 1987). The 
method was done briefly, following the experiments, culture supernatants were removed 
from RAW264.7 cells (were stored at -80 oC for ELISA) and 500 µl of denaturing solution 
was added directly to the wells. Cells were rested in denaturing solution for 1 - 2 minutes 
to allow complete lysis and the solution was pipetted up and down 10 times to ensure all 
the lysate was collected. 
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 The samples were allowed to sit for 5 minutes before being frozen at -20 oC for later 
analysis but not exceeded 30 minutes. 
To extract RNA, 50 µl of 2 M sodium acetate, pH 4.0 was added to the cell lysates 
respectively and mixed thoroughly by inversion. Then, 500 µl water saturated phenol was 
added, mixed by inversion, followed by 100 µl of 1-bromo-3-chloropropane, and shaken 
vigorously by hand to ensure proper mixing. Samples were cooled on ice for 15 minutes 
then centrifuged for 20 minutes, 15000 g, at 4 oC. And then, the upper aqueous phase 
containing mostly RNA was transferred to RNase- and DNase free Eppendorf tube and 
500 µl of isopropanol was added to precipitate the RNA. Samples were incubated at -20 
oC until needed for the next step.  
Next, samples were centrifuged at 15000 g for 20 minutes at 4 oC. The supernatant was 
discarded and the gel-like precipitates (RNA) were retained then dissolved in 300 µl of 
denaturing solution. And then, 300 µl of isopropanol were added and the samples were 
incubated at -20 oC for at least 30 minutes (1 hour).  
Samples were incubated at -20 oC until needed for the next step or after which they were 
centrifuged for at 15000 g for 10 minutes at 4 oC. The supernatants were discarded and 
the pellets were re-suspended in 500 µl of 75 % ethanol and vortexed for 10 seconds to 
mix, and then incubated for 15 minutes at room temperature to dissolve any residual 
guanidinium thiocyanate. At this point, samples were stored at -20 oC until RNA 
extraction could be completed. 
Samples were centrifuged for at 15000 g for 10 minutes at 4 oC, and the supernatant was 
discarded. The pellets were air dried for around 15 - 30 minutes in a laminar flow hood 
at room temperature, and then the RNA was dissolved in 30 µl of RNase- and DNase- 
free water and incubated for 15 minutes at 60 oC to ensure complete solubilisation of the 
RNA.  
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To remove any residual genomic DNA, samples were treated with the DNase 1 kit 
(Sigma, UK). To the solubilised RNA, 3 μl of 10 x reaction buffer and 3 μl amplification 
grade (Deoxy-ribonuclease I) DNase 1 (1 unit/μl) were added and samples were left to 
stand at room temperature for 15 minutes. To stop the reaction, 3 μl stop solution was 
added to each tube. Samples were then incubated at 70 oC for 10 minutes, and then placed 
on ice ready to quantify the total RNA concentrations using nanodrop 2000 ready for 
reverse transcription (please see section 2.4.2). RNA purity was assessed by observing 
the ratio of absorbance at 260 nm and 280 nm. The accepted RNA purification ratio was 
1.8 - 2.1 for any RNA sample to be considered as a pure.  
 
2.4. 2. Reverse transcription. 
Total RNA samples were first diluted using RNase or DNase free water grade by taking 
0.5 μg of each RNA sample to be diluted up to 9 µl in a thin walled PCR tubes. And then, 
all samples were reverse transcript to complementary deoxyribonucleic acid (cDNA) 
using high capacity RNA to cDNA reverse transcriptase kit following the supplier’s 
instructions (Life Technologies Ltd) by preparing the master mix accordingly to the 
number of RNA samples that were needed to be reverse transcript for each reaction by 
adding 10 µl/ sample of the reverse transcriptase buffer.  
Then, 1 µl / sample of the reverse transcriptase enzyme were added to the master mix. 
Then, 11 µl/ sample of the master mix were added in equal amount into each diluted RNA 
sample. The reverse transcription run conditions were 37 ºC for 1 hour (60 minutes) 
stopped by heating at 95 ºC for 5 min, and then the run was held at 4 ºC using 96 well 
thermal cycler machine (Vertti).  All samples were stored at -20 ºC until used. 
The qPCR primers for murine LPCAT-2, LPCAT-2 open reading frame (ORF), TNF-α, 
IL-10, IL-6, TLR-4, TLR-2, CD14, COX-2, PPAR-ᵞ, iNOS, CD206 and all the reference 
gene (GAPDH) were designed using Primer Express 6 software version 6.1.10 (Life 
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technologies Ltd, UK) to amplify 100 bp product for all the targets (please see table 1 for 
primer sequences).  
The specificity of each sequence was checked by NCBI nucleotide basic local alignment 
search tool (BLAST) (Altschul et al., 1990).  
The sequences for hairpin, self-dimer and heterodimer were also checked using 
oligoanalyser 3.1 (Integrated DNA Technologies). The sequences are given in table 1. 
 
2.4.4. Real time –Polymerase chain reaction (PCR). 
The cDNA from the reverse transcription reaction (please see section 2.4.2) was amplified 
using Power SYBR Green kit according to the supplier’s instructions. Briefly, the cDNA 
(0.5 μl) from RT reaction was used for each PCR reaction.  
The qPCR (Real time PCR) reaction conditions were 95 oC for 10 minutes at the holding 
stage, followed by 40 cycles in which including the denaturation at 95 oC for 30 seconds, 
annealing at 53 oC for 60 seconds, and then, the extension at 72 oC for 120 seconds 
followed by a final 6 minutes extension at 72 oC. All primers were designed and checked 
using primer express software ‘Primer Express 6 software version 6.1.10’.  All Primers 
that have been used are shown in Table1.  
Fold increase values were calculated as (2^-(∆∆Ct)) i.e. RQ = 2 power –(∆∆Ct); pCMV6 
without LPS or Pam3CSK4 is represented as 1 fold increase (2^-(0) =1). All data were 
normally distributed (please see table 2 in Appendix 1, material and methods 
supplements). 
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Reference & 
target Genes 
Sequence Melting 
Temperature 
(ºC) 
Human 
LPCAT-2 
(ORF)* insert 
Forward 5׳ –GCT GCC CTC ATT CAA 
CATT - 3׳ (18) 
 
60 
Reverse 5׳ –CAA CTA GAG GGA CTT 
GTG CAT TC - 3׳ (23) 
 
 
60 
Murine 
LPCAT-2 
ORF* insert 
Forward  5׳ –CAG ACT GTT ACG GGC 
TTT GCA - 3׳ (21) 
Reverse 5׳ – ACC TGA TGT CGC TCG CTT  
TT  - 3׳  (20) 
 
 
60 
Human 
LPCAT-2 ** 
Forward  5׳ –GCA CAC GCT CCC CTT 
GACT - 3׳ (19) 
Reverse 5׳ –TTA TGG CCC ACT GCA ATC 
GT - 3׳ (20) 
 
 
60 
GAPDH ** Forward  5׳ –CCT CGT CCC  GTA GAC 
AAA ATG - 3׳ (21) 
Reverse 5׳ –TCT CCA CTT TGC CAC TGC 
AA - 3׳ (20) 
 
 
60 
Murine 
LPCAT-2 ** 
Forward  5׳ –GCA CAC GCT CCC CTT 
GACT - 3׳ (19) 
Reverse 5׳ – TTA TGG CCC ACT GCA ATC 
GT- 3׳ (20) 
 
 
 
60. 
 
 
Murine IL-
10** 
Forward  5׳ –CTT GCA CTA CCA AAG 
CCA CAA G- 3׳ (22) 
Reverse 5׳ –GGA AGT GGG TGC AGT 
TAT TGT CT- 3׳ (23) 
 
 
60 
 
Murine  
IL-6** 
Forward 5׳ – AGA AGG AGT GGC TAA 
GGA CCA A - 3׳ (22) 
Reverse 5׳ – ACG CAC TAG GTT TGC 
CGA GTA - 3׳ (21) 
 
 
60 
Murine TNF-
α** 
Forward 5׳ – AGG ACC CAG TGT GGG 
AAG CT - 3׳ (20) 
Reverse 5׳– AAA GAG GAG GCA ACA 
AGG TAG AGA- 3׳ (24) 
 
 
 
60 
Murine TLR-
4** 
Forward 5׳ – ACT CTG ATC ATG GCA 
CTG TTC ATC T - 3(25) 
Reverse 5׳ – TCA GCA AAG TCC CTG 
ATG ACA TTC C - 3׳(25) 
 
 
60 
Murine 
TLR2** 
Forward  5׳ – AGG GAT CCG GGT GGT 
AAA AA - 3׳(20) 
Reverse 5׳ – CAG CCG AGG CAA GAA 
CAA AG - 3׳ (20) 
 
 
60 
Murine 
CD206** 
Forward  5׳ – AAA TGG AGC CGT CTG 
TGC AT- 3׳ (20) 
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Reverse 5׳ – AAG TGC AAT GGA CAA 
AAT CCA A - 3׳ (22) 
 
 
 
 
59.4 
Murine iNOS 
** 
Forward  5׳ – CGC CTT CAA CAC CAA 
GGT TG- 3׳ (20) 
Reverse 5׳ – TCA GAG TCT GCC CAT TGC 
TG - 3׳ (20) 
 
 
60 
Murine 
CD14** 
Forward   5׳ –GCA GTG GCC TTG TCA 
AGA- 3׳(18) 
Reverse 5׳ – GCA TGA CGA GGA CCC 
GTA A - 3׳ (19) 
 
 
60 
Murine 
PPARγ** 
Forward  5׳ –CCA CTC GCA TTC GTT 
TGA CA  - 3׳ (20) 
Reverse 5׳ – TCG CTC AGC TCT TCC  
GAA GTG- 3׳ (21) 
 
 
 
60 
Murine COX-
2** 
Forward 5’- CCA CAG TCA AAG ACA CTC 
AGG TAG A-3’(25) 
Reverse 5’- CCA GGC ACC AGA CCA AAG 
AC  -3’(20) 
 
Table 1. All primers sequences for Real time –Polymerase chain reaction (RT-PCR). 
 
*This primer was used to check the overexpression of LPCAT2 insert gene in mammalian 
cells.   
Note: Human or murine LPCAT2 Open Reading Frame insert (ORF)* insert 
** These primers were used for the routine daily work RT-PCR work. 
 
2.7. Agarose gel electrophoresis. 
Product size and primer specificity was confirmed using agarose gel electrophoresis. PCR 
samples had 2.5 μl of loading buffer (orange G dye) added and then were loaded into a 
1 % (w/v) Tris-acetic acid EDTA (TAE) agarose gel.  
Gels were made by dissolving agarose within an appropriate volume of TAE buffer (40 
mM Tris-base, l0 mM EDTA and 0.1 % acetic acid) which was heated in a microwave 
for 1 minute and then cooled to 50 °C, and then 4 μL SyBer safe (10000 x) was added to 
the gel to enable visualization of DNA under UV light (Appendix1, materials, 1.3.2 and 
1.3.2).  
 70 
 
Gels were run at 60 – 100 V according to the size of the product for an appropriate time. 
Bands were checked for presence and size using Ultra Violet Products (UVP) image gel 
documentation system linked to a PC. 
 
2.8. Cloning and expanding a Plasmid carrying the murine LPCAT-2 
inserts. 
The True ORF Gold plasmid which has kanamycin resistance for colonies selection on 
Luria Britani Agar (LB-Agar) containing 25 µg/ml kanamycin (Appendix 1, figure 3, 
(1.1) Material support information Figures) were expanded by transformation of 1 µg/ml 
of plasmids (pCMV6 -entry vector plasmid (4.9 kb)) with or without the inserts of the 
murine LPCAT-2 by cloning into 10 µL of Alpha-gold competent cells in Eppendorf 
tubes incubated on ice for 30 minutes (optimum temperature to mix the DNA plasmid 
with E. coli competent cells).  
Then, heat shock using heat block at 42 ˚C for 45 seconds (special temperature to let the 
membrane of E. coli become porous and for the Plasmid DNA clone having the 
kanamycin resistance gene for selection in E. coli colonies grown on Luria Britani (LB)-
plate containing 25 µg/ml of kanamycin (KAN); to enter the cells). Followed by this was 
the cooling on ice for 2 minutes to close the pore in the cell membrane of E coli competent 
cells. Incubation in a shaking incubator for 1 hour at 37 ˚C (optimum temperature for E. 
coli growth on KAN-LB-plate) followed.  
Then, the mix was diluted (Transformed competent) into (1 %, 10 %, 50 %, 100 %) using 
SOC medium (appendix 1). 100 µL was transferred onto an LB plate with kanamycin 
concentration of 25 µg/ml (Appendix 1, (1.2.1), culture media, material and methods), 
and incubated at 37 ˚C overnight no more than 18 hours.  
The next day one single colony of the transformed cells was transferred into LB broth 
with kanamycin concentration of 60 µg/ml (Appendix 1, (1.2.2 and 1.2.3), culture media, 
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material and methods), and then incubated overnight for the best yield of plasmid at 37 
˚C in shaking incubator. 
 The transformed kanamycin resistant E. coli growth was confirmed by the obvious 
turbidity with in the LB-Broth tubes in comparison with no growth of competent cells 
alone that showed clear LB-broth.   
 
2.8.1. Purification of the Plasmid with or without the murine LPCAT-2 
inserts. 
Alpha- gold competent cells (E. coli) culture, incubated overnight at 37 ˚C in a shaking 
incubator were harvested by transferring 2 ml of it into 2 ml micro-centrifuge tubes and 
then spun at 12,000 g for 1 minute. And then, the cell pellets which are contained the 
Plasmids with or without the murine LPCAT-2 inserts were kept to be purified using the 
MiniPrep Kit following the supplier instructions.  
Briefly; the MiniPrep purification procedure was applied in a sterile environment using 
benzyl flame. All cell pellets were re-suspended by adding 200 µl of Re-suspension 
solution that containing RNase enzyme with a mild vortex until homogeneous (to ensure 
good recovery i.e. incomplete resuspension would result in poor recovery). And then 
followed by adding 200 µl of cell lysis solution was added into all tubes with gentile 
mixing (6-8 times) immediately and incubated for no more than 5 minutes at room 
temperature (RT) in order to avoid permanent supercoiled plasmid denaturing as a result 
of prolong alkaline lysis.  
Then, 350 µl of neutralised/Binding solution were added into all Eppendorf tubes with 
gentile inverted (4 - 6 times). Then all samples were centrifuged at 12000 xg at 4 ºC for 
10 minutes (the cell debris, protein, lipids, SDS, and chromosomal DNA would 
precipitate and fallen out of the solution as viscous cloudy precipitate). 
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 In addition, if the supernatant was contained large amount of floating particulates after 
centrifugation, then the supernatant was re-centrifuged before proceeding to the next 
steps.  
Meanwhile the silica- column tubes were prepared by placed it into a new fresh Eppendorf 
tubes which is provided within the kit by adding 500 µl of column solution. Then column 
tubes were centrifuged at 12000 x g for 1 minute.  
And then, the clear supernatant from the previous tubes were transferred into column 
tubes respectively and then the samples were centrifuged at 12000 xg at 4 ºC for 1 minute.  
Then, 500 µl of the optional wash solution were added into each sample after discarding 
the liquid of the previous step (it is necessary to avoid nuclease contamination of the final 
plasmid product), were re-centrifuged at 12000 xg at 4 ºC for 1 minute.  
And then, 750 µl of the wash solution were added into each sample, and then were re-
centrifuged within the same speed and time. And then, all samples were re-centrifuged at 
high speed for 2 minutes without adding any washing solution to remove the excess 
ethanol.  
Finally, 100 µl of elute solution were added into each sample after transferring the silica 
column into new fresh tubes with clear labelling, then centrifuged at 12000 xg for 1 
minutes at 4 ºC. The MiniPrep purified plasmid DNA concentration for all samples were 
quantified using nanodrop 2000 and were stored at -80 ºC until used.  
 
2.8.2. Western blotting (WB).  
2.8.2.1. Total lysate preparation and protein quantification. 
The cells lysate of transfected RAW264.7 were prepared using the 
radioimmunoprecipitation assay buffer (RIPA buffer) (Collett & Erikson, 1978; Abate & 
Jackson, 2015) (Appendix 1, material and methods, 1.5) to lyse the cells into protein from 
the transfected and non-transfected cells, then keep all samples on ice for 30 minutes and 
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then the samples were sonicated using an ultrasound probe to have high concentration of 
protein. And then the protein in each sample was quantified using micro BCA Assay Kit 
following the supplier instructions.  
A sterile phosphate buffer saline (PBS), pH (7.2 - 7.4) was used as a reagent diluent to 
prepare the dilutions within this assay for both the standard and protein samples as well. 
The total volume that added to each well of the 96 wells plate was 200 including 100 µl 
of each standard or a protein sample respectively. And then 100 µl of the working solution 
of the detection reagent which is prepared immediately in a ratio of (25: 24: 1) to three 
components (A: B: C).  
The micro- BCA standard reagent stock was 2 mg/ml of bovine serum albumin (BSA) 
was used to prepare the working solution started with the highest concentration 200 µg/ml 
by adding 50 µl from the micro-BCA standard reagent stock into 450 µl of PBS followed 
by 6 serial dilutions in 6 sterile 1.5 ml Eppendorf tubes that had 250 µl of PBS and the 
blank tube had PBS only. All protein samples (1: 25 or 1: 50) were prepared by adding 
(96 or 98) µl of PBS respectively into each well, and then (4 or 2) µl of each sample were 
added respectively at room temperature. Then 100 µl of micro-BCA detection reagent 
was added into all wells including the standard. The 96 well was sealed using plate sealer. 
 The plate was shaken gently for 1 minute using plate shaker and was subsequently 
incubated at 37 ºC for 2 hours. The protein concentration was assessed using versa max 
microplate reader with SoftMax Pro 2.4.1 Software which is depended on the absorbance 
in a micro-plate reader at 595 nm. A standard curve was produced between absorbance 
value and protein concentrations, and the test sample was calculated based on comparison 
to the standard curve using 5 - parameter statistical model. 
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2.8.2.2. Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis 
(SDS–PAGE). 
The protein samples in a concentration of (10 – 20) µg within a 20 µL of each sample as 
a maximum volume to be loaded into each well of the precast-gel (NuPAGE® Bis-Tris 
Gels), 10 µL of SeeBlue, and 10 µl of biotin marker were loaded into gel. The gel 
electrophoresis was run using XCell SureLockTM Mini-cell following the supplier 
instructions.  
Briefly; protein samples were prepared using 12.5 µl of NuPAGE® loading sample buffer 
(4x) and 5 µl of NuPAGE® reducing reagent (10 x) and deionised water up to 50 µl, and 
10 µL of biotin marker were vortex and incubated in dry heat block at 70 ºC for 10 
minutes. And then, the samples were placed on ice prior loading into precast-gel.  
Then, NuPAGE® Western blotting running buffer (SDS running buffer) stock (10 x). The 
(1 x) NuPAGE® was prepared by adding 100 ml of the stock NuPAGE running buffer 
(10 x) (Appendix 1, Materials, 1.4) into 900 ml of deionised water. Then, the NuPAGE 
gel (10 % polyacrylamide Bis-Tris-Cl buffered gel (pH 6.4) was washed using deionised 
water and running buffer prior inserting into the XCell SureLockTM and sealed using the 
wedge. And then, 200 ml of running buffer were added into upper buffer chamber which 
were covering the wells.  
Then, 20 µl of each sample, 10 µL of SeeBlue, 10 µl of biotin marker were loaded into 
gel, the 600 ml of the running buffer were added into outer buffer chamber. And then, the 
XCell SureLockTM Mini-cell Novex system was attached into the power supply and run 
at 200 V for an hour at room temperature. 
 
2.8.2.3. Western immuno-blotting transfer. 
 After the NuPAGE® SDS-PAGE electrophoresis and prior to NuPAGE® Western 
blotting transfer buffer, and the NuPAGE® transfer blot using the XCell SureLockTM 
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Mini-cell Novex system apparatus. The SDS-PAGE protein samples were transferred into 
polyvinylidene difluoride (PVDF) membrane following the supplier instructions. 
It runs at 30 V for 90 minutes. Briefly; NuPAGE® Transfer buffer (20 x) as a stock was 
used to prepare the working solution in a concentration of (1x) by adding 50 ml of the 
NuPAGE® Transfer buffer, 100 ml of Methanol (200 ml for two gels), and 849 ml of 
deionised water (dd-H2O) (749 ml for two gels). The gel was removed from the 
electrophoresis system tank (as described in section 2.8.2.2).  
Then, the plates were removed and the gel were placed between 2 pieces; first one of filter 
papers were placed on the top of the gel (filter papers were previously cut in the same 
size of the gel prior the soaking in 1 x transfer buffer). And then, the PVDF membrane 
was placed facing the gel surface (it was cut in the same size of the gel and pre-soaked 
into methanol for 15 seconds and in deionised water for 2 minutes and then, placed in the 
transfer buffer for 55 minutes).  
Next, the second filter paper was placed on the PVDF membrane and any trapped air 
bubbles were removed using a roller. Then, two pre-soaked blotting pads were placed 
into the cathode (-) core of the Blot, and then the gel/membrane assembly were carefully 
pickup and were placed on blotting pads in the current orientation (please see figure 1), 
so that the gel was closed to the cathode core, then two more blotting pads were placed 
over the gel/membrane assembly.  
Then, the anode (+) were placed on top of the pads and the blot was firmly hold together 
and slide it into the guide rails on the lower buffer chamber. The gel tension wedge was 
inserted into the lower buffer chamber and was locked in position, then the blot modulate 
was filled with 1 x transfer buffer until the gel/membrane assembly covered, and then the 
600 ml was added into outer buffer chamber.  And then, the lid was placed on the unit 
and connected into electrical lead to the power supply. The transfer process was run using 
30 Volt (V) constant for 90 minutes at room temperature.  
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2.8.2.4. Western blotting ECL detection. 
ECL substrate is an enhanced chemiluminescent substrate that used to detect horseradish 
peroxidase (HRP) activity from antibodies and other western blot probes. 
 Prior to the ECL detection, WB membrane were blocked using the blocking buffer which 
consisted of 0.1 % or 0.05 % of skimmed milk (due to its low-fat content and cheaper 
price) in PBS tween (PBS-T20).  
Then the detection steps were subsequently done using the purified anti DDk mouse mAb 
clone 4C5 (Anti-flag Ab/ Goat-anti-mouse) or Anti-LPCAT2 Antibody as a primary Abs 
with a dilution (1: 1000) and Goat -Anti Mouse-IgG or Goat -Anti Rabbit -IgG 
respectively as a secondary Ab (1: 1000).  
And then, incubated for 10 minutes at room temperature using the snap system apparatus 
or for at 1 hour at room temperature or overnight at 4 ˚C for the ordinary WB on a rolling 
shaking machine. Subsequently, were followed by three times washes using 30 ml of 0.1 
PBS-T 20 for Snap system or 0.05 % PBS-T 20 for ordinary WB on shaker machine post 
adding the primary or the secondary Ab.  
And then, the bands were checked according to their molecular weight using UVP gel 
documentation system linked to a PC. Developing colour for protein detection was 
performed by using enhanced chemiluminescence (ECL) to detect peroxidase activity 
from HRP-conjugated antibody.  
According to the manufacturer’s instructions, the membrane was removed after washing 
with TBS, dry on a paper towel and laid out on a plastic sheet. And then, the detection 
substrate solution was carefully pipetted over the entire membrane inside the tray of 
imaging system. The protein bands were visualized by a gel documentation system using 
EC3 imaging system.   
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2.8.2.5. Stripping and Re-probing buffer for WB membrane. 
50 ml of re-probing solution was prepared by adding 28.65 g guanidium HCl (Gn-HCl) / 
50 ml, (0.2 %) i.e. 100 µl of Triton x - 100 (Tx - 100) / 50 ml, (0.1 M) i.e. 358 µL of β-
mercaptoethanol (BME) was prepared by dissolving (Gn-HCl) with 20 mM Tris-Cl (pH= 
7.5) until 50 ml in hot water.  
And then, Tx-100 (100 µl) was added followed by adding 358 µl of BME and the re-
probing procedure was applied inside the fume cabinet by adding 25 ml of the re-probing 
buffer for the WB membrane, incubate for 5 minutes. It was followed by 4 washes using 
0.05 % PBS-T20 for 5 minutes each wash.  
Then incubate the membrane with extra 25 ml of re-probing buffer followed by 4 times 
washes for 5 minutes each using 0.05 % PBS-T20 on shaker for all washes and re-probing 
steps. This procedure was useful to get rid of the previous Antibodies (Abs) without 
affecting the protein bands which were remained within their position on the PVFD 
membrane.     
 
2.9. Establishing a stable transfected RAW264.7 cell line culture. 
RAW264.7 cells were plated in a concentration of 1 x 106 cell/ well (2.5 ml complete 
DMEM medium) incubated at 37 ºC for 24 hours. Then, the murine LPCAT-2 was over-
expressed (as descried in section 2.2.1.4).  
Further, RAW264.7 cells with over-expressed murine LPCAT2, and untreated 
RAW264.7 cells were plated in a concentration of 5 x 105 cell /well (500 µL of DMEM 
medium) in a 12 well plate and were respectively treated with DMEM medium with a 
concentration of (0, 500, 600, 700) µg/ml/well (500 µL DMEM medium) of the G418 
antibiotic, in duplicates (2 wells for each treatment).  
Then, the plate was incubated at 37 ºC within 5 % CO2 humidity atmosphere. The wells 
also were checked daily under inverted microscope and the medium containing G418 
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were changed daily for 5 - 6 days. And then, a concentration of 200 µg/ ml of G418 were 
used as maintaining medium of the stable transfected cells clone.  
The maintaining media were changed every 3 days for extra 9 days in order to check the 
stability.  Finally, the stable cell line was frozen and stored at -80 ºC after adding 10% 
DMSO (freezing medium) as a cell stock storage after analysing the overexpression of 
the LPCAT2 in RAW264.7 cells using western blotting (WB) and real time quantitative 
polymerase chain reaction (RT-PCR). RAW264.7 that stably over-expressed the murine 
LPCAT-2 will be termed ‘LPCAT-2++’ in chapter 5, and transfected RAW26.7 cells with 
empty vector will be termed ‘pCMV6’ in chapter 5. 
 
2.9.1. Killing curve of RAW264.7 cell culture. 
RAW264.7 cells (passage 9) were plated in two plates of 96 well plates, started in a 
concentration of (105 cells/ml)/ well (150 µL) in duplicate dilution.  
Different concentrations of the antibiotic Geneticin (G418) (800,700, 600, 500, 400, 200, 
0) µg/ml were applied and then, the medium containing the antibiotic were changed every 
three days for the first week, and then, daily for the second week and the confluence of 
the cells were checked daily using the inverted microscope until the whole cells were 
dead in all wells.  
This procedure was done in order to optimise the convenient concentration of the G418 
antibiotic to establish a stable overexpression of murine LPCAT-2 in mammalian cell line 
that used to select the cells that has the resistant gene to neomycin antibiotic as well as its 
ability to kill the murine RAW264.7 cells which were lacked with this gene.  
 
2.9.2. Transient transfected RAW264.7 cell line culture. 
RAW264.7 cells were plated in a concentration of 1 x 106 cell/ well (2.5 ml DMEM 
medium) (WB) or 0.5 x 106 cell/ well (2.5 ml DMEM medium) (ELISA or qPCR) 
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Incubated for 24 hours at 37 ºC. And then, 2.5 µg of DNA plasmid with or without cDNA 
clone of murine LPCAT-2 was transfected into RAW264.7 using 9 µl of lipofectamine 
2000 transfected reagent respectively.  
A non-transfected RAW264.7 cells were kept as a negative control in duplicate for 48 
hours transfection to be analysed with the over-expressed LPCAT-2 respectively using 
western immune-blotting and real time qPCR. 
 
2.11. Enzyme Linked Immune-Absorbent Assay (ELISA). 
2.11. Mouse TNF-α or IL-6 cytokines enzyme linked immune-absorbent 
assay (ELISA). 
ELISA experiments were performed to assay the protein expression of TNF-alpha, or IL-
6 following the manufacturer’s instructions. Briefly, capture antibody; anti-TNF-α (0.8 
µg/ml) or anti-IL-6 (2 μg/ml). Capture antibody was made to bind to the wells of a  
Maxisorp 96 wells ELISA plate (The wells were coated with diluted capture antibody 
using PBS as a diluent, sealed and incubated overnight at 4 ºC).  
Then IL-6 or TNF-α plates were washed three times with PBS/0.05 % v/v Tween-20. 
Then, any non-specific binding sites on the surface were blocked using 1 % w/v BSA in 
PBS for 1 hour at room RT. Further, the plates were washed three times.  
Then, the plates were incubated with serially diluted recombinant cytokine standards, test 
samples for 2 hours at RT or overnight at 4 oC. The plates were then washed to remove 
unbound antigen. And then, a 50 ng/mL or 150 ng/ml of the detection antibody was added 
and were incubated at RT for 2 hours with a subsequent washing to remove the unbound 
antibody-enzyme conjugates.  
This was followed by the addition of 100 μl/well of streptavidin horseradish peroxidase 
(Streptavidin-HRP) at dilutions ratio (1 : 40) using the diluent reagent (1 % BSA in PBS) 
and then, the plates were incubated for 30 minutes at RT.  
 80 
 
The plates were washed for three times and then, 100 µl of the substrate solution which 
is the colour reagent Tetramethylbenzidine (TMB) for 30 minutes at RT.  
Finally, 50 µl of the stop solution; 2 M sulphuric acid (2 M H2SO4) were added to each 
well.  
The absorbance of the plate wells was measured using the versa max micro-plate reader 
with SoftMax pro version 2.4.1 software to determine the presence and quantity of antigen 
5-parameter statistical model.  
 
2.12. Data analysis and statistics. 
At least, three independent experiments for qPCR and for ELISA were done in duplicate. 
qPCR results were analysed using a number of algorithms. The PC-Miner software (Zhao 
et al., 2005) was used to calculate the Cycle Threshold and the Efficiency values of the 
genes of interest.  
The ELISA protein was normalised against the total RNA concentration (Muratore et al., 
2014) and re-analysed due to the cytotoxicity of the lipofectamine 2000 transfection 
reagent.  
The one-way analysis of variance (ANOVA) including Tuckey as a multiple comparison 
for all pairs columns and t-test which is provided by the GraphPad Prism 5 software was 
used to statistically analyse the data of both RT-PCR and ELISA and the P-value < 0.05 
was considered significant. Normal distribution was determined using Sigma Plot 13.0 as 
well as SPSS® software according to (Shapiro and Wilk, 1965), and all data were found 
to be normally distributed (for an e.g. Please see table 5 in Appendix 1). 
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Chapter 3: 
Transient over-expression of LPCAT-2 in 
RAW264.7 cells 
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Introduction. 
 
As described in chapter 1, sepsis is a life-threatening organ dysfunction caused by a 
dysregulated host response to infection. This dysregulated response results in an 
overwhelming inflammatory response to infection, especially to bacterial infection. No 
specific therapy for sepsis exists and the morbidity and mortality from this condition 
therefore remains high with a consequent huge economical and healthcare impact (Angus 
et al., 2006; Cheng & Shi, 2009; Guzzo et al., 2011; The Global Sepsis Alliance, 2016). 
Lipopolysaccharide (LPS) the endotoxin of Gram–negative bacteria, is an important 
trigger of sepsis and recognition of LPS by macrophages produce the inflammatory 
response to infection that can elicit sepsis.  (Cohen, 2002; Strassheim et al., 2002; Hoesel 
& Ward, 2004; Płóciennikowska et al., 2015).  Therefore, understanding the mechanisms 
and molecular pathways by which macrophages respond to signals such as LPS, will be 
key to deriving therapies to combat the uncontrolled inflammatory response which is the 
hallmark of sepsis.  
Work from the Jackson laboratory and others have shown that the phospholipid 
metabolizing enzyme Lysophosphatidylcholine acyltransferase (LPCAT) can control 
inflammatory responses to LPS in macrophages (Jackson et al., 2008; Sevastou et al., 
2013). It was previously shown that LPCAT has a role in inflammatory responses using 
pharmacological inhibitors, although the precise LPCAT species responsible could not be 
determined (Jackson et al., 2008). Availability of the gene sequences and cloning of 
LPCAT species allowed the identification of four major family members (LPCAT1-4) 
each with different but overlapping activities. (Chen et al., 2006; Shindou et al., 2007; 
Edwards & Constantinescu, 2009; Hishikawa et al., 2008; Morimoto et al., 2010; Zheng 
et al., 2012; Shindou et al., 2013; Morimoto et al., 2014).  The challenge is therefore to 
determine which LPCAT species is responsible for regulating the inflammatory response 
to LPS and other bacterial factors. This knowledge will allow new insights in to the 
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mechanisms of inflammation and will be required for new therapies aimed at these targets 
to be developed.  
Recent work has suggested that LPCAT-2 is the major species responsible for facilitating 
inflammatory responses in macrophages (Abate et al., 2016, Al-Rammah et al., 2016). In 
addition, it has been shown that LPCAT-2 is inducible in response to LPS and other 
bacterial ligands (Shindou et al., 2007; Morimoto et al., 2010, 2014) Mounting evidence 
suggests therefore, that LPCAT-2 is induced in macrophages in response to bacterial 
infection and can drive the inflammatory response in these cells.   
To determine the importance of LPCAT-2 is response to infection, the current chapter 
explores the role of LPCAT-2 in the inflammatory response of macrophages by 
transfecting and overexpressing the gene for LPCAT-2 in these cells. Overexpression of 
LPCAT-2 would be hypothesized to enhance the inflammatory response to LPS and other 
bacterial ligands. The cellular readouts for inflammatory responses in overexpression of 
LPCAT-2 are cytokines known to be produced by macrophages in TLR4-dependent 
responses to LPS. These include TNFα, IL-6, IL-10 and IFN-γ, and they have been shown 
to be predominantly important in the development of septic shock (Doherty et al., 1992; 
Silva & Cohen, 1992; Rothe et al., 1993; Dellinger et al., 2004; Daniel, 2010). In addition, 
as there are many bacterial causes of sepsis, including Gram positive organisms, other 
molecules that can stimulate different TLR pathways were used. To explore other TLR 
ligands, this project used the synthetic triacylated lipoprotein Pam3CSK4 which is a 
TLR1/2 ligand with similar structure to lipoprotein cell wall components found in both 
Gram positive and Gram negative bacteria.  
This chapter explores the gene expression profiles of RAW264.7 cells transfected with 
LPCAT-2 (LPCAT-2+) and using pCMV6 empty vector plasmid as control. Transient 
transfection of RAW264.7 cells using Lipofectamine 2000 and a plasmid carrying the 
murine LPCAT-2 was used to study the overexpression of (LPCAT-2). In addition, 
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silencing of the LPCAT-2 gene using specific siRNA sequences, is a convenient method 
of proving the role of LPCAT-2 in the inflammatory responses.  Therefore, experiments 
were also performed to evaluate the effect of silencing of the over-expression of LPCAT-
2 in the inflammatory readouts. 
 
3.1. Cloning of murine and human Lysophosphatidylcholine 
acyltransferase – 2 (LPCAT -2). 
 
 A single colony of transformed competent bacteria i.e. transformed with pCMV6 plasmid 
with or without the murine (mLPCAT-2) was inserted onto separate Luria Britania (LB) 
plates with kanamycin (KAN) 25 µg/ml and diluted in four different dilutions: (1 %, 10 %, 
50 % and 100 %) (Please see section 2.8. in materials and methods).  
The plate with 50 % or 100 % diluent transformed cells showed many colonies compared 
with 1% transformed cells which showed few colonies. In addition, non-transformed 
competent bacteria (i.e. bacteria not possessing the gene for kanamycin resistance) 
showed no growth while the non-transformed competent cell colonies on a plate without 
kanamycin showed full growth of colonies. This is shown in figure 3.1. 
Purification of the plasmid with or without the mLPCAT-2 clones was performed after 
the transformed colonies were selected by transferring 1 single colony from the LB Plate 
with 25 µg/ml of kanamycin into LB-Broth with 60 µg/ml of kanamycin overnight at 37 
ºC in a shaking incubator (for more details, please see 2.8. materials and methods.).  
Next, the purified miniprep plasmid and the mLPCAT-2 recombinant gene was checked 
by traditional PCR and agarose gel electrophoresis to confirm the existence of the inserted 
genes (1730 bp) within the pCMV6-Entry vector (4919 bp) Plasmid as shown in figure 
3.2.  
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Figure 3.1. Competent bacteria transformed with  or without Plasmid containing 
murine LPCAT-2 (mLPCAT-2 and hLPCAT-2).  
 
 (A): Transformed competent cells with the murine LPCAT-2 gene with SOC medium (a 
nutrient- rich microbial growth medium) mixture incubated at 37 ºC in a shaking 
incubator for 1 hour prior to inoculation on Louria Britania (LB) agar plates with 
25µg/mL Kanamycin (KAN) overnight at 37 ºC in a shaking incubator that showed the 
single colonies.  
(B): Transformed competent cells with the human LPCAT-2 gene with SOC medium 
mixture incubated at 37 ºC in a shaking incubator for 1 hour prior to inoculation on Louria 
Britania (LB) agar plates with 25 µg/mL Kanamycin (KAN) overnight at 37 ºC in a 
shaking incubator that showed the single colonies.  
(C): Non-transformed competent cells with no colonies.   
(D): Non-transformed competent cells on LB plate without Kanamycin with bacterial 
colonies. 
  
C D 
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Figure 3.2. Agarose gel electrophoresis confirmation of miniprep purification and 
cloning of the PCR product from murine LPCAT-2 recombinant gene in pCMV6 - 
entry vector (4.919 kb) Plasmid. 
 
 (A) PCR product performed with conventional PCR format on agarose gel 
electrophoresis which shows the murine (Lane 1 and 2) LPCAT-2 recombinant gene 
(1731 bp) in pCMV6 - Entry vector (4.919 kb) Plasmid.  
(B) MiniPrep Plasmid (pCMV6 - Entry vector (4.919 kb)) carrying the murine LPCAT-
2 (Lane 1 - 4) recombinant gene which shows three bands: Linear, more super coiled and 
nicked open circular.  
Lane 5: Molecular DNA Ladder. 
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3.2. Transient expression of Murine Lysophosphatidylcholine acyltransferase 
– 2 (LPCAT -2) in RAW264.7 cells. 
 
To optimise the transfection, two different transfection reagents (Lipofectamine 2000 and 
Jet Prime) at four different volumes (6, 9, 12, 15) µl, (please see section (2.2.1.4) and 
(2.2.1.5), materials and methods), were used to express LPCAT-2 in RAW264.7 for 48 
hours. Transfection was transient due to the cytotoxicity of the transfection reagent. 
Figure 3.3, shows an obvious reduction in the number of the viable transfected cells with 
increasing concentration of the transfection reagent.  
This also shows that the number of cells treated with Lipofectamine 2000 was greater 
than the number of cells treated with JetPrime. This was due to the difference in the 
number of RAW264.7 cells per well in each experiment set; 1 x 106 cells/well for 
Lipofectamine 2000 as against 2 x 105 cells/well for JetPrime transfection reagent.  
However, Lipofectamine 2000 reagent was toxic to the transiently transfected RAW264.7 
cells with a miniprep purified plasmid carrying the murine LPCAT-2 genes but not the 
JetPrime, although its efficiency is better than the efficiency of JetPrime.  
Therefore, Lipofectamine 2000 transfection reagent was selected for use for all the future 
experiments. To confirm the LPCAT-2 expression, the protein samples were checked by 
western blot using anti-Flag antibody as shown in Figure 3.4.  
western blot results show protein expression bands of LPCAT-2 which shows two bands 
at a molecular weight of 56 and 35 KD in the transfected RAW264.7 using mouse Anti-
flag antibody. The band at 35KD is suggested to be another isoform of LPCAT-2.   
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Figure 3.3. Transfection of RAW264.7 cells using JetPrime and Lipofectamine 2000 
transfection reagents after 48 hours (Using inverted microscope, X10).  
 
Cell proliferation is reduced with the type of transfection reagents and their 
concentrations related to the starting concentration of RAW264.7 cells (2 X 105) and (1 
X 106) cells/ 2.5 mL complete DMEM medium for JetPrime and Lipofectamine 2000 
transfection respectively as below:  
(A) RAW264.7 cells alone as a control without Jet Prime transfection reagent after 48 
hours. (B) RAW264.7 cells with 6 µL of Jet Prime after 48 hours.  (C) Transfected 
RAW264.7 cells with 2 µg of purified plasmid carrying murine LPCAT-2 insert and 6 
µL JetPrime showing a reduction in cell number after 48 hours. (D) Control, non-
transfected RAW264.7 cells without Lipofecamine2000 (E) RAW264.7 cells with 6 µL 
of Lipofecamine2000 transfection reagent after 48 hours. (F) Transfected RAW264.7 
cells with 2.5 µg of a purified plasmid carrying murine LPCAT-2 insert and 6 µL 
Lipofectamine 2000 transfection reagent after 48 hours. (G) Control, non-transfected 
G 
F E D 
C B A 
H I 
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RAW264.7 cells without Lipofecamine2000 transfection reagent after 48 hours. (H) 
RAW264.7 cells with 9µL of Lipofecamine2000 after 48 hours. (I) Transfected RAW264.7 
cells with 2.5 µg of a purified plasmid carrying murine LPCAT-2. recombinant gene and 9µL 
Lipofectamine 2000 after 48 hours. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure: 3.4. Western blotting confirmation of murine LPCAT-2 expression in 
RAW264.7 cells using JetPrime. 
 
(A) or Lipofectamine 2000 (B) transfection reagents, detected using Anti-Flag Ab. Lane 
1 – control untransfected RAW 264.7 cells, Lane 2 – RAW cells transfected with 6 uL of 
transfection reagent, Lane 3 – RAW cells transfected with 9 uL transfection reagent. 
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3.3. Expression of murine LPCAT-2 in transiently transfected 
RAW264.7 murine macrophages. 
 
A transient transfection is an important step to ensure inserting a single LPCAT-2 
isoform; through a transfection process using the MiniPrep purified pCMV6 - entry vector 
(4.919 kb) plasmid carrying the recombinant murine LPCAT-2 into mammalian cells. 
RAW264.7 cells were used as a model of murine macrophages to investigate the role of 
the LPCAT-2 enzyme in the immune response in these cells.  
Murine LPCAT-2 gene was transiently transfected into RAW264.7 cells using 
Lipofectamine 2000 transfection reagent and the MiniPrep purified pCMV6 - entry vector 
(4.919 kb) plasmid carrying the recombinant murine LPCAT-2 gene. The plasmid was 
previously amplified by transformation of competent bacteria (E. coli). The LPCAT-2 
overexpression was confirmed using RT-PCR (see Figures 3.4 and 3.5). The mean values 
in fold increase is shown in table 2. 
The achievement of satisfactory gene over-expression (as shown by the fold increase) 
relative to Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) expression was 
important as this would determine the reliability of subsequent results.  
First, transiently transfected RAW264.7 cells (LPCAT-2+) were plated in 6 well plates at 
a cell concentration of 5 x 105 cells/ well in 2.5 ml of complete DMEM. Transiently 
transfected cells showed a higher expression of LPCAT-2 (6.46 -fold increase; P < 0.03) 
compared to control RAW264.7 cells with empty vector. This is shown in Figure 3.5 
below. RAW264.7 cells that transiently over-expressed the murine LPCAT-2 will be 
termed ‘LPCAT-2+’, RAW264.7 cells with empty vector will be termed ‘pCMV6’,  
Increased LPCAT-2 protein expression was confirmed by Western blotting using specific 
Anti-Flag antibody (Figure 3.5).  
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Figure 3.5. Confirmation of Murine LPCAT-2 gene over expression in RAW264.7 
cells by RT-PCR. 
 
This shows a significant over-expression of LPCAT-2 in the LPCAT-2 transfected cells 
(LPCAT-2+) (Red Bar) after 24 hours incubation at 37 ºC compared to cells transfected 
with empty vector (pCMV6) (Blue Bar) (Fold increase = 6.46; * P = 0.0264; n = 4), 
pCMV6 = RAW264.7 cells transfected with empty vector plasmid; LPCAT-2+ = 
RAW264.7 cells transfected with murine LPCAT-2 gene.  
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3.4. LPS-stimulated induction of LPCAT-2 in RAW264.7 cells 
transiently over-expressed murine LPCAT-2.  
 
To explore the successful over-expression of the LPCAT-2 gene, further experiments 
were conducted to compare the gene expression of LPCAT-2 and its effects on immune 
responses. Stimulation of RAW264.7 cells with LPS produced a significant increase in 
LPCAT gene expression in cells over-expressing the LPCAT-2 gene (Figure 3.6).  
RAW264.7 cells were transiently transfected by plasmid with or without murine LPCAT-
2 insert using Lipofectamine 2000 transfection reagent.  
These cells were subsequently stimulated with LPS for 6 hours at 37 ºC. As shown in 
Figure 3.6, LPS treatment stimulates LPCAT-2 expression but this is significantly 
upregulated (P= 0.0001) in cells transfected with LPCAT-2 gene (LPCAT-2+) compared 
to pCMV6 cells. The mean values in fold increase is shown in table 2. 
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Figure 3.6. RT-PCR confirmation of LPCAT-2 gene expression in RAW264.7 cells 
stimulated with LPS  
 
LPCAT-2 was significantly over-expressed in LPCAT-2+ cells (Red Bar) without LPS 
compared to pCMV6 (Blue Bar) (4.4 fold increase) and this was equivalent to the LPS-
induced expression of LPCAT-2 in pCMV6 cells.  However, LPCAT-2 expression was 
much higher when LPCAT over-expressing cells (LPCAT-2+) were stimulated with LPS 
(E coli lipopolysaccharide (LPS) O111:B4) (19.9 fold increase). Data represented the 
mean of four independent experiments (n = 4) ± standard error. * = P < 0.01, ** = P < 
0.001, *** = P < 0.0001, pCMV6 = RAW264.7 cells transfected with empty vector 
plasmid; LPCAT-2+ = RAW264.7 cells transiently transfected with murine LPCAT-2 
gene.  
  
 LPS + - + - 
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3.5. Induction of TNF-α and IL-6 gene expression in RAW264.7 cells 
transiently transfected with murine LPCAT-2. 
 
Following the successful over-expression of mLPCAT-2 in RAW264.7 cells, further 
experiments were conducted to investigate the effects of this overexpression on innate 
immune responses using expression of the pro-inflammatory cytokines tumour necrosis 
factor (mTNF-α) and interleukin-6 (mIL-6).  
When LPCAT-2+ and pCMV6 cells were stimulated with LPS for 6 hours at 37 ºC, 
mTNF-α and mIL-6 mRNA were significantly up-regulated (P = 0.0001, n = 4) compared 
with LPS-stimulated pCMV6 cells (Figure 3.7A and B). The mean values in fold increase 
is shown in table 2. 
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Figure 3.7A. LPCAT-2 overexpression up-regulates pro-inflammatory cytokine, 
TNF-α in RAW264.7 that Transiently over-expressed LPCAT-2 stimulated with 
lipopolysaccharide (LPS). 
 
pCMV6 and LPCAT-2+ cells were stimulated with 1 µg/ml LPS for 6 hours at 37 ˚C and 
analysed by RT-PCR normalised against the CT values of GAPDH. Overexpression of 
LPCAT-2 led to significantly increased gene expression of TNF-alpha compared to the 
pCMV6 cells. Data represented the mean of four independent experiments (n = 4) ± 
standard error, ** = P < 0.001, *** = P < 0.0001, pCMV6 = RAW264.7 cells transfected 
with empty vector plasmid (Blue Bar), LPCAT-2+ = RAW264.7 cells transfected cells 
with murine LPCAT-2 (Red Bar).  
 
LPS + - + - 
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Figure 3.7B. LPCAT-2 overexpression up-regulates pro-inflammatory cytokines 
(IL-6) in transient transfected RAW264.7 cells stimulated with lipopolysaccharide 
(LPS). 
 
pCMV6 and LPCAT-2+ cells were stimulated with 1 µg/ml LPS for 6 hours at 37 ˚C and 
analysed by RT-PCR normalised against the CT values of GAPDH. Overexpression of 
LPCAT-2 led to significantly increased gene expression of IL-6 compared to the pCMV6 
cells.  
Data represented the mean of four independent experiments (n = 4) ± standard error.  
* = P < 0.05, *** = P < 0.0001, pCMV6 = RAW264.7 cells transfected with empty vector 
plasmid (Blue Bar); LPCAT-2+ = RAW264.7 cells transfected with murine LPCAT-2 
gene (Red Bar).  
 
 
 
 
 
 LPS + - + - 
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3.6. Induction of IL-10 gene expression in RAW264.7 cells transiently 
transfected with murine LPCAT-2.  
 
Experiments were also conducted to investigate the expression of the anti-inflammatory 
cytokine IL-10 in cells over expressing LPCAT-2. LPS stimulation of RAW264.7cells 
transfected with an empty vector plasmid (pCMV6) produced a significant induction of 
IL-10 (mIL-10) gene expression (Figure 3.8). The mean values in fold increase is shown 
in table 2.  
However, in comparison, LPS- stimulation of RAW264.7 cells transfected with the 
LPCAT-2 plasmid (LPCAT-2+) induced much less IL-10 (Figure 3.8). Interestingly, 
transfection of RAW264.7 cells with LPCAT-2 led to an increase in IL-10 gene induction 
in unstimulated cells (Figure 3.8).  
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Figure 3.8. LPCAT-2 over-expression down-regulates IL-10 in LPS-stimulated 
RAW264.7 cells.  
 
RT-PCR analyses showing LPCAT-2 significantly blunts IL-10 mRNA expression in 
LPCAT-2+ cells (Red Bar) compared to pCMV6 cells (Blue Bar) (P < 0.0001). In the 
absence of LPS stimulation LPCAT-2+ cells showed a higher induction of IL-10 mRNA 
compared to the pCMV6 cells. (P < 0.0003). Data represented the mean of four 
independent experiments (n = 4) ± standard error. *= P < 0.01, **= P < 0.001, ** = P < 
0.0001, pCMV6 = RAW264.7cells transfected with empty vector plasmid; LPCAT-2+ = 
RAW264.7 cells transfected with murine LPCAT-2 gene.  
 
 
 
 LPS + - + - 
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3.7. Enzyme-Linked Immunosorbent Assay (ELISA) for TNF-alpha and 
IL-6 protein in RAW264.7 cells stimulated with LPS. 
 
To confirm the effects of LPCAT over expression on macrophage responses, cytokine 
protein expression was investigated by ELISA. RAW264.7 cells transfected with 
LPCAT-2 (LPCAT-2+) and RAW264.7 cells transfected with empty vector (pCMV6) 
were treated with LPS and supernatants were collected after 24 hours and analysed for 
TNF-alpha and IL-6 protein concentration by ELISA (Figure 3.9 A and B). The mean 
values in pg/ml is shown in table 2. 
The cytokine protein concentration values were normalised against total RNA 
concentrations (Muratore et al., 2014) (see section 2.11, materials and methods). 
Normalisation against the RNA concentrations was done because this provided a suitable 
yardstick against which the protein concentrations can be measured.  
The toxic effect of the combination of the plasmid with the LPCAT-2 recombinant protein 
and the Lipofectamine transfection reagent reduces the number of viable cells in the 
transfected RAW264.7 cells.  
The results (Figure 3.9) show that there is significant upregulation of TNF-α and IL-6 
protein production (P = 0.0001) in LPCAT-2+ cells treated with LPS. 
 
 
 
 
 
 
 
 
  
 100 
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Figure 3.9A. Enzyme-Linked Immunosorbent Assay (ELISA) for TNF-α in in 
RAW264.7 cells stimulated with LPS 
 
LPCAT-2 over-expression up-regulates pro-inflammatory cytokine, TNF-α in cells 
stimulated with LPS. TNF-α protein concentrations were calculated after normalisation 
of the ELISA values against the total RNA concentrations (please see 2.11, material and 
methods). Results are presented as Mean ± Standard error (SE) from four independent 
experiments (n = 4), * = P < 0.01, ** = P < 0.001, *** = P < 0.0001, pCMV6 = 
RAW264.7 cells transfected with empty vector plasmid (Blue Bar); LPCAT-2+ = 
RAW264.7 cells transfected with murine LPCAT-2 gene (Red Bar).  
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Enzyme-linked immunosorbent assay (ELISA)  for IL-6 in RAW264.7
stimulated with LPS normalised against total RNA concentration
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Figure 3.9B. Enzyme-Linked Immunosorbent Assay (ELISA) for IL-6 in in 
RAW264.7 cells stimulated with LPS. 
 
LPCAT-2 over-expression up-regulates IL-6 cytokines in cells stimulated with LPS. IL-
6 protein concentrations were calculated after normalisation of the ELISA values against 
the total RNA concentrations (please see 2.11, material and methods). Results are 
presented as Mean ± Standard error (SE) from four independent experiments (n = 4),  
** = P < 0.001, *** = P < 0.0001, pCMV6 = RAW264.7cells transfected with empty 
vector plasmid (Blue Bar), LPCAT-2+ = transient transfected RAW264.7 cells with 
murine LPCAT-2 gene (Red Bar).  
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3.8. TLR2 ligand-stimulated induction of LPCAT-2 in RAW264.7 cells 
transiently transfected with LPCAT-2.  
 
Previous results (Figures 3.7 - 3.9) showed that LPCAT-2 over expression in RAW264.7 
cells significantly up-regulates inflammatory cell responses to LPS. TLR4 is the 
macrophage cell membrane surface receptor for LPS. However, it is important to find out 
if LPCAT may also affect responses to other TLR ligands as this will help to elucidate 
mechanistic approaches to the regulation of the inflammatory response.  
The effect of Pam3CSK4 stimulation on LPCAT-2 gene expression is shown in Figure 
3.10, The mean values as a fold increase is shown in table 2. 
 It can be seen that transfection with LPCAT-2, as expected, results in increased LPCAT-
2 expression but this expression is significantly further increased when cells are 
stimulated with Pam3CSK4 for 6 hours at 37 ºC.    
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Figure 3.10. Over-expression of murine LPCAT-2 in untreated and Pam3CSK4-
stimulated murine macrophages using RT-PCR.   
  
 This shows a significant over-expression of LPCAT-2 in the LPCAT-2+ (Red Bar) after 
24 hours’ incubation at 37 ºC compared to pCMV6 (Blue Bar) (Fold increase = 5. 5; * P 
= 0.0001; n =4), ***= P <0.0001; Results are presented the mean± Standard error (SE) 
from four independent experiments (n = 4), * = P < 0.01, ** = P < 0.001,  
*** = P < 0.0001. pCMV6 = RAW264.7 cells transfected with empty vector plasmid; 
LPCAT-2+ cells = RAW264.7 cells transfected with murine LPCAT-2 gene.  
  
 Pam3CSK4 + - +   - 
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3.9. Expression of TNF-α and IL-6 in transiently transfected and non-
transfected RAW264.7 cells stimulated with Pam3CSK4. 
 
Experiments were conducted to study if the LPCAT-2 gene over-expression would affect 
inflammatory cell responses to the TLR2 ligand Pam3CSK4. This was done by measuring 
gene expression of the pro-inflammatory cytokines TNF-α and IL-6. RAW264.7 cells 
were transiently transfected by plasmid with or without murine LPCAT-2 recombinant 
gene, using Lipofectamine 2000 transfection reagent for 48 hours at 37 ºC.  
Then both transfected and RAW264.7 cells with empty vector plasmid (pCMV6), were 
stimulated with Pam3CSK4 for 6 hours at 37 ºC. As can be seen in Figure 3.11, 
overexpression of LPCAT-2 significantly upregulated TNF-α and IL-6 gene expression 
(P < 0.0002 and < 0.0001 respectively). 
Interestingly, as can be seen in Figure 3.11, The mean values as a fold increase is shown 
in table 2. LPCAT-2+ (over-expression of LPCAT-2) cells alone, without Pam3CSK4 
stimulation, induced a significant induction of TNF-α gene expression compared to 
pCMV6 cells (RAW264.7 transfected with empty vector plasmid). However, this effect 
was not so evident for the induction of IL-6. 
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Figure 3.11A. LPCAT-2 overexpression up-regulates pro-inflammatory cytokine, 
TNF-α in  RAW264.7 cells stimulated with Pam3CSK4 using RT-PCR analysis 
system. 
 
pCMV6 and LPCAT-2+ cells were stimulated with 0.5 µg/ml Pam3CSK4 for 6 hours at 
37 ˚C and analysed by RT-PCR normalised, against the CT values of GAPDH. 
Overexpression of LPCAT-2 led to significantly increased gene expression of TNF-alpha 
(3.75 fold increases) in untreated pCMV6 cells and LPCAT-2+ respectively. However, it 
shows significantly up-regulated TNF-α in both cells, which is significantly higher in 
Pam3CSK4 stimulated LPCAT-2+ cells (Red Bar) compared to stimulated pCMV6 cells 
(Blue Bar) (21.3 vs 30.9) fold increase. Data represented the mean of four independent 
experiments (n = 4) ± standard error. **= P < 0.001, *** = P < 0.0001, pCMV6 = 
RAW264.7 cells transfected with empty vector plasmid; LPCAT-2+ cells = RAW264.7 
cells transfected with murine LPCAT-2 gene.  
 
 
 
 
 
Pam3CSK4 + - +   - 
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Figure 3.11B. LPCAT-2 overexpression up-regulates pro-inflammatory cytokine, 
IL-6 in RAW264.7 cells stimulated with Pam3CSK4 using RT-PCR analysis system. 
 
pCMV6 and LPCAT-2+ cells were stimulated with 0.5 µg/ml Pam3CSK4 for 6 hours at 
37 ˚C and analysed by RT-PCR normalised, against the CT values of GAPDH. 
Overexpression of LPCAT-2 led to significantly increased gene expression of TNF-alpha 
(1 fold increases) and (45.9) in untreated pCMV6 cells and LPCAT-2+ respectively. 
However, it shows significantly up-regulated IL-6 in both cells, which is significantly 
higher in Pam3CSK4 stimulated LPCAT-2+ cells (Red Bar) compared to stimulated 
pCMV6 cells (Blue Bar) (114.9 vs 40228.9) fold increase. Data represents The mean of 
four independent experiments (n = 4) ± standard error., *** = P < 0.0001. pCMV6 = 
RAW264.7 cells transfected with empty vector plasmid; LPCAT-2+ cells = RAW264.7 
cells transfected with empty murine LPCAT-2 gene.  
 
  
 
Pam3CSK4 + - +   - 
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3.10. IL-10 expression in transiently transfected and non-transfected 
RAW264.7 cells with Pam3CSK4.  
 
Experiments were also conducted to compare the induction of the anti-inflammatory 
cytokine IL-10, between transient RAW264.7, with or without, LPCAT-2 recombinant 
protein on plasmid vector, in four independent experiments, that the overexpression of 
LPCAT-2 gene has already checked and confirmed using RT-PCR analysis. The results 
show that RAW264.7, with or without Pam3CSK4 stimulation, is inducing IL-10 (45.9 
vs 14.4) and (1 vs 0.8) fold increase respectively (pCMV6 vs LPCAT-2+). The results of 
IL-10 induction are shown in Figure 3.12, The mean values as a fold increase is shown in 
table 2. 
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Figure 3.12. IL-10 gene expression in RAW264.7 cells stimulated with Pam3CSK4 
using RT-PCR analysis.  
 
RT-PCR analysis shows LPCAT-2 significantly reduces IL-10 mRNA expression in 
LPCAT-2+ cells (0.8 fold increase) (Red Bar) compared to pCMV6 cells (Blue Bar). (P 
= 0.0001). In the Pam3CSK4 stimulation for both cells; pCMV6 cells showed a 
significant higher induction of mIL-10 mRNA compared to the LPCAT-2+ cells (45.9 vs 
14.4, P = 0.027). There is significant induction of IL-10 gene expression in both LPCAT-
2+ and pCMV6, with significant differences, and much higher IL-10 induction in 
Pam3CSK4 induced pCMV6 cells. LPCAT-2 overexpression significantly down-
regulated IL-10 in LPCAT-2+ cells compared to pCMV6 cells which induced significantly 
higher IL-10 by Pam3CSK4 stimulation. Data represented the mean of four independent 
experiments (n = 4) ± standard error. * = P < 0.03, ** = P < 0.001, *** = P < 0.0001. 
pCMV6 = RAW264.7 cells transfected with empty vector plasmid; LPCAT-2+ cells = 
RAW264.7 cells transfected with empty murine LPCAT-2 gene.  
  
 Pam3CSK4 + - + - 
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3.11. Investigation the effect of LPCAT-2 silencing in the inflammatory 
response in LPS- induced RAW264.7 cells.  
 
Having established that over-expression of LPCAT-2 in macrophages increases the 
inflammatory response to TLR stimulation, we wanted to determine if the opposite was 
also true i.e. if inhibiting LPCAT-2 expression would decrease the inflammatory 
responses of the macrophages. We hypothesised therefore, that if LPCAT-2 were relevant 
in the inflammatory response of macrophages, successfully silencing the gene encoding 
this enzyme would result in a significant decrease in the expression of inflammatory 
cytokines such as TNF-α and IL-6. To inhibit LPCAT-2 expression, the technique of 
small interfering RNA (siRNA) was used (Hamilton & Baulcombe, 1999) (see materials 
and methods section 2.2.1.6. LPCAT-2 gene silencing). 
 
3.12. LPCAT-2 gene silencing in RAW264.7 stimulated with LPS.  
 
To establish the involvement of LPCAT-2 in the inflammatory responses of macrophages, 
the over-expressed LPCAT-2 gene was silenced and cell responses to subsequent 
stimulation by LPS was investigated. The success of a satisfactory gene silencing 
efficiency is vital, as this will determine the reliability of subsequent findings.  
In this project, approximately 88 % LPCAT-2 gene silencing was achieved, the mean 
values as a fold increase is shown in table 2. This is shown in Figure 3.13. RAW264.7 
over-expressing LPCAT-2 gene is termed ‘LPCAT-2+’. 
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The effect of silencing overexpressed LPCAT-2  on  LPCAT-2 gene
expression in RAW264.7 cells stimulated with LPS.
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Figure 3.13. LPCAT-2 expression in RAW 264.7 cells transiently over-expressing 
LPCAT-2 and treated with siRNA to knockdown LPCAT-2 gene expression in the 
absence and presence of LPS stimulation.  
 
The data was normalised against the CT values of GAPDH using RT-PCR analysis. 
RAW264.7 cells over-expressing the LPCAT-2 gene were treated with siRNA to knock-
down LPCAT-2 gene expression. LPCAT-2 was down-regulated (silenced) by a mean 
factor of (70 - 80 %). siRNA LPCAT-2 gene silencing knocked down LPCAT-2 
expression by 70% in the absence of LPS and by 88 % in LPS-stimulated cells.  
** = P < 0.01, *** = P < 0.0001, Data represented as Mean ± SE, from three independent 
experiments (n = 3).  LPCAT-2+ = RAW264.7 transiently overexpressing LPCAT-2 gene.  
  
 
LPS     +    -    +   - 
     +    -    + 
    -   +      -       + 
    Neg siRNA 
    LPCAT-2 siRNA 
     - 
 111 
 
3.13. Expression of TNF-α and IL-10 in silencing transfected RAW264.7 
cells with LPCAT-2. 
 
After the successful silencing of the over-expressed LPCAT-2 gene, further experiments 
were conducted to compare the gene expression of the pro-inflammatory cytokine TNF-
alpha, and the anti-inflammatory cytokine IL-10, between samples containing the 
negative siRNA and LPS, LPCAT-2 siRNA and LPS (Silenced over-expressed LPCAT-
2 genes). 
The findings of the comparison are illustrated in figure 3.14. There is an increase in IL-
10 when the RAW264.7 cells with the silenced LPCAT-2 are stimulated with LPS. See 
figure 3.14(A & B), the mean values as a fold increase is shown in table 2. 
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Figure 3.14A. The effect of silencing LPCAT-2 on TNF-α expression in stimulated 
and non-stimulated RAW264.7 cells. 
 
The data was normalised against the CT values of GAPDH using RT-PCR analysis. The 
silencing LPCAT-2 was significantly down-regulated TNF-α in the silencing over-
expressed LPCAT-2 is decreasing the TNF-α 1 vs (1.2; LPCAT-2+ with negative siRNA), 
and, it when the cells are stimulated with LPS, the TNF-α gene expression is significantly 
reduced due to the effect of silencing LPCAT-2 with fold increased, 15.4 vs (49.2; 
LPCAT-2+ with negative SiRNA + LPS) (P = 0.0001, n = 3).  
** =P < 0.01, *** = P < 0.0001, Data represented as Mean ± SE, from three independent 
experiments (n = 3). LPCAT-2+ = RAW264.7 transiently overexpressing LPCAT-2 gene.  
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The effect of silencing overexpressed LPCAT-2 on IL-10
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Figure 3.14B. The effect of silencing LPCAT-2 on IL-10 expression in stimulated 
and non stimulated RAW264.7 cells. 
 
The data was normalised against the CT values of GAPDH using RT-PCR analysis. The 
silencing over-expressed LPCAT-2 was significantly up-regulated the inflammatory 
cytokine (IL-10) in the non-stimulated silencing; LPCAT-2+ cells as a fold increase, 1 vs 
4.9; LPCAT-2+ with negative siRNA and it is increased more when the both cells were 
stimulated with LPS, but higher in the silencing overexpressing LPCAT-2 in a fold 
increase; 357.3 vs (260.2; LPCAT-2+ cells with negative siRNA, (P= 0.0001, n = 3).  
* = P < 0.01, *** = P < 0.0001, Data represented as Mean ± SE, n = 3. LPCAT-2+ = 
RAW264.7 cells transiently overexpressing LPCAT-2.  
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 + 
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Summary of results. 
 
Table 2 summarised the results of chapter 3; successful overexpression of LPCAT-2 in 
murine macrophages, RAW264.7 cells using Lipo-fectamine and JetPrime transfection 
reagents prior LPS stimulation, showed that Lipofectamine superior to JetPrime. 
Therefore, this project has used 9 µl of Lipofectamine transfection reagent as a protocol 
for all experiments. Overexpressing cells produce greater inflammatory gene expression 
(TNF-α, IL-6 and IL-10) LPS or Pam3CSK4 induced RAW264.7 cells, and TNF-α, IL-6 
protein production in LPS induced RAW264.7 cells (Please see table 2), these results 
have agreed with Abate et al., (2016), Alrammah et al., (2016) that LPCAT-2 is inducible 
and a key role in regulating inflammatory responses, while (Shindou et al., (2007); 
Morimoto et al., (2010, 2014) revealed to the inducible properties of LPCAT-2. 
Silencing the over-expressed LPCAT-2 in cells causes significant reduction in 
inflammatory gene expression (TNF-α) when stimulated with LPS. This agreed with 
recent results obtained by our laboratory in which LPCAT-2 silenced in MM6 cells using 
shRNA also caused a reduction in inflammatory cytokine production (Abate & Jackson, 
2015). However this project used siRNA and RAW264.7 cell line to silence over-
expressed LPCAT-2 and shows clear evidence of the role of LPCAT-2 in macrophage 
inflammatory responses i.e. these findings together revealed that LPCAT-2 has a vital 
role in regulating the induction of proinflammatory cytokines (Mayr et al., 2014; Kumar, 
2014; Lozano et al., 2014; Ogura et al., 2014; Singer et al., 2014; Henriksen et al., 2015; 
Singer et al., 2016; Jeganathan et al., 2017). 
The molecular mechanisms by which LPCAT-2 induces these effects should now be 
investigated and this is performed in Chapter 4. 
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Mean (fold increase vs empty vector pCMV6 control) 
           
 
 
 
A 
Target  pCMV6 LPCAT-2+ pCMV6  
+ LPS 
LPCAT-2+  
+LPS 
LPCAT-2 1 6.46 - - 
LPCAT-2 1 4.4 2.9 17.6 
TNF-α 1 3.2 74.4 259.8 
IL-6 1 6.6 30863.8 85800.2 
IL-10 1 8.9 143.6 28.7 
 
B 
LPCAT-2 1 5.5 1.4 9.4 
TNF-α 1 3.75 21.3 30.9 
IL-6 1 45.9 114.9 40228.9 
IL-10 1 0.8 45.9 14.4 
Mean (pg/ml vs empty vector pCMV6 control) 
 
C 
TNF-α 4.6 45.6 7777 17371.7 
IL-6 3.1 315.8 5705.5 16785.8 
Mean (fold increase vs empty vector pCMV6 control) 
 
 
D 
Target LPCAT-
2+ + Neg 
siRNA 
LPCAT-2+ 
+ LPCAT-
2 siRNA 
LPCAT-2+ 
+ Neg 
siRNA+ 
LPS 
LPCAT-2+ 
+ LPCAT-
2 siRNA 
+LPS 
LPCAT-2 1 0.3 2.54 0.31 
TNF-α 1 1.2 49.2 15.4 
IL-10 1 4.9 260.3 357.3 
 
Table 2. The effect of over-expressed LPCAT-2 and silencing overexpressing 
LPCAT-2 on inflammatory responces in LPS or Pam3CSK4 induced murine 
macrophages, RAW264.7 cells. 
 
A: Gene expression of over-expressed LPCAT-2 in LPS stimulated RAW264.7 cells 
(gene expression). Mean (fold increase vs empty vector pCMV6 control). B: The effect 
of over-expressed LPCAT-2 in Pam3CSK4 - stimulated RAW264.7 cells (gene 
expression). Mean (fold increase vs empty vector pCMV6 control). C: The effect of over-
expressed LPCAT-2 on protein release (pg/ml) in LPS-induced RAW264.7 cells. Mean 
(pg/ml vs empty vector pCMV6 control).  
D: The effect of silencing over-expressed LPCAT-2 in LPS- stimulated RAW264.7 cells 
(gene expression). Mean (fold increase vs empty vector pCMV6 control). pCMV6 = 
RAW264.7 + empty vector, LPCAT-2+ = RAW264.7 cells transiently transfected with 
LPCAT-2, Mean (fold increase vs empty vector pCMV6 control).       
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Chapter 4: 
Mechanism of action of LPCAT-2 in the 
inflammatory response to bacterial ligands 
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4.1. Mechanism of action of LPCAT-2 in the inflammatory response to 
bacterial ligands. 
A fundamental reason for the investigation of LPCAT and inflammation has been the lack 
of specific treatments for sepsis (Angus et al., 1997; Daniels, 2011; Global Sepsis 
Alliance, 2016).  Sepsis is regarded, at least initially, as an overwhelming inflammatory 
response to infection (Adib-Conquy et al., 2000; Adib-Conquy et al., 2012; Boomer et 
al., 2014; Global Sepsis Alliance, 2016). Triggering infections include Gram-negative 
and Gram-positive bacteria and their associated molecular patterns (Schorr et al., 2007; 
Daniels, 2011; Adhikari et al., 2010; Global Sepsis Alliance, 2015; Moskowitz et al., 
2017; Minasyan et al., 2017). The excessive, sustained and uncontrolled activation of 
macrophages in sepsis leads to a vicious cascade of inflammatory mediator release that 
amplifies the inflammation to the detriment of the host (Rangel-Frausto et al., 1995; 
Płóciennikowska et al., 2015).   
As part of the first line of host defence during infection the PRR are a family of receptors 
present on the cell membrane or in the cytosol of cell such as  monocytes, macrophages 
and dendritic cells that recognise pathogen-associated molecular patterns (PAMPs) (Kim 
et al., 2007; Płóciennikowska et al., 2015). As a result of recognition of the PAMPs, TLRs 
trigger the induction of pro-inflammatory mediators helping to eradicate infection (Chen 
et al., 2011; Płóciennikowska et al., 2015).  
LPS is recognied by TLR4 on the cell surface facilitated through LPS-binding 
protein(LBP) to form complexes, which are transferred and bind to soluble CD14 
(sCD14) or membrane-bound CD14 which binds to the extracellular domain of TLR4-
MD2 complexes. The CD14 and MD2 act as accessory proteins for LPS/TLR4 binding 
(Ulevitch & Tobias 1999; Heumann & Roger 2002; Płóciennikowska et al., 2015), 
followed by TLR4 oligomerisation and activation of the down stream signaling cascade 
(Płóciennikowska et al., 2015).    
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As the previous results (Chapter 3) showed that LPCAT-2 has a key role in macrophage 
inflammatory responses to LPS and other bacterial ligands, we now sought to elucidate 
the mechanism of action of LPCAT-2 in the inflammatory response. As TLR recognition 
of bacterial PAMPs is key for the signaling and responses of macrophages, this chapter 
explored the role of LPCAT-2 in the expression of the LPS receptors TLR4 and CD14. 
In addition, we investigated the effect of LPCAT-2 on the expression of TLR2, the 
receptor for the synthetic triacylated lipoprotein Pam3CSK4 which is a TLR1/2 ligand with 
similar structure to lipoprotein cell wall components found in both Gram positive and Gram 
negative bacteria.  
To further elucidate the mechanisms of LPCAT-2 action in macrophages, the role of 
LPCAT-2 on lipid mediators was also studied. LPS is identified to stimulate COX-2 
(Funk, 2001), and this suggested that the overexpression of LPCAT-2 would also 
significantly increase inducible COX-2 expression. Recent studies have confirmed that 
the peroxisome proliferator-activated receptors (PPARs) and in particular (PPAR-γ) have 
important roles in the regulation of macrophage phenotype (Karp et al., 1991; Mueller et 
al., 1998; von Knethen et al., 2007; Chawla, 2010). This, coupled with the role of PPAR-
γ in lipid metabolism, suggested that LPCAT-2 might have effects on PPAR-γ and this 
was therefore investigated in the current project.  
We hypothesise that PPAR-γ upregulates fatty acid oxidation and supports an M2 
macrophage phenotype whereas LPCAT-2 utilises fatty acids for phospholipid synthesis 
and would be associated with an M1 inflammatory phenotype of macrophage activation. 
This was examined by determining the expression of iNOS as a molecular marker of M1 
macrophages and CD206 as a marker of M2 macrophages (Mandal et al., 2011) in cells 
over expressing LPCAT-2 or where LPCAT-2 gene expression was silenced.  
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Figure 4.1A. The effect of over-expression of LPCAT-2 on the expression of TLR4, 
in RAW264.7 cells. 
 
RAW264.7 cells were transfected with LPCAT-2 (LPCAT-2+; Red Bar) or untransfected 
(pCMV6; Blue Bar) and stimulated with LPS or without as controls. LPCAT-2+ cells 
show increased expression of TLR4 in unstimulated cells (p<0.005 vs pCMV6). 
Treatment with LPS decreased TLR4 expression in both pCMV6 and LPCAT-2+ cells. 
Data represents the mean of 4 independent experiments (n = 4) ± standard error,  
** = P < 0.01, *** = P < 0.0001 versus pCMV6. pCMV6= RAW264.7 + empty vector 
plasmid, LPCAT-2+ = LPCAT-2 transient transfected RAW264.7 cells.  
 
 
LPS 
   +   -    + - 
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CD14 gene expression in RAW264.7 stmulated with LPS.
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Figure 4.1B. The effect of over-expression of LPCAT-2 on the expression of CD14 
in RAW264.7 cells. 
 
RAW264.7 cells were transfected with LPCAT-2 (LPCAT-2+; Red Bar) or untransfected 
(pCMV6; Blue Bar) and stimulated with LPS or without as controls. LPCAT-2 
transfection induced significant CD14 expression and this was further significantly 
increased after LPS treatment (p<0.0001 vs pCMV6). Data represented the mean of 4 
independent experiments (n = 4) ± standard error, ** = P < 0.01,  *** = P < 0.0001 versus 
pCMV6. pCMV6 = RAW264.7 + empty vector plasmid; LPCAT-2+ = LPCAT-2 transient 
transfected RAW264.7 cells.  
 
 
 LPS     +   -    + - 
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TLR2 gene expression in RAW264.7 cells stimulated with LPS.
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Figure 4.1C. The effect of over-expression of LPCAT-2 on the expression of TLR2 
in RAW264.7 cells. 
 
RAW264.7 cells were transfected with LPCAT-2 (LPCAT-2+; Red Bar) or untransfected 
(pCMV6; Blue Bar) and stimulated with LPS or without as controls. LPCAT-2 
transfection significantly increased the expression of TLR2 in response to LPS in both 
unstimulated and LPS-stimulated cells. (P=0.0052 vs pCMV6). Data represents the mean 
of 4 independent experiments (n = 4) ± standard error, * = P < 0.1, *** = P < 0.001 versus 
pCMV6. pCMV6 = RAW264.7 + empty vector plasmid; LPCAT-2+ = LPCAT-2 transient 
transfected RAW264.7 cells.  
 
 
 LPS     +   -    + - 
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TLR2 gene expression in RAW264.7 cells stimulated with Pam3CSK4 .
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Figure 4.1D. The effect of over-expression of LPCAT-2 on the expression of TLR2 
in RAW264.7 cells. 
 
RAW264.7 cells were transfected with LPCAT-2 (LPCAT-2+; Red Bar) or empty vector 
plasmid (pCMV6; Blue Bar) and stimulated with Pam3CSK4 or without as controls. 
LPCAT-2 transfection significantly increased the expression of TLR2 in response to 
Pam3CSK4 in both unstimulated and LPS-stimulated cells. (P=0.0062 vs pCMV6). Data 
represents the mean of 3 independent experiments (n = 4) ± standard error, * = P < 0.01, 
** = P < 0.001 versus pCMV6. pCMV6 = RAW264.7 + empty vector plasmid; LPCAT-
2+ = LPCAT-2 transient transfected RAW264.7 cells.  
 
  
 Pam3CSK4     +   -    + - 
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4.2. Effect of overexpression of LPCAT-2 on cyclo-oxygenase enzymes 
(COX-2) and peroxisome proliferator-activated receptor–gamma 
(PPAR-γ) expression in RAW264.7 macrophages. 
 
To further elucidate the mechanisms of LPCAT-2 action in macrophages, the role of 
LPCAT-2 on lipid mediators was also studied. LPS is identified to stimulate COX-2 
(Funk, 2001), and this project is suggested that the overexpression of LPCAT-2 would 
also significantly increase inducible COX-2 expression.  
As the previous experiments showed that LPCAT-2 can promote the expression of 
molecules in the TLR-mediated inflammatory pathways while suppressing PPAR-γ, a 
molecule associated with anti-inflammatory phenotype we next investigated if LPCAT-2 
can regulate macrophage phenotypes.  
Recent studies have shown that inhibition of COX-2 using Meloxicam inactivates the 
MAPK pathway and regulates p53 and cell apoptosis, both of which are stimulated via 
TLR4 signalling, which is critical for LPS-induced signalling cascades (Park et al., 2016). 
Several studies have reported that COX-2 regulates p53 activity and inhibits p53-
dependent apoptosis (Choi et al., 2005; Chen et al., 2009) which suggests that LPCAT-2 
might have a role to play in cell cycle and apoptosis.  
RAW264.7 cells with (LPCAT-2+) and without pCMV6  (WT) murine LPCAT-2 insert 
were stimulated with LPS for 6 hours and COX-2 expression was measured by RT-PCR.  
COX-2 was not expressed in cells without LPS treatment (Fig 4.2) confirming this is an 
LPS inducible gene. LPS treatment induced COX-2 expression in RAW264.7 cells and 
this was significantly increased (p<0.0001) in LPCAT-2+ cells (Fig 4.2).  
The opposite effect was seen with PPAR-γ expression in RAW264.7 cells (Fig 4.3). LPS 
treatment caused a down-regulation in PPAR-γ gene expression pCMV6 (WT) cells while 
LPCAT-2+ caused a complete reducing of PPAR-γ expression in cells with or without 
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LPS treatment (Fig 4.3), table 3 is shown the mean values as a fold increase vs pCMV6 
cells. 
Indeed, that the results of the current work suggested that LPCAT-2 has a vital role in 
regulation other enzymes within the macrophages cells, more studies need to be applied. 
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Figure 4.2. The effects of LPCAT-2 over-expression on COX-2 expression in 
RAW264.7 macrophages.  
  
RAW 264.7 cells either transfected with LPCAT-2 (LPCAT-2+) (Red Bar) or with empty 
vector (control, WT) (Blue Bar) were stimulated with LPS for 6 hours, COX-2 gene 
expression was determined by RT-PCR. LPS treatment is required for COX-2 expression 
(inducible) and COX-2 expression was significantly increased in LPCAT-2+ cells. Data 
represents the mean of three independent experiments (n=3) ± standard error.  
***= P < 0.0001. pCMV6  = RAW264.7 + empty vector plasmid, LPCAT-2+ = 
RAW264.7 cells transiently transfected with murine LPCAT-2.  
 
 
  
  
 LPS     +   -    + - 
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PPAR- gene expression in RAW264.7 cells stimulated with LPS.
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Figure 4.3. The effects of LPCAT-2 over-expression on PPAR-γ expression in 
RAW264.7 macrophages.   
 
RAW 264.7 cells either transfected with LPCAT-2 (LPCAT-2+) (Red Bar) or with empty 
vector (control, WT) (Blue Bar) were treated with LPS for 6 hours or untreated controls 
and PPAR-γ gene expression was determined by RT-PCR. LPS treatment decreased 
PPAR-γ gene expression in pCMV6  cells. LPCAT-2 overexpression (LPCAT-2+) 
significantly down-regulated PPAR-γ gene expression in both LPS stimulated and 
unstimulated pCMV6 cells.  
Data represents the mean of three independent experiments (n=3) ± standard error. 
 **= P < 0.001, ***= P < 0.0001. pCMV6 = RAW264.7 + empty vector plasmid, 
LPCAT-2+ = RAW264.7 cells transiently transfected with murine LPCAT-2.  
 
 
 
 
 
 
 
 LPS     +   -    + - 
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4.3. The effect of the selective peroxisome proliferator-activated 
receptor–gamma (PPAR-γ) antagonist T0070907 on LPCAT-2 
expression. 
 
Recent studies have confirmed that the peroxisome proliferator-activated receptors 
(PPARs) and in particular (PPAR-γ) have important roles in the regulation of macrophage 
phenotype (Karp et al., 1991; Mueller et al., 1998; von Knethen et al., 2007; Chawla, 
2010; Assunção et al., 2017). This, coupled with the role of PPAR-γ in lipid metabolism, 
suggested that LPCAT-2 might have effects on PPAR-γ.  
The results in Figure 4.3 show that transfection of RAW264.7 macrophages with LPCAT-
2 inhibits PPAR-γ expression. It was therefore important to examine if inhibition of 
PPAR-γ could also affect LPCAT-2 expression. For this, the selective PPAR-γ antagonist 
T0070907 (2-Cloro-5-nitro-N-4-pyridinylbenzaminde) at a concentration of (0.1 and 1 
mM) or vehicle (DMSO) were added to RAW264.7 cells.   
The cells were then treated with LPS (1 µg/ml) for 6 hours at 37 ºC. Expression of 
LPCAT-2 gene was determined by RT-PCR.  
Interestingly, when PPAR-γ was inhibited by treating the cells with the selective -gamma 
antagonist, T0070907, the level of LPCAT-2 gene expression increased. This increase in 
LPCAT-2 expression was found to be dependent on the concentration of the PPAR-γ 
antagonist and therefore a dose-response relationship linking the two molecules was 
established (Figure 4.4), Table 3 is shown the mean values as a fold increase vs control 
RAW264,7. 
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Effect of selective PPAR- antagonist on LPCAT-2 expression using Real time
polymerase chain reaction(RT-PCR) analysis.
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Figure 4.4. RT-PCR analysis of the effect of selective peroxisome PPAR-γ antagonist 
T0070907 on LPCAT-2 expression.   
 
RAW264.7 cells were either untreated (control)) or treated with or without the selective 
PPAR-γ antagonist T0070907. Addition of PPAR-γ antagonist T0070907 was found to 
enhance expression of LPCAT-2 in a dose-dependent manner in response to LPS. Data 
represented the mean of three independent experiments (n= 3) ± standard error.  
 *= P < 0.05 vs control, **= P < 0.001 ***= P < 0.0001. Control= RAW264.7 cells.  
  
 
LPS (Iµg/ml     +  +    + - 
   -   -     0.1     1     T0070907 (mM) 
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4.4. The effect of LPCAT-2 overexpression on the expression of M1 and 
M2 macrophage markers inducible nitric oxide synthase (iNOS) and 
CD206.  
  
As the previous experiments showed that LPCAT-2 can promote the expression of 
signalling molecules in the TLR-mediated inflammatory pathways while suppressing 
PPAR-γ, a molecule associated with anti-inflammatory phenotype we next investigated 
if LPCAT-2 can regulate macrophage phenotypes.  
Macrophage M2 or alternatively activated phenotype is promoted by several transcription 
factors, including PPARγ (Bouhlel et al., 2007). Toll-like receptor signaling, particularly 
TLR4 stimulated by LPS and other microbial ligands, drives macrophages to a 
preferentially M1 or classically activated phenotype (Stein et al., 1992).   
PPAR-γ has been shown to promote an anti-inflammatory (M2), alternatively activated 
macrophage phenotype by reprogramming macrophages for oxidative metabolism by 
increseaing fatty acid oxidation and mitochondrial biogenesis (Chawla, 2010).  
This project hypothesis, PPAR-γ upregulates fatty acid oxidation and supports an M2 
macrophage phenotype where LPCAT-2 utilises fatty acids for phospholipid synthesis 
and would be associated with M1 inflammatory phenotype of macrophage activation. 
This was examined by determining the expression of iNOS as a molecular marker of M1 
macrophages and CD206 as a marker of M2 macrophages (Mandal et al., 2011). 
Therefore, this project has investgated the possible role of LPCAT-2 in macrophages 
polarisation i.e. M1 or M2 like phenotype by using specific markers (iNOS for M1 and 
CD206 for M2). 
RAW264.7 cells with either the transfected murine LPCAT-2 insert (LPCAT-2+) or 
vector pCMV6  (WT) were stimulated with Pam3CSK4 (TLR2 ligand) or LPS (TLR4 
ligand) for 6 hours at 37 ºC and the expression of iNOS and CD206 was measured by RT-
PCR. As shown in Figure 4.5, overexpression of LPCAT-2 leads to a significant 
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expression of iNOS in unstimulated cells and this was further significantly increased in 
cells stimulated with either LPS (Fig 4.5a) or Pam3CSK4 (Fig. 4.5b).Furthermore, cells 
transfected with LPCAT-2 were seen to have a significant decrease in the expression of 
the M2 marker CD206 when stimulated with either LPS or Pam3CSK4 (Fig 4.5 c, d), 
table 3 is shown the mean values as a fold increase vs pCMV6 cells. 
It is becoming recognised that lipid metabolism may be fundamental to the metabolic 
regulation of the inflammatory response (Croasdell et al., 2015; Assunção et al., 2017). 
In this regulation, lipid catabolism and fatty acid oxidation are associated with oxidative 
phosphorylation, M2 phenotype and lipid synthesis is liked to glycolysis and the M1 
phenotype (Croasdell et al., 2015).  
Therefore, this suggests that it appears from the previous project results, that LPCAT-2 
can antagonize this function of PPAR-γ by which the two molecules have opposite 
functions. Consequently, PPAR-γ may suppress LPCAT-2 expression and promote an 
M2 macrophage phenotype, whereas activation of LPCAT-2 can suppress the activation 
of PPAR-γ and would promote an M1 phenotype, i.e. these results suggested that the 
LPCAT-2 might have a vital role  in Macrophages polorisation (M1-M2 polarisation). 
Therefore, all these results of this project in this chapter and in chapter 3 together, 
suggested that the overexpression of LPCAT-2 has promote the M1 like phenotype but 
not M2.  
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iNOS gene expression in RAW264.7 cells stimulated with LPS.
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Figure 4.5A. The effect of LPCAT-2 over expression on iNOS expression in 
RAW264.7 stimulated by LPS using RT-PCR analysis. 
 
Transfection of RAW264.7 cells with LPCAT-2 (LPCAT-2+) results in significant iNOS 
expression in untreated pCMV6 cells and significantly increased iNOS expression after 
treatment with LPS.  
Data represented the mean of three independent experiments (n=3) ± standard error.  
** = P < 0.005, *** = P < 0.0001, pCMV6 = RAW264.7 + empty vector plasmid (Blue 
Bar);  LPCAT-2+ = RAW264.7 cells transiently transfected with LPCAT-2 (Red Bar).  
 
 
 
 
 LPS 
+ - +   - 
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iNOS gene expression in RAW264.7 cells stimulated with Pam3CSK4.
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Figure 4.5B. The effect of LPCAT-2 over expression on iNOS expression in 
RAW264.7 stimulated by Pam3CSK4 using RT-PCR analysis. 
 
Transfection of RAW264.7 cells with LPCAT-2 (LPCAT-2+) results in significant iNOS 
expression in untreated pCMV6 cells and significantly increased iNOS expression after 
treatment with Pam3CSK4. 
Data represented the mean of three independent experiments (n=3) ± standard error.  
** = P < 0.05 ***= P < 0.005. pCMV6 = RAW264.7 + empty vector plasmid (Blue Bar);  
LPCAT-2+ = RAW264.7 cells transiently transfected with LPCAT-2 (Red Bar).  
 
 Pam3CSK4 
      +       - +     - 
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CD206 gene expression in RAW264.7 cells stimulated with LPS.
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Figure 4.5C. The effect of LPCAT-2 over expression on CD206 expression in 
RAW264.7 stimulated by LPS using RT-PCR analysis. 
 
LPCAT-2 overexpression resulted in significant inhibition of CD206 expression in cells 
treated with LPS, while it is significantly increased in pCMV6 treated with LPS. Data 
represent the mean of 4 independent experiments (n = 4) ± standard error.  
 *** = P < 0.0005, pCMV6 = RAW264.7 + empty vector plasmid (Blue Bar);  LPCAT-
2+ = RAW264.7 cells transiently transfected with LPCAT-2 (Red Bar).  
 
 
 
 
LPS    +    - +     - 
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CD206 gene expression in RAW264.7 cells stimulated with Pam3CSK4.
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Figure 4.5D. The effect of LPCAT-2 over expression on CD206 expression in 
RAW264.7 stimulated by Pam3CSK4 using RT-PCR analysis. 
 
LPCAT-2 overexpression resulted in significant inhibition of CD206 expression in cells 
treated with LPS, while it is significantly increased in pCMV6 treated with Pam3CSK4. 
Data represent the mean of three independent experiments (n=3) ± standard error.  
* = P < 0. 05, ** = P < 0.005, pCMV6 = RAW264.7 + empty vector plasmid (Blue Bar);  
LPCAT-2+ = RAW264.7 cells transiently transfected with LPCAT-2 (Red Bar).  
 
 
 
  
 Pam3CSK4     +   -      +   - 
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Summary of results. 
Potential mechanisms, the over-expressed LPCAT-2 shows a key regulatory role in the 
inflammory responses in chapter 3 as well as  its effect in this chapter on the expression 
of receptors after 6 hours  stimulation with LPS in RAW264.7 cells by down regulation 
TLR4 and upregulation of TLR2 and CD14, and when the cells were stimulated with 
Pam3CSK4, over-expressed shows highly increasing in TLR2 gene expresseion after 6 
hours stimulation, the current results suggest that LPCAT-2 could has a controlling role 
in polymicrobial sepsis (Schorr et al., 2007; Adhikari et al., 2010; Global Sepsis Alliance, 
2015; Moskowitz et al., 2017; Minasyan et al., 2017). The implications of over-expressed 
LPCAT-2 played antagonised properties to PPAR-γ function (PPAR-γ has been shown to 
promote an anti-inflammatory (M2)), interstigly, when PPAR-γ inhibited by adding the 
selective -gamma antagonist, T0070907 to RAW264.7 cells, the level of LPCAT-2 gene 
expression upregulated. This increase in LPCAT-2 expression was found to be dependent 
on the PPAR-γ antagonist concentration and therefore a dose-response relationship 
connecting the two molecules was established, the other evidence that over-expressed 
LPCAT-2 induced COX-2 which is inducible enzyme as well and has an important role 
in prostaglandin synthesis, these results were coupled with iNOS (marker for M1) and 
CD206 (marker for M2) gene expression revealed the possible role of of LPCAT-2 in 
macrophages polarisation i.e. the current findings (Please see table 3) coupled with 
chapter 3 results suggested that the LPCAT-2 might have a vital role  in macrophages 
polorisation by promoting M1 like phenotype but not M2. (M1-M2 polarisation) (Chawla, 
2010; Mandal et al., 2011).  
Thus the successful transient overexpressing of LPCAT-2 would allowed this project to 
explore the role of LPCAT-2 in a stably over-expressed cell line with murine LPCAT-2 
in chapter 5. 
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Mean (fold increase vs empty vector pCMV6 control) 
           
 
 
 
 
A 
Target  pCMV6 LPCAT-2+ pCMV6  
+ LPS 
LPCAT-2+  
+LPS 
TLR4 1 1.8 0.3 0.7 
CD14 1 4.9 2.6 19.2 
TLR2 1 0.5 3.1 4.1 
COX-2 1 1.5 1628 2659.4 
PPAR-γ 1 0.2 0.4 0.19 
iNOS 1 23.4 44.5 281.4 
CD206 1 0.89 3.2 0.7 
 
B 
TLR2 1 5.9 1.8 9.6 
iNOS 1 15.7 50.9 261.8 
CD206 1 0.56 1.5 0.5 
 
 
C 
 Control 
(RAW264.7 
cells) 
RAW264.
7+LPS 
 
RAW264.
7 + LPS + 
0.1 mM 
T0070907 
(mM) 
RAW264.7 + LPS + 1 mM 
T0070907  
1 3.37 5.38 9.76 
 
Table 3. The effect of over-expressed LPCAT-2 on gene expression using RT-PCR 
analysis. 
 
 A: TLR4, TLR2, CD14, COX-2, PPAR-γ. iNOS and CD206 in LPS induced murine 
macrophages, RAW264.7 cells.  
B: TLR2, iNOS and CD206 in Pam3CSK4 induced murine macrophages, RAW264.7 
cells.  pCMV6 = RAW264.7 + empty vector, LPCAT-2+ = RAW264.7 cells transiently 
transfected with LPCAT-2, Mean (fold increase vs empty vector pCMV6 control). 
C: RT-PCR analysis of the effect of selective peroxisome PPAR-γ antagonist T0070907 
on LPCAT-2 expression. Control = RAW264.7 cells,  PPAR-γ antagonist (T0070907). 
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Chapter 5: 
Stable overexpression of LPCAT-2 
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Establishing a stably transfected RAW264.7 cells with a plasmid 
containing a murine LPCAT-2 gene (LPCAT-2++). 
Previous work in our laboratory (Jackson et al., 2008a) and fromm other workers 
(Shindou et al., (2007), suggested that LPCAT-2 might regulate the inflammatory 
responses to LPS in macrophages. In addition, Moromoto and co-researchers (2010 & 
2014) over-expressed the LPCAT-2 gene to study the early production of PAF and found 
that LPCAT-2 was highly highly expressed in inflammatory cells activated by LPS 
stimulation through TLR4 (Moromoto et al., 2010 & 2014), but they did not explore its 
effect on more general inflammatory responses including cytokine production. Having 
previously, successfully achieved transient over-expression of LPCAT-2 (see chapter 3), 
this project aimed to establish a stable cell line overexpressing the LPCAT-2 gene in 
RAW264.7 cells to study its role in the inflammatory response. A macrophage cell line 
consistently overexpressing LPCAT-2 would clearly offer many advantages in studying 
the role of LPCAT-2 in the inflammatory response. These include avoiding the 
cytotoxicity of repeated use of the transfection reagents, the high variability in the cell 
number between the control (RAW264.7 cells + empty vector plasmid) and the transient 
over-expressed LPCAT-2 cells (LPCAT-2+) as well as better economy in the in vitro 
laboratory work.  
Stable transfection of the cells, would avoid the need for repeated transfection 
experiments, which require more reagents, repeated cloning of the plasmid with and 
without the murine LPCAT-2 gene inserts, then purifying these plasmids, shorteing the 
physical efforts and the period of time to apply the experiments, the period of time 
between repeated experiments.  It would also offer more uniform cell concentrations for 
each independent experiment.  
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To achieve stable over-expression of LPCAT-2 required achieving three challenging 
steps as following: 
The first crucial step was to establish the optimum concentration of Genticin antibiotic 
(G418) that killed the RAW264.7 cells which lacked the neomycin antibiotic resistance 
gene by using the killing curve method (please see section 2.9.1). The second step was to 
insert the LPCAT-2 gene into RAW264.7 cells using the transient transfection method 
using lipofectamine 2000 transfection reagent (please see section 2.9.2). 
The third challenging step was establishing stablely transfected RAW264.7 cells with 
plasmid carrying the LPCAT-2 gene inserts using G418 (please see section 2.9), then 
using RT-PCR (please see section 2.4 ) and wetern bloting (please see section 2.8.2) to 
confirm the expression of the LPCAT-2 gene and protein respectively. 
Using the stably over-expressing LPCAT-2 cell line established in this chapter has shown 
that  LPCAT-2 might have a vital role in the regulation of inflammatory cytokines gene 
expression and protein release. These results confirm that, LPCAT-2 might be a useful 
target for the development of therapies aimed at controlling the inflammatory response. 
 
 
5.1. Killing curve of RAW264.7 cells. 
The first critical step for establishing a stable cell line is selection based on antibiotic 
resistance and therefore, determining the optimal antibiotic concentration for selecting 
the stable cell lines (the mammalian cell colonies of RAW264.7 cells) that would be 
transfected with the plasmid carrying the murine LPCAT-2 (LPCAT-2 clones). The 
transfection process (please see 2.2.1.5 in material and methods) changed the RAW264.7 
cells to Geneticin antibiotic (G418) resistant cells by taking the Neomycin resistance gene 
within the plasmid that is carrying the murine LPCAT-2 clones into the cells.  
A kill curve is a dose-response experiment whereby cells are subjected to increasing 
amounts of antibiotic to determine the minimum antibiotic concentration that is needed 
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to kill all the cells over the course of one week (Davies & Jimenez,1980). In order to 
determine the optimal antibiotic concentration (killing curve), RAW264.7 cells were 
plated at cell concentration of 105 cells /well (150 µl) in the first well, and then a doubling 
dilution of the antibiotic was done for the rest of the wells (until well number 12 in rows). 
The cells were then treated with different concentrations of the antibiotic G418 (0 - 800 
µg/ml) in each well (150 µl). The killing curve was observed for 13 days of the 
experiment in the non-transfected RAW264.7 cells. Low dose was defined as the 
antibiotic concentration at which minimal visual toxicity was apparent after 7 days of 
antibiotic treatment, and this was observed at 200 µg/ml of G418; optimal dose was 
defined as the lowest antibiotic concentration at which all cells were killed after one week 
of antibiotic treatment, and this were 500 µg/ml of G418. High dose was taken as the 
antibiotic concentration at which visual toxicity was evident within the first 2 - 3 days of 
antibiotic treatment, and this were 800 µg/ml of G418.  
It was observed, as expected, that increasing doses of G418 were directly related to 
reduced numbers of viable RAW264.7 cells lacking the neomycin resistance gene as 
shown in Figure 5.1. 
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Figure 5.1. RAW264.7 cell killing using G418 antibiotic for three days to select stable 
cell colonies.  
 
 (A) Cells incubated with the highest antibiotic concentrations (700 µg /ml) were all dead 
(C) after 2-3 days compared with RAW264.7 cells without G418 (B & D). Therefore, 
700 µg /mL of G418 was chosen to be the highest safe dose to start establishing stable 
transfected cells. The experiment was performed in 96 well plates, in duplicate, at cell 
concentration of 105 cells /well (150 µL). 
  
C A 700 µg/ml 
B D 0 µg/ml 
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5.2. Transfection of the LPCAT-2 gene into the RAW264.7 cell line. 
Having established the optimum concentrations of Geneticin (G418) that will kill 
untransfected RAW264.7 cells, we next needed to transfect the cells with plasmid 
containing  the LPCAT-2 and the neomycin resistance genes. Figure 5.2 shows the 
micrographs of the differences in the concentration of the viable stable transfected 
RAW264.7 cells (LPCAT-2++).  
The highest viable cell concentration was in the wells that treated with DMEM medium 
containing 500 µg/mL of G418 within different periods of times compared with the cell 
that treated with 600 or 700 µg/mL of G418. The negative control for each treatment was 
RAW264.7  (control).  
Transfected RAW264.7 cells with 9 µl of lipofectamine 2000 transfection reagent and 2.5 
µg of pCMV6 control- entry vector (4.9 kb) plasmid, carrying the clones of murine 
LPCAT-2 which have the Neomycin resistant gene, and treated with DMEM medium 
without G418, were viable, and proliferated during the experiment days.  
Furthermore, on the ninth day of treatment with G418 antibiotic, the selected stable cell 
clones were treated with a maintaining medium (DMEM medium containing 200 µg/mL 
of G418) for 10 extra days. 
Furthermore, on the ninth day of treatment with the maintaining medium (DMEM 
medium containing 200 µg/mL of G418), the stable cell line clones were ready to be 
frozen, although they were left longer than 10 days, and treated with the maintaining 
medium to confirm that they were the stable cell line.  
These results were confirmed and analysed using RT-PCR and western blotting, which is 
shown in Figure 5.3.  
For the RT-PCR, there was a 3.6 fold increase in the expression of the murine LPCAT-2 
gene (P = 0.0387).  
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pCMV6  LPCAT-2+  after 5 days treatment with G418 
 
 
 
A 
500 µg/ ml 500 µg/ ml 600 µg/ ml 700 µg/ ml 
    
 
LPCAT-2+  after 7 days treatment with G418 
B 
500 µg/ ml 600 µg/ ml 700 µg/ ml 
   
C 
LPCAT-2++  after 9 and 19 days treatment with G418 respectively 
200 µg/ ml 
   
D 
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Figure 5.2. Establishing stable transfected RAW264.7 cells with a murine LPCAT-
2 gene insert (LPCAT-2++) images taken under the inverted microscope (x10). 
 
Pane A shows pCMV6, LPCAT-2+ cells treated with DMEM medium containing (500, 
600 & 700) µg /mL of G418 respectively after 5 days.   
Pane B shows: LPCAT-2+ cells treated with DMEM medium containing (500, 600 & 
700) µg /mL of G418 respectively after 7 days which have the Neomycin resistant gene.  
Pane C shows: LPCAT-2++ cells treated with DMEM medium containing 200 µg /mL of 
G418 after 9 days.  
Pane D shows: LPCAT-2++ treated with DMEM medium containing 200 µg /mL of G418 
after 19 days. 
pCMV6 = RAW264.7 cells +empty vector plasmid, LPCAT-2+= RAW264.7 cells 
transiently transfected with murine LPCAT-2 insert, LPCAT-2++= RAW264.7 cells 
stably transfected with murine LPCAT-2 insert. 
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5.3. Expression of LPCAT-2 in stably transfected RAW264.7 cells 
(LPCAT-2++). 
 
Expression of murine LPCAT-2 in a cell that are  stably transfected  with murie LPCAT-
2 gene  was confirmed by the real time PCR. The stable transfected RAW264.7 cells with 
murine LPCAT-2 gene insert (LPCAT-2++) and empty vector plasmed control (pCMV6) 
cells were plated in 6 well plates at a concentration of 1 X 106 cells/ well. RNA was 
extracted and reverse transcribed as detailed in chapter 2. To check for genomic DNA 
contamination, negative controls consisting of reactions that lacked RT (diluted RNA 
samples) were run to assess the effectiveness of the DNase treatment (as described in 
section 2.4.1). This gave negative results indicating there was no genomic DNA 
contamination of the samples. The qPCR has also no template controls (water samples 
with each primer mix) in every run and returned undetectable results.  
The melting curve analysis was used as indicator to assess whether the PCR assays have 
produced a single and specific product. Results from this analysis showed that the melting 
temperatures of the PCR products were clearly single product for each target and the 
graphs showed no primer dimers present in the reaction plates which indicated the 
products were specific. All primers were designed and checked (please see section 2.4.3).  
Results of the RT-PCR experiments for the LPCAT-2 gene over-expression is shown in 
Figure 5.3. This shows that LPCAT-2 is significantly over-expressed in LPCAT-2++ cells 
compared to pCMV6 cells ( RAW264.7 cells) (P = 0.0378), table 4 is shown the mean 
values as a fold increase vs pCMV6 cells. 
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Figure 5.3. LPCAT-2 gene expression in the LPCAT-2++ cells and in pCMV6 cells. 
 
LPCAT-2 gene expression by RT-PCR from LPCAT-2++ (Red Bar) and pCMV6 cells 
(Blue Bar). Figure shows a significant over-expression of LPCAT-2 after 24 hours 
incubation at 37 ºC without LPS stimulation (P = 0.0378). Data represents the mean of 
three independent experiments (n = 3) ± standard error. *= P < 0.05 vs pCMV6. pCMV6 
= RAW264.7 cells + empty vector plasmid, LPCAT-2++ = stable transfected RAW264.7 
cells with murine LPCAT-2.  
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In addition to the gene expression of LPCAT-2 in RAW264.7 stably transfected with 
murine LPCAT-2 (LPCAT-2++)  and pCMV6 (RAW 264.7 cells + empty vector plasmid) 
cells as assesses by RT-PCR, it was important to determine if the stably transfected cells 
also could produce LPCAT-2 protein. Western blotting experiments were used to assess 
protein production. Figure 5.4 shows the results of western blotting experiments on the 
LPCAT-2++ and pCMV6 cells.  
The results show the expression of endogenous LPCAT-2 protein in pCMV6 cells and 
the over expression of LPCAT-2 protein in LPCAT-2++ cells In addition, when anti-Flag 
antibody was used to detect the protein, only the stably transfected cells expressed the 
flag-tagged protein. This confirms the protein expression in the stably transfected cells.  
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Figure 5.4. Western blotting confirmation of murine LPCAT-2 expression in 
LPCAT-2++ cells and non-transfected RAW264.7 cells without LPS. 
 
 (A) The expression bands of endogenous murine LPCAT-2 protein in control RAW264.7 
(pCMV6) cells (lane 1) and LPCAT-2++ cells (lane 2) respectively using anti- LPCAT-
2 as primary antibody. 
(B) The expression band of flag-tagged protein in control RAW264.6 –pCMV6 cells (lane 
1), and LPCAT-2++ cells (lane 2) respectively using anti-FLAG as primary antibody, 
pCMV6 = RAW264.7 cells + pCMV6 empty vector plasmid, and LPCAT-2++ = 
RAW264.7 cells stably transfected with murine LPCAT-2. 
  
 A           1              2               
 B              1              2             
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5. 4. Expression of LPCAT-2 in RAW264.7 cells stimulated with LPS. 
LPS can induce the expression of LPCAT-2 in macrophages and LPCAT-2 is thus an LPS 
inducible gene (Jackson et al, 2008). To analyse if the cells stably transfected with 
LPCAT-2 would show increased expression of LPCAT-2 in response to LPS stimulation 
stably transfected cells (LPCAT-2++ cells) and the pCMV6 cells (RAW264.7 cells + 
empty vector plasmid) were stimulated with 1 µg/ml of LPS for various times between 0 
and 24 hours at 37 ˚C.  RT-PCR analysis showed that cell stimulation with LPS resulted 
in the induction of the LPCAT-2 gene expression in LPCAT-2++ cells and in the pCMV6 
cells but LPCAT-2 induction from the LPCAT-2++ cells was significantly higher 
(P=0.0026), table 4 is shown the mean values as a fold increase vs pCMV6 cells. 
. The peak of gene expression was at 8 hours post LPS stimulation in both LPCAT-2++ 
and in pCMV6 cells (Figure 5.5), the mean values as a fold increase is shown in table 4. 
Similar results were obtained for LPCAT-2 protein expression determined by western 
blotting (Fig 5.6). 
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Figure 5.5. LPCAT-2 gene expression in in RAW264.7 cells stimulated with LPS.  
 
The over-expression of murine LPCAT-2 in LPS stimulated murine macrophages; in both 
LPCAT-2++ cells (Red Bar) and in the pCMV6 cells (Blue Bar), but with a higher 
expression in the former, within an LPS stimulation time course. The peak of LPCAT-2 
gene expression of the LPS-stimulated LPCAT-2++ cells was at 8 hours post-stimulation 
with a significant difference between LPCAT-2++ cells and the pCMV6 cells.  Results 
were confirmed using RT-PCR analysis in three independent time course experiments. 
Data represents the mean of three independent experiments (n = 3) ± standard error.  
* = P < 0.05, ** = P < 0.01, *** = P < 0.0001 vs pCMV6.  pCMV6 = RAW264.7 cells + 
empty vector plasmid, LPCAT-2++  = stable transfected RAW264.7 cells with LPCAT-2 
gene.  
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Figure 5.6. Western blot showing expression of LPCAT-2 in  LPCAT-2++ and 
pCMV6 (empty vector) cells following treatment with LPS.  
 
The blot shows the increased expression of LPCAT-2 in the stably LPCAT-2++ cells 
stimulated with LPS time-course (0 - 24) hours, compared with endogenous LPCAT-2 
expression in pCMV6 cells. Representative blot from three independent experiments 
using anti-LPCAT-2 as primary antibody. 
 
  
 
              LPS time course      0              2            4           8         12           24     hour 
56KD 
56KD 
LPCAT-2++ cells 
pCMV6 cells 
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5.5. The effect of Lysophosphatidylcholine acyltransferase (LPCAT) - 2 on pro-
inflammatory cytokines in LPS - stimulated macrophages. 
 
The effect of the stably over-expressed LPCAT-2 on the inflammatory response of 
RAW264.7 macrophages was determined by analysing inflammatory gene expression in 
response to LPS. The stable transfected cells (LPCAT-2++) and the pCMV6 cells 
(RAW264.7 cells + empty vector) were plated in 6 well plates at a cell concentration of 
1 X 106 cells/ well (2.5 ml DMEM medium), and then stimulated with 1 µg/ml of LPS for 
various times (0 and 24 hours at 37 ºC. The inflammatory cytokines mTNF-α and IL-6 
were determined by RT-PCR. Results for mTNF-α showed an up-regulation in both 
LPCAT-2++ and in pCMV6 cells, with a much higher expression in the former (Figure 
5.7). The peak of gene expression was found to be at 8 hours induction in both LPS- 
induced- LPCAT-2++ and in pCMV6 cells, with a significant increase in TNF-αexpression 
in the LPCAT-2++ cells (P = 0.005. The mean values as a fold increase is shown in table 
4. 
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Figure 5.7. Murine Tumour necrosis factor (mTNF-α) gene expression in RAW264.7 
cells stimulated with LPS. 
 
These results show that mTNF-α was up-regulated in both LPCAT-2++ cells (Red Bar) 
and in the pCMV6 cells (Blue Bar) within an LPS stimulation time course, but with a 
much higher expression in LPCAT-2++ cells. The peak of mTNF-α gene expression of the 
LPS-stimulated LPCAT-2++ cells were at 8 hours post-induction with a significant 
difference in the expression levels compared with pCMV6 cells. Results were confirmed 
using RT-PCR analysis in three independent time course experiments. Data represents 
the mean of three independent experiments (n = 3) ± standard error. * = P < 0.05,  
** = P < 0.005.  pCMV6 = RAW264.7 cells + empty vector plasmid, LPCAT-2++ = stable 
transfected RAW264.7 cells with LPCAT-2 gene.  
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Experiments to investigate IL-6 expression followed the procedures for the TNF-α 
experiments. Results for IL-6 expression showed that LPS significantly up-regulates the 
cytokine mIL-6 in both LPCAT-2++ cells and in pCMV6 cells (Figure 5.8) but with a 
much higher expression of the cytokine in the LPCAT-2++ cells (P=0.0078). The peak of 
IL-6 gene expression was at 8 hours post-induction in both LPS-induced LPCAT-2++ and 
in pCMV6 cells, the mean values as a fold increase is shown in table 4. 
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Figure 5.8. Expression of murine interleukine-6 (mIL-6) in RAW264.7 cells 
stimulated with LPS. 
 
The LPCAT-2++ (Red Bar) and the pCMV6 cells (Blue Bar) were stimulated to the time 
course stimulation with 1 µg/ml of LPS for 0 - 24 hours. These results show that IL- 6 
was up-regulated in both LPCAT-2++ cells and in the pCMV6 cells within an LPS 
stimulation time course, but with a much higher expression in the LPCAT-2++ cells except 
at 4 hours post-LPS stimulation where the pCMV6 cells showed a higher mIL-6 
expression. The peak of IL-6 gene expression in the LPS-stimulated LPCAT-2++ cells was 
at 8 hours post-induction with a significant difference in gene expression between the 
LPCAT-2++ cells and the pCMV6 cells. Results were confirmed using RT-PCR analysis 
in three independent time course experiments (n = 3). Data represents the mean of three 
independent experiments (n = 3) ± standard error. * = P < 0.05, ** = P < 0.01, *** = P < 
0.0001. pCMV6 = RAW264.7 cells + empty vector plasmid, LPCAT-2++ = stable 
transfected RAW264.7 cells with LPCAT-2 gene.  
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Summary of the results. 
The results from this chapter are summarised in Table 4. This chapter developed a stably 
transfected murine macrophage cell line that over-expessed LPCAT2. Killing curves of 
RAW264.7 cells were used to select the lower (200 µg/ml), optimal (500 µg/ml), higer 
(800 and 700 µg/ml) concentration of G418 antibiotic to select the stable cells that carried 
the resistant gene of neomycin antibiotic gene within the plasmid carrying mLPCAT-2. 
Cells transiently transfected with plasmid carrying mLPCAT-2 (LPCAT-2+) were treated 
with (500, 600 and 700) µg/ml of G418 antibiotic to establish the stablely over-expressing 
LPCAT-2 gene insert (stable transfected cells (LPCAT-2++).  
RT-PCR results confirmed the LPCAT-2 gene over-expression and the protein expression 
was confirmed by Western blotting.  The expression of LPCAT-2 in LPS-induced stably 
transfected RAW264.7 is shown as a LPS stimulation time course (0 -24) hours (Table 
4), the same expression of LPCAT-2 protein was confirmed using western blotting, then 
the effect of LPCAT-2 on pro-inflammatory cytokines (TNF-α, IL-6) in LPS- stimulated 
RAW264.7 cells were confirmed using gene expression (table 4). 
Thus, the development of a stably transfected macrophage cell line over-expressing 
LPCAT2 has been demonstrated and these cells can be used to demonstrate the role of 
LPCAT2 in the inflammatory response (Alrammah, 2015). Such experiments and 
approachs suggest that LPCAT-2 might be a useful target in controlling the inflammatory 
response. 
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Table 4. 
The effect of over-expressed LPCAT-2 on the gene expression of the inflammatory responces in LPS induced murine macrophages, 
RAW264.7 cells.  
This table shows the mean value in fold increase vs empty vector pCMV6 control. pCMV6 and LPCAT-2++ cells stimulated with LPS to the 
time course stimulation with 1 µg/ml of LPS for 0 - 24 hours. Row 1: LPCAT-2 gene expression in RAW264.7 cells stimulated with LPS.  
Row 2: Expression of TNF-α in RAW264.7 cells stimulated with LPS. Row 3: Expression of mIL-6 in RAW264.7 cells stimulated with 
LPS. 
Row 4 and 5: LPCAT-2 gene expression in RAW264.7 cells without LPS.  pCMV6 = (RAW264.7 cells + empty vector), LPCAT-2++ = 
stable transfected RAW264.7 cells with LPCAT-2 gene). 
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LPCAT-2 1 4.3 1.4 4.7 2.1 7.9 2.6 14.9 1.8 5.4 0.8 4.5 
  mTNF-α 1 1.8 101.3 120 77.2 136.5 67.4 174.5 53.6 73.5 10.9 34.1 
IL-6 1 6.5 698.9 481.3 6442 1650.8 18090.9 44797.5 3888.1 6944.9 3603.5 8292 
pCMV6 LPCAT-2++ 
1 4.15 
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Chapter 6: 
Discussion, Conclusions &  
Future work 
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6.1. Discussion. 
  
Sepsis is an overwhelming inflammatory response to infection that has proved extremely 
difficult to treat (Angus et al., 2001; 2011; The Global Sepsis Alliance, 2015 and 2016; 
Shankar-Hari et al., 2016; Rhodes et al., 2017). Therefore, much research has been 
devoted to the understanding of the pathophysiological mechanisms underlying sepsis 
and the identification of potential new therapeutic targets.  
 
In this setting and building on previously established links between LPCAT and 
inflammatory responses in macrophages (Jackson et al., 2008), this project aimed to detail 
the role of LPCAT-2 in the inflammatory response with the potential of identifying 
LPCAT-2 as a novel therapeutic target. In particular, this was achieved using molecular 
techniques to both over express and to knock down LPCAT-2 in macrophages. The 
successful application of these techniques has significantly added to knowledge on the 
role of LPCAT-2 in the inflammatory response and suggests that future research could 
utilize LPCAT-2 and related proteins as potential new therapeutic targets.  
 
Key findings from the current study are that LPCAT-2 can be successfully over expressed 
in a murine macrophage cell line and the over expression of LPCAT-2 significantly 
increases TNF-α and IL-6 gene expressions and protein production, while the anti-
inflammatory IL-10 gene expression was significantly decreased. Moreover, over 
expression of LPCAT-2 significantly decreased the gene expression of TLR4, PPAR-γ 
and CD206 (a marker of M2 macrophages) while it significantly increased CD14, TLR2, 
COX-2 and iNOS gene expression (M1 markers). 
 
Importantly, silencing the transient over expression of murine LPCAT-2 resulted in a 
significant reduction in TNF-alpha and a significant increase in IL-10 gene expression. 
Taken together, these results firmly establish that LPCAT-2 is pivotal to the inflammatory 
response in macrophages and the work has also resulted in the RAW264.7 cell line stably 
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overexpressing LPCAT-2 that will be required for further studies and the development of 
molecules that target the expression of this gene for sepsis therapies.  
 
6.1.1. Over-expression of LPCAT-2 in RAW264.7 cells induces an 
inflammatory phenotype. 
 
Previous work has established that inhibition of LPCAT enzymes leads to the down-
regulation of a number of inflammatory genes stimulated by bacterial endotoxin (LPS) 
(Schmid et al., 2003; Jackson et al., 2008). Until recently, when LPCAT enzymes were 
sequenced and cloned, it was not possible to specifically determine which particular 
LPCAT member was responsible for these actions. The availability of LPCAT sequence 
data came from important experiments that identified four major LPCAT enzyme 
LPCAT1, LPCAT-2, LPCAT3 and LPCAT4 isoforms (Chen et al., 2006; Nakanishi et 
al., 2006; Shindou et al., 2007; Zhao et al., 2008; Hishikawa et al., 2008). 
 
To prove that a protein causes a specific effect, not only should the effects be measured 
when that protein is knocked down but also when that protein is overexpressed. An 
important aim of this project was to determine the role of LPCAT-2 in controlling the 
macrophage inflammatory response to bacteria by specifically over expressing and 
knocking-down LPCAT-2.  
 
Shindou et al., (2007) over-expressed the murine LysoPAFAT/LPCAT-2 for the first time 
to study the role of LPCAT-2 on PAF biosynthesis in inflammatory cells. However, the 
effect of LPCAT-2 on cellular inflammatory responses has not been investigated.  
Shindou and co-workers showed not only lysoPAF acetyltransferase (LPAFAT) activity 
(which converts lysoPAF into PAF), but also LPCAT activity required Ca2+ in the LPS 
induced macrophage activation (Shindou et al., 2007), but this project does not look at 
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the effects of Calcium ions in the media on LPCAT-2 expression or activity, therefore 
more studies needed to cover this area.  
 
To confirm the over-expression of LPCAT-2, the protein expression was analysed by 
western blot using an anti-FLAG antibody. Interestingly, western analysis showed that, 
the LPCAT-2 protein expression in the transfected cells was seen as two bands at 35 and 
56 kd, that were not present in the control RAW264.7 cells (which lacks the Flag–tag 
within normally expressed LPCAT-2). The second band, 35 Kd might be another isoform 
of LPCAT-2 generated by alternative splicing. This should be explored in future studies. 
However, expression of FLAG-tagged protein supports the successful over expression of 
LPCAT-2 in this work and confirms the use of cells over expressing LPCAT-2 in studies 
of the inflammatory response.  
 
Ferrario et al., (2016) have reported that LysoPC (LPC) may suppress the host 
inflammatory responses to LPS, and thus re-acylating LPC to form PC molecules, could 
reduce the amount of LPC, therefore increase the inflammatory process, and possibly 
raise both the severity and mortality in inflammatory diseases such as sepsis.  
 
In agreement with this suggestion, research has demonstrated that septic patients have 
significantly decreased levels of LPC (Hong & Song, 2008; Cho et al., 2011). Activation 
of RAW264,7 cells by LPCAT was shown previously not to be dependent on LPC and to 
reduce LPC (Jackson et al., 2008).  Thus, the activity of the inducible over-expressed 
LPCAT-2 in this project would be expected to reduce the level of LPC due to formation 
of PC molecules by re-acylation of the membrane LPC by the remodeling pathway.  
 
Moreover, the transient over-expression of LPCAT-2 gene expression in RAW264.7 cells 
was successfully confirmed both before and after LPS stimulation. LPS was seen to 
increase the expression of the transfected LPCAT-2 gene.  A similar effect was also seen 
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when Pam3CSK4, a TLR2/1 ligand, was used to stimulate the RAW264.7 cells to study 
the effect of overexpressing LPCAT-2 on the inflammatory responses to different 
bacterial ligands. 
 
A previous study has reported that LPCAT-2 remains induced at 16 hours post LPS 
stimulation using 100 ng/ml LPS from S. minnesota in CHO-K1 cells (Shindou et al., 
2007). In the current study, using RAW264.7 cells stably transfected with LPCAT-2, 1 
μg/ml of LPS from E. coli was used and the LPCAT-2 gene expression was significantly 
increased at 4 - 8 hours post LPS and reduced at 12 hours post LPS treatment and 
completely declined after 24 hours. The difference in LPCAT-2 expression kinetics in 
these studies is possibly due to the cell type, LPS concentrations used and the different 
bacterial strain of LPS. Our work did not reveal any toxicity to the RAW264.7 cells when 
LPS was used at this concentration. In addition, several studies have used 1 µg/ml of LPS 
as stimulus and over these time points did not report any toxicity to murine macrophage 
(RAW264.7 cells). (Li et al., (2000) (Liu et al., 2007; Iyer et al., 2010).  
 
TLR4 is activated through LPS, augmented by LPS binding protein (LBP) which 
cooperates with MD2 and CD14 complexes, and stimulates both MAPKs and NF-KB 
signaling pathways to induce proinflammatory mediators and cytokines that play a key 
role in controlling cell proliferation and differentiation as well as the cellular responses 
regulating cytokines and stresses (Johnson & Lapadat, 2002; Caivano, 1998). The 
maximal MAPK expression occurs 20 - 30 minutes’ post LPS treatment in human and 
murine monocytes and macrophages (Bian et al., 2003). In agreement with our results, 
this suggests that the increased gene expression of LPCAT-2 will be early in the response 
of the cells to LPS.  
 
LPCAT-2 has been seen to be highly expressed in inflammatory cells and to be activated 
by LPS stimulation through TLR4 (Morimoto et al., 2010). This group showed LPCAT-
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2 phosphorylation at Ser-34, after 30 minutes post LPS stimulation led to increasing lyso-
PAFAT activity. In agreement with this, the current project did not measure LPCAT-2 
expression at less than two hours after LPS stimulation.  
 
However, unlike these other studies, we explored the effect of LPCAT-2 over-expression 
as well as inhibition, on phenotypic responses of cells stimulated with LPS. Thus, it has 
shown that over-expression of LPCAT-2 led to enhanced levels of pro-inflammatory 
cytokine production in RAW 264.7 macrophages while inhibition of this LPCAT-2 
expression resulted in significant inhibition of the mediator production. 
 
Morimoto and co-workers also established the rapid PAF biosynthesis in 30 seconds by 
using protein kinase Cα (PKCα) to phosphorylate LPCAT-2 at Ser34 following PAF or 
ATP-stimulation (Morimoto et al., 2014). However, it is unclear whether incorporation 
of arachidonic acid in the cellular membrane either elevated or decreased its 
bioavailability for subsequent production of eicosanoid. This project agreed with their 
results in relation to LPCAT-2 effects on inflammatory response by up-regulating PAF 
in the remodeling pathway post LPS stimulation, however this project does not measure 
PAF, but it explores the cytokines production and release. Although the study of 
Morimoto et al., (2010; 2014) did not explore cytokine gene expression and protein 
release, as the current project has demonstrated, it does support the fact that LPCAT-2 is 
inducible in the inflammatory cells due to extracellular stimuli, unlike, LPCAT1 which 
is a non-inducible isoform. However, the mechanism of action of LPCAT-2 is still not 
well understood (Harayama et al., 2009; Morimoto et al., 2010; Shindou et al., 2009; 
Shindou et al., 2013; Morimoto et al., 2014).   
 
An important result determined during the investigation of the effects of over-expressed 
LPCAT-2 on the inflammatory response, was that inflammatory mediator production was 
significantly up regulated in the RAW264.7 cells transiently transfected with the LPCAT-
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2 insert. This suggests that LPCAT-2 has a pro-inflammatory role in macrophages by 
enabling induction of inflammatory molecules such as IL-6 and TNF-α in response to 
bacterial molecules LPS and Pam3CSK4 (Brunialti et al., 2006).  
 
The current project confirmed that there is a significant increase in pro-inflammatory 
cytokine gene expression, (eg TNF-α and IL-6), in RAW264.7 cells in response to LPS 
or Pam3CSk4. However, the novel finding is that this increase in cytokine expression is 
significantly enhanced in cells transfected with LPCAT-2. Thus, for the first time, we 
have established that LPCAT-2 gene expression is linked to increased inflammatory gene 
expression in macrophages. 
 
It is tempting to speculate that continued upregulation of LPCAT-2 gene expression could 
lead to increased inflammatory gene expression seen in various chronic inflammatory and 
autoimmune disorders, for instance; thyroiditis, type I diabetes, rheumatoid arthritis 
(Hirano,1992; Tan et al.,1990), systemic sclerosis (Feghali et al.,1992), mesangial 
proliferative glomerulonephritis and psoriasis, and neoplasms for examples, cardiac 
myxoma, renal cell carcinoma, multiple myeloma, lymphoma, and leukaemia 
(Hirano,1992).  More significantly in the context of the current study is that regulation of 
LPCAT-2 gene expression could be linked to the dysregulated inflammatory response 
seen in sepsis. 
 
Results from the over-expression of LPCAT-2 and the expression of LPCAT-2 in 
inflammatory cells (Shindou et al., (2007), and the previous work in our laboratory 
(Jackson et al., 2008a) strongly suggest that LPCAT-2 could be responsible for the 
inflammatory responses to LPS and other bacterial ligands in macrophages.  
 
While the over expression of LPCAT-2 gene in macrophages enhanced a range of pro-
inflammatory responses, it was important to demonstrate the pro-inflammatory role of 
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this LPCAT isoform by also inhibiting the gene expression. LPCAT-2 was silenced in 
RAW264.7 cells using the specific siRNA technology and with this model a strong level 
of silencing (80%) LPCAT-2 was achieved, When LPCAT-2 was silenced and the cells 
were stimulated with LPS, there was a significant reduction in inflammatory cytokine 
production including TNF-α compared with control cells. This agrees with recent results 
obtained by our laboratory in which LPCAT-2 was silenced in MM6 cells using shRNA 
(Abate & Jackson, 2015). Similar results were obtained in cells stimulated with the TLR2 
ligand Pam3CSK4.  
 
Furthermore, the results of this work also show that LPCAT-2 influences the 
inflammatory response at the protein level. Cytokine release was assayed by enzyme-
linked immunosorbent assay (ELISA) for TNF-α and IL-6 protein expression in the 
presence and absence of LPS stimulation. A problem due to the fact that the transfected 
RAW264.7 cells grow at different rates compared with control cells meant that 
standardisation against protein amounts (the usual method) was not possible. To 
overcome this, the ELISA results were normalized against the total RNA concentrations 
as suggested by (Muratore et al., 2014).  
 
The cytokines, IL-6 and TNF-α release was induced after 6 hours of LPS-stimulation in 
RAW264.7 cells and the amounts of these proteins was significantly higher in the cells 
that over-expressed LPCAT-2. These results suggest that LPCAT-2 has a key role in 
regulating the inflammatory response, to infection and therefore is a potential target for 
novel anti-inflammatory or anti-sepsis drug development. However, more details are 
required about the pathways and mechanisms of action of LPCAT-2 in this regard before 
any therapeutic molecules could be developed.  
 
In this project, the molecular techniques of gene expression and gene silencing were 
utilised. In particular, the small interfering RNA (siRNA) technique (Hamilton and 
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Baulcombe, 1999) was used. The excellent sequence-specificity (Deng et al., 2014) of 
the LPCAT-2 isoform that was used provided a high degree of confidence in the accuracy 
of specific overexpression of LPCAT-2 and silencing (in contrast to the co-silencing of 
other LPCAT enzymes). The high efficiency properties (Gao et al., 2014) of the siRNA 
technology, make it stand-out among other gene-silencing techniques and led to its use in 
the silencing of the over-expressed LPCAT-2 gene in this project.  
 
Although RAW cells transiently over-expressing LPCAT-2 have been extremely useful 
in determining the potential role of LPCAT-2 in macrophage responses, it would be 
desirable to produce a stable transfectant for long-term studies. Thus, this project also 
attempted to create a stably transfected cell line using RAW264.7 murine macrophages 
transfected with the pCMV6-Entry plasmid carrying the inserts clones of murine LPCAT-
2 and Lipofectamine 2000 transfection reagent.  
 
Xu et al., (2007) had used a concentration of 600 µg/mL of Geneticin for establishing a 
stable transfected RAW264.7 cells to study the role of Toll like receptor in innate 
immunity. In this project we used the same concentration of Geneticin (600 µg/mL) in 
both killing curve and establishing a stable transfected RAW264.7 with murine LPCAT-
2 to study the role of LPCAT-2 in inflammatory responses. Our experiments have 
produced a stably transfected macrophage cell line for the development of future studies 
on LPCAT-2 and the inflammatory response. 
 
6.1.2. Potential mechanisms of action of LPCAT-2 in the inflammatory 
response to bacterial ligands. 
 
This study has shown through gene over-expression and gene silencing techniques, that 
LPCAT-2 plays a key role in macrophage inflammatory responses to LPS and other 
bacterial ligands.  Moreover, the inhibition of inflammatory responses when the LPCAT-
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2 gene is knocked down in other leukocytes, including the human monocyte cell line 
MM6, confirms the central role of LPCAT-2 regulation of leukocyte inflammatory 
responses (Abate and Jackson 2015).   
 
This study has also confirmed that LPCAT-2 is inducible, unlike LPCAT1 which is 
constitutively expressed, which also suggests a role in the inflammatory response. In these 
regards, LPCAT-2 might be similar to other inducible enzymes such as COX2 with which 
it might link in regulating phospholipid metabolism. The control of inflammatory gene 
responses to bacterial ligands by LPCAT-2 leads to the question of potential mechanisms 
through which these effects are manifest and whether inducible LPCAT-2 activity has 
wider implications for macrophage activation. These will be necessary points to consider 
if LPCAT-2 might become a target for novel anti-inflammatory and anti-sepsis therapies.  
 
Regulation of TLR ligand induced pathways may be at several possible control points. It 
is well established that LPS signaling via TLR4 proceeds via translocation of TLR4 to 
membrane lipid raft domains – membrane regions enriched in cholesterol, sphingolipids 
and certain phospholipids that serve as signaling platforms for the assembly of signaling 
complexes. (Brown & London 2000; Triantafillou et al., 2002, Jackson & Parton, 2004; 
Triantafillou et al., 2004). 
 
Soong et al., (2004) has also demonstrated TLR2 is translocated to the lipid raft domain 
of the plasma membrane following the stimulation of the cells with its ligand. Thus, 
regulation of TLR translocation to lipid raft domains might be a key process mediated by 
LPCAT-2. Previous studies have shown that LPCAT regulates LPS-induced translocation 
of TLR4 into lipid raft domains thereby affecting the subsequent down-stream signaling 
events (Jackson et al., 2008a).   
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However, in these previous studies, the sequence and cloning of LPCAT enzymes was 
not available and the existence of the different family members was not known. 
Therefore, it was unknown, which of the LPCAT proteins modulated this LPS-induced 
response (Jackson et al., 2008a). The role of LPCAT on the translocation of the TLR2 
has not been investigated (Jackson et al., 2008; Schmid et al., 2003).  
 
LPS-induced LPCAT-2 has been shown to be activated in RAW264.7 cells via MAPK-
activated protein kinase 2(MK2) located downstream of p38 MAPK (p38α and p38δ), 
mainly expressed in macrophages (Hale et al., 1999). Whether MK2 is required for the 
pro-inflammatory responses initiated by LPCAT-2 as seen in the current study has not 
been investigated but would aid future determination of mechanisms.   
 
Based on these previous studies, the findings from this project suggest that 
overexpression of the enzyme LPCAT-2 could induce cellular responses to LPS by 
regulating the translocation of TLR4 into membrane lipid raft domains. It would be 
expected also LPCAT-2 knocked down with a specific siRNA technique could block the 
expression of LPCAT-2 and down regulate cellular responses to LPS by preventing the 
translocation of TLR4 into membrane lipid raft. Results obtained in this study with 
Pam3Cys suggest that LPCAT-2 can also regulate the inflammatory responses to other 
bacterial ligands signaling through TLR2 (Ozinsky et al., 2000; Soong et al., 2004) 
possibly by controlling assembly of their receptor complexes within membrane raft 
domains in RAW246.7 cells.  
 
Whether LPCAT-2, an enzyme that normally re-acylates LysoPC (LPC) can regulate 
TLR4 translocation to membrane raft domains via this mechanism or another mechanism 
remains unknown. However, LPCAT is responsible for forming new PC component 
species from LPC re-acylation with unsaturated fatty acids (Chilton et al., 1996). The 
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synthesis of PC has been shown to be crucial for all cell survival (van der Luit et al., 
2002; Jackson et al., 2008).  
 
In addition, evidence suggests that the biosynthesis of PC could be controlled in response 
to the lipid requirements of the vesicular trafficking (McMaster et al., 2001; Bankaitis et 
al., 2002). It would be expected that monocyte and macrophage cell membrane 
composition would influence the fluidity as well as enhancing the lipids and protein 
movement within and about the lipid raft regions (Rouquette-Jazdanian et al., 2002).  
 
Furthermore, LPCAT is responsible for adding the unsaturated fatty acids (arachidonic 
acids) to Lyso-PC (LPC) to form a new PC molecular species (Yamashita et al., 1997). 
Subsequently, the balance between LPC and its acylation to PC, which is catalysed by 
LPCAT, could represent a crucial control point for the survival and functioning of the 
innate immune system cells.  
 
The dysregulation of this balance could result in inappropriate cellular responses toward 
infectious stimuli that would allow the progression of systemic inflammation and organ 
injury (Van der Luit et al., 2002; Fuchs et al., 2005). This suggests that the LPCAT-2 
might regulate monocyte and macrophage inflammatory responses through both 
regulating arachidonate availability for mediator formation as well as facilitating the 
formation of signaling complex and innate responses to inflammatory stimuli.  
 
Additionally, Rouquette-Jazdanian et al., (2002) have revealed that 
glycerophospholipids, for instance, phosphatidylcholine (PC) are components of lipid 
rafts. Any modification of the PC fatty acyl composition within these regions could alter 
the localization of LPS signaling receptors and thereby effect LPS induced responses. 
LPCAT-2, through regulating the physical state of the lipid microenvironment in 
membrane rafts might modulate the signaling receptor response to LPS (Jackson et al., 
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2008; Yamashita et al., 2014). Through regulating the membrane PC acylation with 
unsaturated fatty acids, LPCAT might regulate membrane fluidity (Darmani et al., 1993; 
Jackson et al., 2004).  
 
6.1.3.  Effect of LPCAT-2 on macrophage polarisation. 
 
Macrophages can be activated to elicit different functions through interactions with their 
environment. Macrophages can be ‘polarized’ towards a pro-inflammatory phenotype 
expressing pro-inflammatory cytokines and antimicrobial factors (‘classical activation' or 
M1 polarization) by microbial agents like lipopolysaccharides (LPS). Macrophages can 
also be polarized toward the generation of anti-inflammatory mediators and promote 
tissue remodeling factors, critical for resolution of inflammation and tissue repair 
(‘alternative activation' or M2 polarization) induced by anti-inflammatory cytokines (IL-
13, IL-4) (Shaykhiev et al., 2009). 
 
In research on Microglia/Macrophages, in vitro stimulation with LPS and interferon-γ 
(IFNγ) promoted the differentiation of “classically activated” M1 microglia/macrophages 
that released destructive proinflammatory mediators (Ding et al., (1988). In contrast, 
interleukin (IL)-4 and IL-10 induce an “alternatively activated” M2 phenotype that 
possesses neuroprotective properties (Kigerl et al., 2009; Goerdt et al., 1999; Durafourt 
et al., 2012).  
 
The dualistic roles of distinctly polarized macrophage populations have been reported in 
several studies related to the presence of LPS. For example, it was reported that the 
activation of pattern recognition receptors (PPR) via invading pathogens are induced as 
part of the M1-like macrophage phenotype (innate immunity activation) (Mukhopadhyay 
et al., 2006).  
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In this project, specific phenotypic markers of macrophage activation have been used to 
confirm the activation phenotype (M1 or M2) of the macrophage cell models used. Thus, 
induction of iNOS gene expression was used as a classical M1 marker for macrophages 
that are programmed to release pro-inflammatory mediators including iNOS, TNF-α, IL-
6 (Ding et al., 1988).  
 
The inducible nitric oxide synthase (iNOS) is over-expressed in different types of cells 
including macrophages, hepatocytes and astrocytes, and stimulated in response to varied 
immune modulating molecules, for examples; lipopolysaccharide (LPS), interleukin (IL)-
1, interferon gamma (IFN-γ), tumour growth factor beta (TGF-β) and pro-inflammatory 
cytokines (Moncada et al., 1991; Li and Verma, 2002; Liu and Malik, 2006) i.e. the iNOS 
is highly expressed in LPS induced the murine cells, RAW264.7 cells which have been 
chosen in this project. In contrast, CD206 expression was used as a marker for M2-Like 
macrophage phenotype that down-regulate the pro-inflammatory cytokines but express 
the anti-inflammatory cytokine IL-10. Interleukin-10 (IL-10) was chosen in this project 
because it is a crucial anti-inflammatory cytokine that regulates the immune response of 
almost all leukocytes (Bonizzi & Karin, 2004). Results from this project also showed that 
the IL10 is a key regulatory cytokine. 
 
In addition, it was noted that M2-like macrophages showed significant increase in 
expression of PPAR-γ. Through measurement of these markers, an important finding of 
the current study was that increased expression of LPCAT-2 induces the polarization of 
macrophages from M2-like phenotype into M1-phenotype. This property of LPCAT-2 
may be important in conditions, such as sepsis, that display an overwhelming M1 
phenotype that cannot be regulated. 
  
This project results suggest that LPCAT-2 has a vital role in shifting the macrophage 
phenotyping into M1 rather than M2 and this would have an outcome on the discovery of 
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new specific anti-septic therapies, i.e. the activation of macrophage phenotypes as either 
M1 or M2 depends on the nature of the stimuli. Ding and fellow researchers showed the 
main targets of IL-10 on antigen-presenting cells and lymphocytes. It has been observed 
that IL-10 inhibits the antigen-presenting capacity of monocytes and macrophages by 
down-regulating cell surface levels of MHC class II, co-stimulatory molecules such as 
CD86 and adhesion molecules such as CD58 (Ding et al., 1993).  
 
Moreover, IL10 also prevents the function of dendritic cells by reducing the production 
of the IL-12 and the expressions of MHC class II and co-stimulatory molecules (McBride 
et al., 2002). In addition, IL-10 promotes Th2- phynotype through preventing the 
production of IFN-γ of T lymphocytes (Romagnani 1995). Then, directly blocks the 
proliferation of CD4+ T cells and the production of cytokines, for instance; IL-2, IFN-γ, 
IL-4, IL-5, and TNF-alpha (Joss et al., 2000), accordingly impairing cellular immune 
responses, and controls the imbalance of the Th1/Th2 i.e. M1/M2 –phenotype of 
macrophages. In the current project, overexpression of LPCAT-2 was shown to down-
regulate IL-10 expression, suggesting that LPCAT-2 promotes a pro-inflammatory 
phenotype in macrophages.  
 
Consequently, this project, aimed to understand more about the mechanism of action of 
the inducible LPCAT-2 isoform. Recent studies have confirmed that the peroxisome 
proliferator-activated receptors (PPARs) and in particular (PPAR-γ) have important roles 
in the regulation of macrophage phenotype (Karp et al., 1991; Mueller et al., 1998; von 
Knethen et al., 2007, Chawla, 2010).  
 
This, coupled with the role of PPAR-γ in lipid metabolism, suggested that LPCAT-2 
might have effects on PPAR-γ. Interestingly, when PPAR-γ was inhibited by treating the 
cells with the selective PPAR-γ antagonist, 2-Chloro-5-nitro-N-4-pyridinyl-benzamide 
(T0070907), the level of LPCAT-2 gene expression increased. This increase in LPCAT-
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2 expression was found to be dependent on the concentration of the PPAR-γ antagonist 
and therefore a dose-response relationship linking the two molecules was established. 
 
Furthermore, the effect of LPCAT-2 on the LPS-induced PPARγ expression was 
investigated and it was found that the over-expression of LPCAT-2 significantly 
suppressed LPS-induced PPAR-γ expression in macrophages. PPAR-γ has been shown 
to promote an anti-inflammatory (M2) alternatively activated macrophage phenotype by 
reprogramming macrophages for oxidative metabolism by upregulating fatty acid 
oxidation and mitochondrial biogenesis (von Knethen et al., 2007; Chawla, 2010). 
 
It appears from the current results, that LPCAT-2 can antagonize this function of PPAR-
γ and that the two molecules have opposite functions. Thus, PPAR-γ may suppress 
LPCAT-2 expression and promote an M2 macrophage phenotype whereas activation of 
LPCAT-2 can suppress the activation of PPAR-γ and would promote an M1 phenotype. 
Moreover, it is becoming recognised that lipid metabolism may be central to the 
metabolic regulation of the inflammatory response (Assunção et al., 2017; Croasdell et 
al., 2015). 
 
In this regulation, lipid catabolism and fatty acid oxidation are linked with oxidative 
phosphorylation and an M2 phenotype and lipid synthesis is liked to glycolysis and an 
M1 phenotype (Croasdell et al., 2015). In the current hypothesis, PPAR-γ upregulates 
fatty acid oxidation and supports an M2 macrophage phenotype where LPCAT-2 utilises 
fatty acids for phospholipid synthesis and would be associated with an M1 inflammatory 
phenotype of macrophage activation. This picture is somewhat complicated since it has 
been suggested that other LPCAT isoforms, such as LPCAT3, may have different effects 
on macrophage activation (Zhao et al., (2008). This may be due to the fatty acid substrate 
specificities and other differences between the LPCAT isoforms.  
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To further elucidate the mechanisms of LPCAT-2 action in macrophages, the role of 
LPCAT on lipid mediators was also studied. LPS is known to induce COX-2, and we 
suggested that the overexpression of LPCAT-2 would also significantly increase 
inducible COX-2 expression. Indeed, it was found that, over-expression of LPCAT-2 
while significantly down-regulating PPAR-γ gene expressions, significantly up-regulated 
the expression of COX-2 in transiently transfected RAW264.7 cells.  
 
Recent studies have shown that inhibition of COX-2 using Meloxicam inactivates the 
MAPK pathway and regulates p53 and cell apoptosis, both of which are stimulated via 
TLR4 signaling, which is critical for LPS-induced signaling cascades (Park et al., 2016). 
Several studies have reported that COX-2 regulates p53 activity and inhibits p53-
dependent apoptosis (Choi et al., 2005; Chen et al., 2009) which suggests that LPCAT-2 
might have a role to play in cell cycle and apoptosis. Recently, evidence has emerged that 
LPS can be recognized via TLR4-independent mechanisms, leading to inflammasome 
activation (Kayagaki et al., 2013; Hagar et al., 2013).  
 
Moreover, it was reported that suppressors of cytokine signaling (SOCS3) is involved in 
suppressing the M1 proinflammatory phenotype (Qin et al., 2012). LysMCre-SOCS3fl/fl 
mice which lack SOCS3 are vulnerable to developing LPS-induced sepsis linked with 
enhanced activation of signal transducer and activator of transcription1/3 (STAT1/3) and 
elevated plasma levels of M1 cytokines/chemokines such as IL-1β, TNF-a, IL-6 (Ding et 
al., 1988; Qin et al., 2012).  
 
Rønn, et al., (1982); Li et al., (2006); Chen et al., (2011); Qin et al., (2012) reported that 
important role of SOCS3 in restricting inflammatory responses in myeloid cells has been 
demonstrated in a diversity of animal models for multiple sclerosis, arthritis, allograft 
rejection, lung injury, atherosclerosis, and septic shock.  
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Taken together, these results suggest that LPCAT-2 activation polarises the macrophage 
phenotype into an M1 classically activated cell that is important in clearing bacterial 
infections. Continuous M1 activation however, would allow continuous inflammatory 
responses that could then result in the development of sepsis. Thus, LPCAT-2 may be a 
key molecule for the regulation of macrophage activation and thus an attractive target for 
the development of novel sepsis therapies. 
 
6.1.4. Potential therapeutic strategies. 
 
Sepsis is a life-threatening condition that is estimated to result in as many as 20,000 deaths 
per day Worldwide (Angus et al. 2001). Despite extensive investigations and numerous 
clinical trials, there is currently no approved drug for sepsis (Ward 2012). Although much 
has been learnt about the underlying pathophysiology of sepsis and the inducing infection 
molecules, such as LPS, that mediate an overwhelming inflammatory response, the 
approach of blocking inflammatory mediators has not proved successful in clinical sepsis 
trials (Vincent 2006; Angus 2011).  
 
A better understanding of the mechanisms and control points of the inflammatory 
response are thus urgently needed to provide new targets for diagnostic and therapeutic 
interventions.  A key aim of the current study therefore, was to increase our understating 
of LPCAT-regulated inflammatory responses so that novel therapeutic approaches to 
sepsis could be developed.  
 
Due to the importance to find a novel therapeutic agent in sepsis, Daniels, (2011) 
summarized the potential target sites for developing novel therapeutic agents in sepsis 
including; anti-endotoxin, Toll like receptor (TLR) antagonists- TAK-242, Anti- Tumour 
necrosis factor (TNF), Interleukin (IL) -6 antagonist, anti-Platelet activating factor.   
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However, despite many clinical trials, blocking individual inflammatory mediators has 
proven ineffective in treating sepsis (Peplow & Mikhailidis, 1990; Morimoto et al., 2010 
&2014; Papali et al., 2017; Patel et al., 2017; Rannikko et al., 2017).  Some of this 
disappointment is due to the poor compliance of animal models with human sepsis 
patients and the differences in underlying immunological responses between animals and 
humans (Lilley et al., 2015). It also suggests that we do not concentrate on mediators per 
se but investigate how the inflammatory response is regulated.  
 
TNF-alpha neutralisation was shown to be a useful in reducing the inflammatory reactions 
in cirrhotic rats with induced bacterial peritonitis where TNF-α is increased (Sanchez et 
al.,2013). Hence, blocking TNF-α or IL-1β via TNF-neutralizing antibodies, soluble 
TNF-α receptors or IL-1 receptor has been a suggested as a useful target for the treatment 
of numerous inflammatory diseases such as inflammatory bowel disease and rheumatoid 
arthritis (Dinarello, 2000).  
 
Similarly, IL-6 is a fundamental pro-inflammatory cytokine and an endogenous mediator 
of LPS-induced fever (Roth et al., 1998). Thus, the results of the current project suggest 
that LPCAT-2 might have a crucial role in regulation of these cytokines and control their 
gene expressions as well as their release. Thus, LPCAT-2 might also be a useful target in 
controlling the inflammatory response in a range of conditions.  
 
From the current studies, LPCAT-2 would be an attractive target for the development of 
novel therapies for sepsis and other inflammatory diseases. LPCAT-2 is seen to control 
the inflammatory response to different bacterial ligands, and to many different 
inflammatory mediators. This in itself would make LPCAT-2 attractive target as different 
mediators could be targetted at one time. Moreover, the discovery that LPCAT-2 might 
also play a pivotal role in the polarization of macrophages might allow a different and 
new approach to the treatment of sepsis. Switching macrophage activation states is a 
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promising approach in sepsis as it is becoming realized that sepsis represents a 
fundamental ‘reprogramming’ of the innate immune response to infection.  
 
The most suitable methods that would be employed to inhibit LPCAT-2 present their own 
problems, however. Utilising siRNA approaches in humans would be impractical and 
different versions of gene knockdown would have to be used – possibly using CRISPR 
technology. More promising might be the development of anti-LPCAT-2 chemical 
inhibitors but these would have a long discovery pipeline before a clinical candidate was 
ready.  
 
Furthermore, LPCAT-2 is also essential for immune responses and probably has many 
other functions that simply knocking down all of these would cause additional side 
effects. Thus, further knowledge of the mechanisms of LPCAT-2 activity in different cells 
under different conditions is vital for the development of any therapeutic approach. 
Moreover, other LPCAT family members might also have related functions that would 
need to be elucidated. These aspects are discussed in the ‘future work’ section. 
 
6.2. Conclusions  
1. Overexpression of LPCAT-2 in transiently or stably transfected 
RAW264.7 cells significantly increase TNF-α and IL-6 gene expression as 
well as other inflammatory proteins.  
2. Overexpression of LPCAT-2 in transiently transfected RAW264.7 cells 
significantly decrease IL-10, TLR4 and CD206 (M2-like marker) while 
significantly increasing CD14 and iNOS (M1-like macrophage phenotype 
marker) suggesting that LPCAT-2 induces an M1-like macrophage 
phenotype.  
3. Overexpression of LPCAT-2 in transiently transfected RAW264.7 cells 
significantly increase COX-2 while it is significantly down-regulating 
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PPAR-γ gene expression in transiently transfected RAW264.7 cells. 
Selective inhibition of peroxisome proliferator-activated receptor-gamma 
(PPAR-γ) induces LPCAT-2 expression.  
4. Silencing LPCAT-2 gene expression using siRNA significantly attenuates 
the inflammatory response to infection by reducing inflammatory gene 
expression (TNF-α, IL-6) while significantly increasing IL-10.  
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6.3. Future work.  
1. Further investigate the stably transfected RAW264.7 cells with murine LPCAT-2 
recombinant gene using genomics and proteomics techniques to determine the 
response of LPCAT-2 enzyme in inflammatory response. 
2. Further explore the link between LPCAT-2 expression, macrophage activation and 
polarization.  
3. Explore the mechanism of action of LPCAT-2 in inflammatory responses by 
elucidating its role in responses using other TLRs as well as its proposed network role 
in cell apoptosis through P53.  
4. Analyse the effects of LPCAT-2 expression and knockdown in human cells and animal 
models.  
5. Further studies will be needed to explore the possibility to use the LPCAT-2 enzyme 
as a combination with cytokines and other target as anti-septic agents. 
6- Further studies to explore and understand LPCAT-2 functions at different stages of 
inflammation to discover potential target for medical intervention. 
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Appendix 1: general introduction support information(SI), Materials: Material 
support.  
Appendix 1 : General introduction support information(SI) 
 
 
  
Figure 10. Phylogenetic tree of mouse LPLAT family and summary of characterized LPLATs.   
A phylogenetic tree was drawn by using ClustalW (www.ebi.ac.uk/clustalw). Hishikawa et al., 
PNAS 2008; 105: 2830 - 2835. 
 255 
 
Appendices: 
Appendices 
  
Appendix 1: Materials: Material support. 
 
Materials: 
 
1.1 Material support information Figures.  
 
Schematic of the multiple cloning sites: 
 
  
  
A 
 256 
 
pCMV6-Entry, PS100001. 4919 bp Updated 2-5-2010    B 
 257 
 
 
  
C 
 258 
 
http://204.9.46.202:8080/NoegenAppExt/DrawMapBySKU?drawMap=drawMap&SKU
=RC200168&VECTOR=pCMV6Entry 
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RC200168 The complete (insert plus vector) sequence of [RC200168] clone  D 
 260 
 
 
E 
 261 
 
 
http://204.9.46.202:8080/NoegenAppExt/DrawMapBySKU?drawMap=drawMap&
SKU=MR218203&VECTOR=pCMV6Entry 
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MR218203 The complete (insert plus vector) sequence of [MR218203] 
clone 
   
 
  
F 
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http://www.origene.com/orf_clone/trueclone/NM_017839/RC200168/LPCAT-2.aspx 
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http://www.origene.com/orf_clone/search/orf_nt.aspx?sku=RC200168&type=Human,  
 
 
Figure 11. “pCMV6- Entry Vector 4.9 kb (A) pCMV6-Entry (C-terminal Myc and 
DDK. 
Tagged) that Schematic of the multiple cloning sites: pCMV6- Entry Vector 4.9 kb, (B) 
full Vector sequence; pCMV6-Entry, PS100001. 4919 bp, (C) circular map of The 
complete (human LPCAT-2 insert plus vector)  .(D) RC200168 The complete (insert plus 
vector) sequence of [RC200168] clone (human LPCAT-2), (E) circular map of The 
complete (murine LPCAT-2 insert plus vector). (F) The complete (insert plus vector) 
sequence of [RC200168] clone (murine LPCAT-2), (G) Protein sequencing: for Murine 
LPCAT-2 (H) Murine LPCAT-2 insert /(I) Human LPCAT-2 insert (J) protein 
sequencing of human LPCAT-2.  Updated 2-5-2010, Origene, UK”.  
 
 
https://statistics.laerd.com/spss-tutorials/testing-for-normality-using-spss-statistics.php 
Table 5. The normality test for RT-PCR and ELISA data udsing SSPS version 22. 
https://statistics.laerd.com/spss-tutorials/testing-for-normality-using-spss-statistics.php 
Tests of normality 
  
Kolmogorov-Smirnova Shapiro-Wilk 
Statistic df Sig. Statistic df Sig. 
VAR00001 .219 3 . .987 3 .783 
VAR00002 .297 3 . .917 3 .441 
VAR00003 .310 3 . .899 3 .383 
a. Lilliefors Significance Correction 
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1.2. Total RNA isolation by acid guanidinium thiocyanate-phenol- no 
chloroform extraction from RAW264.7 cell line (Adapted from 
Chomczynski Sacchi (1987)). 
 
Reagents. 
• Guanidinium thiocyanate (4 M) 
• Sodium citrate (0.75 M, pH 7.0) 
• N-laurosarcosine (sarkosyl) (10 %) 
• 2-mercaptoethanol (BME) 
• Sodium acetate (anhydrous) (2M, pH4.0) 
• Glacial acetic acid 
• Water saturated phenol 
• 1 –bromo-3-chloropropane 
• Isopropanol (~100 %) 
• Ethanol (70 % or 75 %) 
• RNase- and DNAse- free water 
 
Denaturing solution: 
Stock denaturing solution was prepared by dissolving 25 g of guanidium thiocyanate in 
29.3 ml of water at 65ºC, followed by 1.76ml of 0.75 M sodium citrate, pH 7.0, and 2.64 
ml of 10 % sarkosyl. Denaturing solution was activated before use by addition of 72 µl 
of 2- mercaptoethanol to each 10ml of the stock solution. 
2 M sodium acetate, pH 4.0: 
16.42 g of sodium acetate (anhydrous) was added to 35 ml of water and 40ml glacial 
acetic acid. And then, the pH was adjusted to 4.0 with glacial acetic acid and the final 
volume was brought to 100ml with water. 
 267 
 
Following the experiments, culture supernatants were removed from RAW264.7 cells and 
500 µl of denaturing solution was added directly to the wells. Cells were rested in 
denaturing solution for 1 - 2 minutes to allow complete lysis and the solution was pipetted 
up and down 10 times to ensure all the lysate was collected. The samples were allowed 
to sit for 5 minutes before being frozen at -20 oC for later analysis. 
To extract the RNA, 50 µl of 2 M sodium acetate, pH 4.0 was added to the cell lysates 
respectively and mixed thoroughly by inversion. Then, 500 µl water saturated phenol was 
added, mixed by inversion, followed by 100µl of 1-bromo-3-chloropropane, and shaken 
vigorously by hand to ensure proper mixing. Samples were cooled on ice for 15 minutes 
then centrifuged for 20 minutes, 15000 g, at 4 oC. 
 And then, the upper aqueous phase containing mostly RNA was transferred to an RNAse- 
and DNAse free Eppendorf tube and 500 µl of isopropanol was added to precipitate the 
RNA. Samples were incubated at -20 oC until needed for the next step.  
Next, samples were centrifuged at 15000  g for 20 minutes at 4 oC. The supernatant was 
discarded and the gel-like precipitates (RNA) were retained then dissolved in 300 µl of 
denaturing solution. And then, 300 µl of isopropanol were added and the samples were 
incubated at -20 oC for at least 30 minutes (1 hour). Samples were incubated at -20 oC 
until needed for the next step or after which they were centrifuged for at 15000 g for 10 
minutes at 4 oC. The supernatants were discarded and the pellets were re-suspended in 
500 µl of 75 % ethanol and vortexed for 10 seconds to mix, and then incubated for 15 
minutes at room temperature to dissolve any residual guanidinium thyocyanate. At this 
point, samples were stored at -20 oC until RNA extraction could be completed. 
Samples were centrifuged for at 15000 g for 10 minutes at 4 oC, and the supernatant was 
discarded. The pellets were air dried for around 15 - 30 minutes in a laminar flow hood 
at room temperature, and then the RNA was dissolved in 30 µl of RNAse- and DNAse- 
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free water and incubated for 15 minutes at 60 oC to ensure complete solubilisation of the 
RNA. 
 To remove any residual genomic DNA, samples were treated with the DNAse 1 kit 
(Sigma, UK). To the solubilised RNA, 3 μl of 10x reaction buffer and 3 μl amplification 
grade DNase 1 (1 unit /μl) were added and samples were left to stand at room temperature 
for 15 minutes. To stop the reaction, 3 μl stop solution was added to each tube. Samples 
were then incubated at 70 oC for 10 minutes, and then placed on ice ready to quantifying 
the total RNA concentrations using Nanodrop 2000 and then ready for reverse 
transcription.  
 
1.2. Culture media: 
 
1.2.1. SOC medium 
 
Components:  
20 g/L Tryptone 
5 g/L Yeast Extract 
4.8 g/L MgSO4 
3.603 g/L dextrose 
0.5 g/L NaCl 
0.186 g/L KCl 
SOC Medium is a nutrient-rich microbial growth medium (a rich broth media) that 
contains peptides, amino acids, water-soluble vitamins, and glucose in a low-salt 
formulation used primarily in the recovery step of Escherichia coli (E. coli) competent 
cell transformations to maximize the transformation efficiency of competent cells. 
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1.2.2. LB Agar (250 ml) 
  
LB broth    (Sigmma-Aldrich, Uk)                                                          5 g 
Bacteriological agar   (Sigmma-Aldrich, Uk)                                         3.75 g 
Molecular water was added to a final volume of 250 ml, sterilized by autoclaving for 15 
minutes at 100 kilopascal (kPa) i.e. 15 pound per square inch or, pound-force per square 
inch (psi or Ibf/in
2).  
1.2.3. LB broth (500 ml) contain: NaCl 5 g, Tryptone 5 g, Yeast extract 2.5 g: 
LB broth                                                                                              10 g   
Molecular water was added to a final volume of 500ml, sterilized by autoclaving for 15 
minutes at 100 kPa i.e. 15 psi (Ibf/in
2).  
 
1.3.1. BCA assay protocol. 
Standard series from 2 mg/mL of BSA stock  
 
                                         A        B      C      D       E      F      G     H 
Required concentration 200     100    50     25     10     5      2.5    0 
Volume of PBS (µL)       450     250   250   250   300   250   250  250  
Volume of BSA (µL)        50       250   250  250   200   250   250    0 
                             (Stock)        (A)    (B)  (C) (D)  (E)  (F) (G) (H) 
1- Micro BCA wells plate layout (96 well): it depends on the samples number 
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2- Micro BCA wells plate layout (96 well): it depends on the samples number 
 1,2 
(standard) 
3,4 
(Unknown) 
5,6 
(Unknown) 
7,8 
(Unknown) 
A 200 1 9 17 
B 100 2 10 18 
C 50 3 11 19 
D 25 4 12 20 
E 10 5 13 21 
F 5 6 14 22 
G 2.5 7 15 23 
H 0(Blank) 8 16 24 
3- Add 100 µL of each standard to column 1, 2. 
4- Add each samples need diluting 1:25 in 100 µL in all remaining well e.g 98 µL PBS 
and 2 µL of protein sample. 
5- Mix the BCA reagents to give a solution of A: B: C of 25:24:1 in 100 µL for each 
well. 
e.g. 24 samples+8 standards= 32 well X 2= 64 + extra 2 for pipetting mistake. = 66    
66 X 100 µL for each= 6.6 mL 
(A) (6600/50) X 25 = 3300 µL 
(B) (6600/50) X 24 = 3168 µL 
(C) (6600/50) X 1   = 132   µL 
6- Add the above amount into a trough, mix to ensure that the crystals are dissolved. 
7- Multi- channel pipette, 100 µL of BCA mix into each well. 
8- Vortex plate for 1 minute on plate mixture and then Incubate or 37 ºC for 2 hrs. 
9- Plate reader: save it as protocol the read the plate. 
10-  Concentration = µg/ mL X 50 (dilution factor) to be ready for western blotting. 
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1.3.2. Gel electrophoresis using Novex system and NuPAGE® Bis – Tris 
Gel for western blotting 
 
Pre – cast gels were used. 10 % polyacrylamide Bis-Tris Cl buffered Gel (pH, 6.4) 
NuPAGE running buffer stock (10X): 
52.3 g Mops 
30.3 g Tris Base 
5 g SDS 
EDTA (0.5 M) = 10 mL 
Heat the protein samples after preparation in a heat block at 70 ºC for 10 minutes, and 
then heat the 20 biotin Marker (Millipore, UK). 
Use 1X running buffer 
Run the gel at 200 V for 90 minutes, Note: keep watching the gel running bands and make 
sure switch it off when they reach the end even before the 90 minutes. 
